

06/13/00



JCS52 U.S. PTO

06-15-00

Box 580 A

Please type a plus sign (+) inside this box → ☐PTO/SB/05 (4/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))	Attorney Docket No.	730/002
	First Inventor or Application Identifier	Clark, John
	Title	Animal Tissue for Xenotransplantation
	Express Mail Label No.	EH643728336US

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
1. <input checked="" type="checkbox"/> * Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)	5. <input type="checkbox"/> Microfiche Computer Program (Appendix)
2. <input checked="" type="checkbox"/> Specification [Total Pages 93] (preferred arrangement set forth below) <ul style="list-style-type: none">- Descriptive title of the Invention- Cross References to Related Applications- Statement Regarding Fed sponsored R & D- Reference to Microfiche Appendix- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings (if filed)- Detailed Description- Claim(s)- Abstract of the Disclosure	6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) <ul style="list-style-type: none">a. <input checked="" type="checkbox"/> Computer Readable Copyb. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy)c. <input checked="" type="checkbox"/> Statement verifying identity of above copies
3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets 20]	ACCOMPANYING APPLICATION PARTS
4. Oath or Declaration [Total Pages 2] <ul style="list-style-type: none">a. <input type="checkbox"/> Newly executed (original or copy)b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. § 1.63(d)) (for continuation/divisional with Box 16 completed)<ul style="list-style-type: none">i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).	7. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).	
8. <input type="checkbox"/> 37 C.F.R. § 3.73(b) Statement of Power of Attorney (when there is an assignee)	
9. <input type="checkbox"/> English Translation Document (if applicable)	
10. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations	
11. <input type="checkbox"/> Preliminary Amendment	
12. <input type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)	
13. <input type="checkbox"/> * Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)	
14. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)	
15. <input checked="" type="checkbox"/> Other: <u>return receipt postcard</u>	

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____

Prior application information: Examiner _____ Group / Art Unit _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number or Bar Code Label		or <input type="checkbox"/> Correspondence address below
(Insert Customer No. or Attach bar code label here)		
022869		
Name		
Address		
City	State	Zip Code
Country	Telephone	Fax

Name (Print/Type)	J. Michael Schiff	Registration No. (Attorney/Agent)	40,253
Signature		Date	Jun 13, 2000

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

ANIMAL TISSUE FOR XENOTRANSPLANTATION

TECHNICAL FIELD

5 This invention relates generally to the fields of carbohydrate chemistry and animals engineered with a genetic knockout. More particularly, it relates to non-human mammals that are engineered to be deficient in the enzyme $\alpha(1,3)$ galactosyltransferase, and consequently do not express the Gal $\alpha(1,3)$ Gal xenoantigen.

REFERENCE TO RELATED APPLICATION

10 This application claims the priority benefit of U.S. Provisional Application 60/204,148, filed May 15, 2000. The priority application is hereby incorporated herein by reference in its entirety.

BACKGROUND

15 The acute shortage of human organs for transplantation is a compelling force towards the development of new sources of suitable tissue. One option that is gathering considerable
20 attention is the use of organs from other animal species. The main challenge to overcome is rendering foreign tissue immunologically compatible with the patient being treated.

25 Tissue from most mammalian species would undergo hyperacute rejection when transplanted into humans. This is because human plasma contains natural antibodies against carbohydrate determinants of the animal tissue, thought to originate through prior immune stimulation by dietary antigen or mucosal microflora. Since the antibodies are pre-formed, rejection occurs within days of the transplant.

The main target for the natural antibodies mediating rejection is cell-surface oligosaccharides expressing the determinant Gal α (1,3)Gal (reviewed by Joziassse et al., Biochim. Biophys. Acta 1455:403, 1999). Humans, apes and Old World monkeys differ from other mammals in that they lack α -galactosyl epitopes in complex oligosaccharides. Other mammals express the Gal α (1,3)Gal epitope prominently on the surface of nucleated cells, including hepatic cells, renal cells, and vascular endothelium — which is especially problematic for xenotransplantation of whole organs.

The Gal α (1,3)Gal epitope is made by a specific enzyme, α (1,3)galactosyltransferase, abbreviated in this disclosure as α 1,3GT. The transferase uses UDP- galactose as a source of galactose, which it transfers specifically to an acceptor oligosaccharide, usually Gal β (1,4)GlcNAc (N-acetyl lactosamine). In mammals that don't express the Gal α (1,3)Gal product, the α 1,3GT locus is inactivated (Gailili et al., Proc. Natl. Acad. Sci. USA 15:7401, 1991). There are frameshift and nonsense mutations within the locus, turning it into a non-functional, processed pseudogene (Laarsen et al., J. Biol. Chem. 265:7055, 1990; Joziassse et al., J. Biol. Chem. 266:6991, 1991).

In humans, N-acetyl lactosamine acceptor oligosaccharides are processed differently. The enzyme α (1,2)fucosyltransferase builds the N-acetyl lactosamine into Fuc α (1,2)Gal β (1,4)GlcNAc, which is blood group H substance. This in turn serves as an acceptor substance for blood group A GlcNAc-transferase, or blood group B Gal-transferase, forming A-substance or B-substance, respectively, depending on the blood type of the individual. Naturally occurring antibodies circulating in the blood are reactive against the alternative carbohydrate determinants that are not self-antigens.

Larsen et al. (Proc. Natl. Acad. Sci. USA 86:8227, 1989) isolated and characterized a cDNA encoding murine α 1,3GT. Joziassse et al. (J. Biol. Chem. 267:5534, 1992) detected four distinct mRNA transcripts, which predict four different isoforms of the α 1,3GT. The full-length mouse mRNA (including 5' untranslated mRNA) was reported to span at least 35-kb of

genomic DNA, distributed over nine exons ranging from 36 base pairs to ~2600 base pairs in length. Numbering in the 5' to 3' direction, the coding region is distributed over Exons 4 to 9. The four transcripts are formed by alternative splicing of the pre-mRNA.

Joziassse et al. (J. Biol. Chem. 264:14290, 1989) isolated and characterized a cDNA
5 encoding bovine cDNA. The coding sequence was predicted to be a membrane-bound protein with a large glycosylated COOH-terminal domain, a transmembrane domain, and a short NH₂ terminal domain.

The porcine α 1,3GT cDNA sequence has been reported from several different laboratories: Strahan et al. (Immunogenetics 41:101, 1995); U.S. Patent 5,821,117; U.S.
10 Patent 5,849,991; and International Patent Application WO 95/28412. The genomic organization of porcine α 1,3GT was reported by Katayama et al. (Glycoconjugate J. 15:83, 1998). Again, the coding region spans six exons, conserving the arrangement present in the mouse genome, and extending over nearly 24-kb.

It has been reported that about 95% of the naturally occurring xenospecific antibody in
15 humans recognize the Gal α (1,3)Gal epitope (McKensie et al., Transpl. Immunol. 2:81, 1994). Antibody in human serum binds specifically to pig endothelial cells in a manner that is inhibitable by Gal α (1,3)Gal, or by Gal α (1,6)Glu (melibiose). New age monkeys have the same naturally occurring antibody, and demonstrate hyperacute rejection of pig organ xenotransplants. The rejection reaction can be obviated in experimental animals by infusing
20 the recipient with the free carbohydrate (Ye et al., Transplantation 58:330, 1994), or by adsorbing antibody from the circulation on a column of Gal α (1,3)Gal or melibiose (Cooper et al., Xenotransplantation 3:102, 1996).

It has been suggested that xenotransplants of pig tissue could provide a source of various tissue components — heart valves, pancreatic islet cells, and perhaps large organs such
25 as livers and kidneys (Cowley, Newsweek, Jan 1/2000). If xenotransplants from non-primates into humans is ever to become viable, then techniques need to be developed to

suppress Gal α (1,3)Gal expression. Possible genetic manipulation strategies are reviewed by Gustafsson et al. (Immunol. Rev. 141:59, 1994), Sandrin et al. (Frontiers Biosci. 2:e1-11, 1997), and Lavitrano et al. (Forum Genova 9:74, 1999).

One approach is to prevent the formation of Gal α (1,3)Gal by providing another
5 transferase that competes with α 1,3GT for the N-acetyl lactosamine acceptor. International Patent Application WO 97/12035 (Nextran-Baxter) relates to transgenic animals that express at least one enzyme that masks or reduces the level of the xenoactive antigens by competing with α 1,3GT. The enzymes proposed are α (1,2)fucosyltransferase (that makes H antigen in humans), α (2,6)sialyltransferase, and β (1,3)N-acetylglucosaminyltransferase. It is thought
10 that once N-acetyl lactosamine has been converted by one of these transferases, it can no longer act as an acceptor for α 1,3GT. The xenotransplantation cells of Application WO 97/12035 have at least one enzyme that reduces Gal α (1,3)Gal expression, and also express a complement inhibitor such as CD59, decay accelerating factor (DAF), or membrane cofactor protein (MCP). Expression of human CD59 in transgenic pig organs enhances organ
15 survival in an ex vivo xenogeneic perfusion model (Kroshus et al., Transplantation 61:1513, 1996).

Another approach is to disassemble Gal α (1,3)Gal after it is formed. International Patent Application WO 95/33828 (Diacrin) suggests modifying cells for xenogeneic transplants by treating tissue with an α -glycosidase. Osman et al. (Proc. Natl. Acad. Sci.
20 USA 23:4677, 1997) reported that combined transgenic expression of both α -glycosidase and α (1,2)fucosyltransferase leads to optimal reduction in Gal α (1,3)Gal epitope. Splenocytes from mice overexpressing human α -glycosidase showed only a 15-25% reduction in binding of natural human anti-Gal α (1,3)Gal antibodies. Mice overexpressing human
25 α (1,2)fucosyltransferase as a transgene showed a reduction of Gal α (1,3)Gal epitopes by ~90%. Doubly transfected COS cells expressing both the glycosidase and the transferase

showed negligible cell surface staining with anti-Gal α (1,3)Gal, and were not susceptible to lysis by human serum containing antibody and complement.

A further alternative is to prevent Gal α (1,3)Gal expression in the first place. Strahan et al. (Xenotransplantation 2:143, 1995) reported the use of antisense oligonucleotides for inhibiting pig α 1,3GT, leading to a partial reduction in expression of the major target for human natural antibodies on pig vascular endothelial cells. Hayashi et al. (Transplant Proc. 29:2213, 1997) reported adenovirus-mediated gene transfer of antisense ribozyme for α 1,3GT and α fucosyltransferase genes in xenotransplantation.

U.S. Patent 5,849,991 (Bresatch) describes DNA constructs based on the mouse α 1,3GT sequence. They are designed to disrupt expression of functional α 1,3GT by undergoing homologous recombination across Exon 4, 7, 8, or 9. The constructs contain a selectable marker such as *neo*^R, *hyg*^R or thymidine kinase. It is proposed that such constructs be introduced into mouse embryonic stem (ES) cells, and recovering cells in which at least one α 1,3GT gene is inactivated. Experiments are reported which produced mice that are homozygous for inactivated α 1,3GT, resulting in lack of expression of Gal α (1,3)Gal epitope, as determined by specific antibody.

U.S. Patent 5,821,117 (Austin Research Inst.) report cDNA sequence data for porcine α 1,3GT. This was used to probe a pig genomic DNA library, and two lambda phage clones were obtained that contain different regions of the porcine transferase gene.

International Patent Application WO 95/28412 (Biotransplant) also report cDNA sequence data for porcine α 1,3GT. It is proposed that genomic DNA fragments be isolated from an isogenic DNA library, and used to develop a gene-targeting cassette including a positive or negative selectable marker.

International Patent Application WO 99/21415 (Stem Cell Sciences, Biotransplant) reports construction of a DNA library from miniature swine. A vector is obtained comprising

a *pgk-neo* cassette, and fragments of the $\alpha 1,3$ GT gene. This is used for homologous recombination to eliminate $\alpha 1,3$ GT activity in porcine embryonic fibroblasts.

Costa et al., Alexion Pharmaceuticals (Xenotransplantation 6:6, 1999) report experiments with transgenic mice expressing the human complement inhibitor CD59, with mice expressing $\alpha(1,2)$ fucosyltransferase, and with $\alpha 1,3$ GT knock-outs. Expression of CD59 in combination of either $\alpha(1,2)$ fucosyltransferase or $\alpha 1,3$ GT null phenotype prevented human serum-mediated cytolysis. Triple combination of all three modifications provided no additional protective effect.

There have been no reports of the use of $\alpha 1,3$ GT inactivated tissue for xenotransplantation into humans. In view of the paucity of available organs for human transplantation, there is a pressing need to develop further options.

SUMMARY OF THE INVENTION

Immunologically compatible animal tissue for xenotransplantation is described in this disclosure. Sequence data for the sheep $\alpha(1,3)$ galactosyltransferase ($\alpha 1,3$ GT) gene is provided, which enables construction of targeting vectors for inactivating the $\alpha 1,3$ GT gene. Successfully targeted cells can be used as nuclear donors for obtaining animals lacking the $\text{Gal}\alpha(1,3)\text{Gal}$ determinant. The tissues can be transplanted into human patients, without being subject to hyperacute rejection by antibodies to the $\text{Gal}\alpha(1,3)\text{Gal}$ determinant normally present in human serum.

One embodiment of the invention is animal tissue devoid of $\text{Gal}\alpha(1,3)\text{Gal}$ determinants, such as can be detected by antibody binding according to standard techniques. Exemplary is tissue from ruminants of the subfamily caprinae, especially sheep. Tissue of this nature suitable for transplantation to humans includes but is not limited to lung tissue, kidney tissue, liver tissue, cardiac tissue, pancreatic tissue, and ocular tissue.

This invention also embodies a polynucleotide construct effective for inactivating an $\alpha 1,3$ GT gene. Exemplary constructs comprise at least two polynucleotide sequences from an ovine $\alpha 1,3$ GT gene in a non-natural arrangement, for inactivating the $\alpha 1,3$ GT gene by homologous recombination, leading to deletion or interruption of the $\alpha 1,3$ GT encoding
5 sequence, or replacement with an alternative sequence. Optionally, the vector comprises an intron sequence of at least 30 consecutive nucleotides homologous to any of recombinant phage plasmids illustrated below, or deposited in support of this disclosure. In certain applications, $\alpha 1,3$ GT gene is inactivated by contacting the cell with the polynucleotide construct of this invention under conditions suitable for homologous recombination of the
10 construct into the genome of the cell.

Another embodiment of the invention is a cell that expresses glycosyl transferase enzymes but does not detectably express $\alpha(1,3)$ galactosyltransferase ($\alpha 1,3$ GT). The cell may be heterozygous or homozygous for inactivation of an $\alpha 1,3$ GT gene.

Such cells and tissues can be obtained from a whole animal such as a sheep that is
15 homozygous for inactivation of an $\alpha 1,3$ GT gene. Such animals can be produced by engrafting into a female of the same species embryo having at least one inactivated $\alpha 1,3$ GT allele. Embryos can be generated, for example, by transfer of a nucleus from a donor cell with an inactivated $\alpha 1,3$ GT gene, to an enucleated recipient cell. If the birthed animal is heterozygous for $\alpha 1,3$ GT inactivation, homozygous inactivation can be achieved by selective breeding, or
20 by a second round of gene targeting to inactivate the second allele.

A further embodiment of this invention is an isolated polynucleotide comprising a sequence of 30 or more consecutive nucleotides contained in (or capable of hybridization with) SEQ. ID NO:1 or 14 to 25, or which is contained in phage deposited in support of this application, but which does not appear in other known sequences, such as SEQ. ID NOS: 3, 5,
25 7, 9, 11, and 13. Included are polynucleotide constructs effective for inactivating a $\alpha(1,3)$ galactosyltransferase ($\alpha 1,3$ GT) gene. Such polynucleotides can also be used in an assay

for determining $\alpha 1,3$ GT expression, in which the polynucleotide is combined with analyte mRNA or cDNA, and the formation of a duplex between the two is correlated with expression of $\alpha 1,3$ GT by the cell.

Another embodiment of the invention is an isolated polypeptide comprising a
5 sequence of 10 or more consecutive amino acids contained in or homologous to SEQ. ID NO:2, or encoded in a polynucleotide of this invention, which is not fully contained in any other known sequence, such as SEQ. ID NOs: 4, 6, 8, 10, and 12. Such polypeptides may have glycosyltransferase activity, or be immunologically cross-reactive with $\alpha 1,3$ GT. In certain contexts, the polypeptides are used to prepare antibody. In other contexts, the polypeptides
10 are used to prepare a $\text{Gal}\alpha(1,3)\text{Gal}$ determinant by combining with a galactose acceptor saccharide in the presence of UDP-galactose.

Further embodiments of the invention are polyclonal and monoclonal antibodies
(including immunoglobulin derivatives and equivalents) that bind specifically to a polypeptide of this invention, but not with other polypeptides. Some such antibodies react with $\alpha 1,3$ GT
15 of other mammalian species, while others are specific for ovine $\alpha 1,3$ GT. They can be used, for example, in an assay to determine $\alpha 1,3$ GT in a sample, in which the sample is combined with the antibody, and any complex formed is correlated with the presence of $\alpha 1,3$ GT.

Cells and tissues of this invention can used to prepare tissue devoid of antibody-
detectable $\text{Gal}\alpha(1,3)\text{Gal}$ determinants for treatment of the human body by surgery or therapy.

20 This invention provides a method of xenotransplantation, comprising transplanting tissue devoid of antibody-detectable $\text{Gal}\alpha(1,3)\text{Gal}$ determinants into a mammal that may have circulating antibody against $\text{Gal}\alpha(1,3)\text{Gal}$ determinants, such as a human.

These and other embodiments of the invention will be apparent from the description that follows.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a chart providing certain sequence data of this invention, which is $\alpha(1,3)$ Galactosyltransferase cDNA in the sheep ($\alpha 1,3$ GT) (SEQ. ID NO:1). The predicted protein sequence is shown below (SEQ. ID NO:2). Numbers 4 to 9 indicate the projected 5' boundaries of Exons 4 to 9 in the genomic sequence.

Figure 2 is a chart comparing the cDNA nucleotide sequence of sheep $\alpha 1,3$ GT (SEQ. ID NO:1) with the bovine homolog (SEQ. ID NO:3). Identical residues are marked with an asterisk (*). The putative start codon is indicated with an arrow (\Downarrow).

Figure 3 is a chart comparing the protein sequence of sheep $\alpha 1,3$ GT (SEQ. ID NO:2) with the bovine homolog (SEQ. ID NO:4). Identical residues are marked with an asterisk (*).

Figure 4 is a half-tone reproduction, showing Southern blot analysis of sheep genomic DNA. Probes for two different $\alpha 1,3$ GT exons yield one band, demonstrating that there is one copy of $\alpha 1,3$ GT in the sheep genome.

Figure 5 is a half-tone reproduction, showing Northern blot analysis of mRNA from sheep fetal fibroblasts. There is a single expressed transcription product for $\alpha 1,3$ GT ~3-kb in size.

Figure 6 is a restriction map for the sheep $\alpha 1,3$ GT gene. Phage clones were obtained for the regions shown, and used to determine intron sequences.

Figure 7 is a map showing sequenced intron regions of $\alpha 1,3$ GT. The areas numbered 1 to 9 in the figure correspond to SEQ. ID NOs:15, 16, 19, 20, 21, 22, 23, 24, and 25, respectively.

Figure 8 is a map showing the design of two targeting vectors for inactivating the $\alpha 1,3$ GT gene by eliminating one of the exons through homologous recombination. Each targeting vector comprises a selectable marker (*neo*), flanked on one side by an intron sequence

of 1-2-kb, and on the other side by an intron sequence of 7-10-kb. A number of vectors have been obtained, including some that target Exon 4, Exon 8, and Exon9.

Figures 9 to 11 are drawings that compare the details of the targeting vectors p0054, p0079, and p0063, respectively, with the region of the $\alpha 1,3GT$ gene sequence targeted for homologous recombination (shown below). These vectors are designed to replace the coding region in Exon 4 with the selectable marker *neo* or *pac*.

Figure 12 is a drawing showing how vectors p0054 and p0079 can be truncated for use in an adeno-associated virus (AAV) vector.

Figure 13 is a drawing that compares targeting vector p0078 (above), with the targeted Exon 8 region of $\alpha 1,3GT$ (below), to be substituted with selectable marker *neo*.

Figures 14 and 15 are drawings that compare targeting vector p0047 and p0046, respectively, with the targeted Exon 9 region of $\alpha 1,3GT$ (shown below), to be substituted with selectable marker *neo*.

Figure 16 is a half-tone reproduction, showing PCR analysis of sheep fetal fibroblasts targeted with the p0054 vector. Using two primers for intron sequences that flank Exon 4 (upper panel), the expected product is 2.8-kb for native $\alpha 1,3GT$, and 2.2-kb after homologous recombination. Using a primer for the selectable marker (lower panel), amplification product is expected only after recombination. The results show that one of the samples is from a fibroblast that has successfully been targeted — replacing Exon 4 with the selectable marker.

Since Exon 4 contains the translation initiation site, this would inactivate the $\alpha 1,3GT$ gene.

Figure 17 is a half-tone reproduction, showing PCR analysis of umbilical chord taken from a sheep fetus, generated by transfer of a $\alpha 1,3GT$ targeted nucleus to a quiescent oocyte, which was implanted into a surrogate female at estrus. Two bands were observed: 2.8 kb, corresponding to the wild type $\alpha 1,3GT$ gene, and 2.2 kb, appropriate for a targeted $\alpha 1,3GT$ gene. These results are consistent with inactivation of the $\alpha 1,3GT$ gene on one haplotype.

DETAILED DESCRIPTION

This invention provides new sequence data for the $\alpha(1,3)$ galactosyltransferase ($\alpha 1,3$ GT) gene in the Black Welsh Mountain sheep. The data includes the cDNA sequence, encompassing the entire $\alpha 1,3$ GT encoding region, and certain portions of the genome sequence, from upstream of the coding region, from introns, and from downstream of the coding region.

The discovery of this sequence and nucleic acids containing them have made it possible to construct targeting vectors designed to disrupt expression of a $\alpha 1,3$ GT gene in eukaryotic cells, particularly sheep cells. Exemplary vectors targeting Exons 4 and 9 of the $\alpha 1,3$ GT gene are shown in **Figure 8**. These exemplary vectors have a knockout sequence flanked by two regions homologous to the genomic sequence. After recombination, the knockout sequence replaces a portion of the gene so as to disrupt transcription of a functioning $\alpha 1,3$ GT — by elimination of Exon 4 or Exon 9, which encompass the translation start and stop codons, respectively. The knockout sequences in these exemplars comprise a selectable marker that facilitates the separation of cells that have been genetically altered after targeting with the vector.

For certain aspects of this invention, mammalian cells that have had an $\alpha 1,3$ GT gene inactivated artificially in at least one haplotype are used to produce animals that do not express the Gal $\alpha(1,3)$ Gal epitope. Nuclear transfer permits a nucleus having an inactivated $\alpha 1,3$ GT gene to be transferred from a donor cell or cell line to an embryonic cell or oocyte. An embryo is then formed, engrafted into the uterus of a surrogate host, and used to birth a live neonate. Where the $\alpha 1,3$ GT gene is homozygously inactivated, the animal or its progeny are already able to supply cells and tissue lacking the Gal $\alpha(1,3)$ Gal epitope. Where the $\alpha 1,3$ GT gene is inactivated in only one haplotype, homozygous inactivation can be achieved by standard cross-breeding techniques. Tissue lacking the $\alpha 1,3$ GT epitope can then be used

for transplantation into humans without risk of antigenicity for the natural antibody that is normally the linchpin for hyperacute rejection of xenografts.

Definitions

5 For purposes of this disclosure, the term Gal α (1,3)Gal (abbreviated GAL) refers to an oligosaccharide determinant present on endothelial cells and other cells of most non-primate mammals, for which humans have a naturally occurring antibody. The usual structure is Gal α (1,3)Gal β (1,4)GlcNAc, although other forms of Gal α (1,3)Gal specifically detectable by the naturally occurring anti Gal α (1,3)Gal in human serum of B blood type are included.

10 Gal α (1,3)Gal is distinct from the Gal α (1,3)[Fuc α (1,2)]Gal β (1,4)GlcNAc determinant characteristic of the human B blood type antigen.

An “antibody detectable” determinant refers to a determinant that is present in an amount and is sufficiently accessible so that it can be detected by an antibody specific for the determinant in an appropriate immunoassay — such as an agglutination reaction, optionally
15 developed with an antiglobulin reagent, or by immunohistochemistry.

The term “ α (1,3)galactosyltransferase” and the abbreviation “ α 1,3GT” refer to the enzyme present in non-primate mammals that catalyzes the formation of the Gal α (1,3)Gal determinant by attaching Gal in the α (1,3) position to the Gal β (1,4)GlcNAc acceptor.

α 1,3GT has the Enzyme Commission designation EC 2.4.1.124. α 1,3GT is not naturally
20 expressed in humans, and the term does not include the galactosyltransferase that forms the human B blood group antigen.

An “acceptor” substance for α 1,3GT is a carbohydrate structure that can act as a substrate and become galactosylated as a result of transferase activity. Acceptors for α 1,3GT include both Gal β (1,3)GlcNAc and Gal β (1,4)GlcNAc (Basu et al., J. Biol. Chem. 248:1700,
25 1973; Blake et al., J. Biol. Chem. 256:5387, 1981).

A transferase is said to be "detectably expressed" by a cell at the mRNA level when mRNA encoding the transferase can be measured in the cell by some suitable technique, such as Northern analysis or PCR-reverse transcriptase. It may also be expressed at the protein level, as detected by a specific antibody or demonstration of the characteristic enzymatic activity. Those of skill in the art will recognize that some cells (such as mature red blood cells) do not express any glycosyl transferases, even though they display certain oligosaccharide determinants. Inhibition of α 1,3GT expression is only meaningful in cells capable of expressing other glycosyl transferase enzymes. Most nucleated mammalian cells can be assumed to have this capability.

A gene is said to be "inactivated" when it is rendered incapable of transcribing a functional protein without further genetic engineering. For example, an inactivated gene may be missing necessary transcription or translation control elements, it may be lacking an essential part of the protein encoding region, or the encoding region may be placed out of phase. In a second example, the gene may be interrupted by an inserted sequence, or mutated in such a way as to interfere with transcription or translation of the gene product. In a third example, the inactivated gene may produce a translation product that has been altered in such a way that it lacks important enzymatic activity of the native gene product.

The term "tissue" refers to a heterogeneous collection of cells responsible for maintaining one or more physiological functions. Of interest for certain embodiments of this invention are organs suitable for transplantation, such as a whole kidney; however, the term also includes organ fragments and other embodiments, such as a piece of connective tissue, or a collection of cells in a medical support device.

The term "embryo" as it is used in this disclosure refers to an organism developing in the uterus of a species of interest at any time after fertilization or intrauterine transfer, not limited to a particular developmental period. The terms "engrafting" or "transplanting", in reference to embryo manipulation, refer to any process known in the art for artificially introducing one or more embryos into the uterus of a female animal.

An "individual" or "subject" refers to any vertebrate animal, usually a member of a mammalian species, including but not limited to domestic animals, non-human primates, and humans.

It is understood that a clinical or biological "sample" encompasses a variety of sample types obtained from a subject and useful in an in vitro procedure, such as a diagnostic test. The definition encompasses solid tissue samples obtained during surgery or autopsy, and liquid samples such as blood, spinal fluid, and fluid obtained by amniocentesis, and various subfractions, enrichments, or solubilized extracts derived from such collections.

A "host cell" denotes a prokaryotic or eukaryotic cell has been genetically altered, or is capable of being genetically altered by administration of an exogenous polynucleotide, such as a bacterial plasmid or recombinant vector. When referring to genetically altered cells, the term refers both to the originally altered cell and to the progeny thereof.

A cell is said to be "genetically altered" when it contains an artificially introduced polynucleotide, or is the progeny of a cell so altered that has inherited an introduced polynucleotide. The polynucleotide may contain a sequence that is heterologous to the cell, it may contain native sequences in an artificial arrangement (e.g., an encoding region linked to a different promoter), or it may provide additional copies of a native encoding sequence. The polynucleotide can be introduced by transfection using electroporation or liposome-mediated transfer, homologous recombination, transduction using a viral vector, any combination thereof, or any other technique known in the art. The polynucleotide will often comprise a transcribable sequence encoding a protein of interest, which enables the cell to express the protein at an elevated level. In the context of the present application, a "genetically altered cell" has a genetic alteration that is inheritable by progeny of the cell. For example, an embryo having genetically altered DNA, if carried to term, will give rise to a neonate that has cells containing the genetic alteration.

The terms "polynucleotide" and "oligonucleotide" are used interchangeably to refer to a polymeric form of nucleotides of any length. Included are genes and gene fragments, mRNA,

tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA and RNA, nucleic acid probes, and primers. Also included are nucleotide analogs, including but not limited to thiol-derivatized nucleosides (U.S. Patent 5,578,718), oligonucleotides with modified backbones (U.S. Patent Nos. 5,541,307 and 5,378,825), and peptide nucleic acids (U.S. Patent No. 5,786,461). The term polynucleotide, as used in this disclosure, refers interchangeably to double- and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention that is a polynucleotide encompasses both a double-stranded form, and each of the two complementary single-stranded forms known or predicted to make up the double-stranded form.

Polynucleotide sequences are said to be in a "non-natural arrangement" when they are joined together or interposed with another sequence in an arrangement not found in nature.

When comparison is made between polynucleotides for degree of identity, it is implicitly understood that complementary strands are easily generated, and the sense or antisense strand is selected or predicted that maximizes the degree of identity between the polynucleotides being compared. A computer program that can be used for finding homologous sequences is the BLAST algorithm (Example 1). For purposes of the present disclosure, percentage of sequence identity is calculated by first aligning the polynucleotide being examined with the reference counterpart, and then counting the number of residues shared between the sequences being compared as a percentage of the region under examination. No penalty is imposed for the presence of insertions or deletions, but insertions or deletions are permitted only where clearly required to readjust the alignment. The percentage is given in terms of residues in the sequence being examined that are identical to residues in the comparison or reference sequence. Particularly desirable polynucleotide sequences preserve the function of the prototype: depending on context, an ability to hybridize with a target sequence, the function of a polypeptide it may encode, or (for certain gene targeting vectors) the ability to facilitate homologous recombination or gene inactivation.

“Hybridization” refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding can occur by Watson-Crick base pairing, Hoogsteen binding, triplex formation, or complexing in any other sequence-specific manner. A hybridization reaction will, on occasion, be a step in a more extensive process, such as part of PCR amplification. Hybridization reactions can be performed under conditions of different “stringency”. Conditions that increase the stringency of a hybridization reaction are widely known (see e.g., Sambrook et al., *infra*). Examples of conditions in order of increasing stringency: incubation temperatures of 25°C, 37°C, 50°C, and 68°C; buffer concentrations of 10 x SSC, 6 x SSC, 1 x SSC, 0.1 x SSC (where SSC is 0.15 M NaCl and 15 mM citrate buffer, pH 7.2) and their equivalent using other buffer systems; formamide concentrations of 0%, 25%, 50%, and 75%; incubation times from 5 min to 24 h; 1, 2, or more washing steps; wash incubation times of 1, 5, or 15 min; and wash solutions of 6 x SSC, 1 x SSC, 0.1 x SSC, or deionized water. Typical conditions of high stringency for the binding of a probe of about 100 base pairs and above is a hybridization reaction at 65°C in 2 x SSC, followed by repeat washes at 0.1 x SSC — or the equivalent combination of solvent and temperature conditions for the particular nucleic acids being studied.

A “hybrid” of polynucleotides, or a “complex” formed between any two or more components in a biochemical reaction (such as antibody and antigen), refers to a duplex or higher-order complex that is sufficiently long-lasting to persist between its formation and subsequent detection.

A “control element” or “control sequence” is a nucleotide sequence involved in an interaction of molecules that contributes to the functional regulation of a polynucleotide, including replication, duplication, transcription, splicing, translation, or degradation of the polynucleotide.

“Operatively linked” refers to an operative relationship between genetic elements, in which the function of one element influences the function of another element. For example, an

expressible encoding sequence may be operatively linked to control elements such as promoters and enhancers that permit transcription, and control elements for translation such as initiation sequences, stop codons, and signals for polyadenylation.

“Heterologous” means derived from a genotypically distinct entity from that of the rest of the entity to which it is being compared. For example, a polynucleotide introduced by genetic engineering techniques into an animal of a different species is said to be a heterologous polynucleotide. A promoter removed from its native coding sequence and operatively linked to a coding sequence with which it is not naturally found linked is said to be a heterologous promoter.

The terms “polypeptide”, “peptide” and “protein” are used interchangeably in this disclosure to refer to polymers of amino acids of any length. The polymer may comprise modified amino acids, it may be linear or branched, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, and/or phosphorylation.

Percentage of sequence identity is calculated for polypeptides by first aligning the polypeptide being examined with the reference counterpart or prototype, and then counting the number of residues shared between the sequences being compared as a percentage of the region under examination. No penalty is imposed for the presence of insertions or deletions, but insertions or deletions are permitted only where clearly required to readjust the alignment. The percentage is given in terms of residues in the sequence being examined that are identical to residues in the comparison or reference sequence. Where substitutions are made, conservative substitutions (in which one amino acid is substituted by another with similar charge, size, hydrophobicity, or aromaticity) are typically better tolerated. Desirable sequences preserve the function of the prototype: for example, the enzymatic activity, the binding of specific substrates, and the binding of specific antibody as detectable in a standard competition inhibition immunoassay.

The term "antibody" as used in this disclosure refers to both polyclonal and monoclonal antibody. The ambit of the term deliberately encompasses not only intact immunoglobulin molecules, but also such fragments and genetically engineered derivatives of immunoglobulin molecules as may be prepared by techniques known in the art, and which
5 retains the binding specificity of the antigen binding site.

An "immunogenic" compound or composition is capable of stimulating production of a specific immunological response when administered to a suitable host, usually a mammal.

An "isolated" polynucleotide, polypeptide, protein, antibody, or other substance refers to a preparation of the substance which is enriched in relation to some of the other
10 components that may also be present in the environment where the substance or a similar substance is initially obtained or occurs naturally. Thus, for example, an isolated substance may be prepared by using a purification technique to enrich it from a source mixture. Enrichment can be measured on an absolute basis, such as weight per volume of solution, or it can be measured in relation to a second, potentially interfering substance present in the source
15 mixture. Enrichments by 2, 10, 100, and 1000 fold achieve improved degrees of purification. A substance can also be provided in an isolated state by a process of artificial assembly, such as by chemical synthesis or recombinant expression. An "isolated" cell is a cell that has been separated from the organism in which it was grown.

A polynucleotide used in a reaction, such as a probe used in a hybridization reaction or
20 a vector used in gene targeting is referred to as "specific" or "selective" if it hybridizes or reacts with the intended target more frequently, more rapidly, or with greater duration than it does with alternative substances. Similarly, a polypeptide is referred to as "specific" or "selective" if it binds an intended target, such as a ligand, hapten, substrate, antibody, or other polypeptide more frequently, more rapidly, or with greater duration than it does to alternative
25 substances. An antibody is referred to as "specific" or "selective" if it binds via at least one antigen recognition site to the intended target more frequently, more rapidly, or with greater duration than it does to alternative substances.

General Techniques

Unless otherwise noted, the practice of this invention can be carried out by employing standard techniques of genetic engineering, protein manipulation, and cell culture. Textbooks that describe standard laboratory techniques include “*Molecular Cloning: A Laboratory Manual*”, 2nd Ed. (Sambrook et al., 1989); “*Oligonucleotide Synthesis*” (M.J. Gait, ed., 1984); “*Animal Cell Culture*” (R.I. Freshney, ed., 1987); the series “*Methods in Enzymology*” (Academic Press, Inc.); “*Gene Transfer Vectors for Mammalian Cells*” (J.M. Miller & M.P. Calos, eds., 1987); “*Current Protocols in Molecular Biology*” and “*Short Protocols in Molecular Biology, 3rd Edition*” (F.M. Ausubel et al., eds., 1987 & 1995); and “*Recombinant DNA Methodology II*” (R. Wu ed., Academic Press 1995). Techniques used in raising, purifying and modifying antibodies, and the design and execution of immunoassays, are described in *Handbook of Experimental Immunology* (D.M. Weir & C.C. Blackwell, eds.); *The Immunoassay Handbook* (Stockton Press NY, 1994); and R. Masseyeff, W.H. Albert, and N.A. Staines, eds., *Methods of Immunological Analysis* (Weinheim: VCH Verlags GmbH, 1993).

Texts that describe reproductive techniques and embryo transfer in animals include “*Manual of the International Embryo Transfer Society: A procedural guide and general information for the use of embryo transfer technology emphasizing sanitary procedures*”, 3rd ed. (Stringfellow et al., Savoy, IL: International Embryo Transfer Society, Savoy IL); and “*Embryo transfer in farm animals: A review of techniques and applications*” (K.J. Betteridge, ed., Agriculture Canada Monographs No. 16, Ottawa, 1977).

Polynucleotides

The polynucleotides of this invention include those containing nucleotide sequences which are found within the $\alpha 1,3$ GT cDNA sequence, shown in SEQ. ID NO:1, or the genomic sequence and its 5' and 3' flanking regions, part of which is shown in SEQ. ID NOs:15 to 25.

Further sequence of the α 1,3GT gene can be obtained by employing standard sequencing techniques known in the art to the phage plasmids deposited in support of this application.

Also included in this invention are polynucleotides containing α 1,3GT-like sequence that is from naturally occurring allelic variants, synthetic variants, and homologs of α 1,3GT
5 with a percentage of residues identical to the α 1,3GT cDNA or gene sequence, determined as described above. It is understood that substitutions, insertions, and deletions can be accommodated within a polynucleotide sequence without departing from the spirit of this invention. In certain embodiments, the polynucleotide sequences are at least 80% , 90%, 95%, 98%, or 100% identical to one of the sequences exemplified in this disclosure; in order of
10 increasing preference. The length of consecutive residues in the identical or homologous sequence compared with the exemplary sequence can be at least about 15, 30, 50, 75, 100, 200 or 500 residues in order of increasing preference, up to the length of the entire clone, gene, or sequence.

Certain polynucleotides of this invention are distinct from polynucleotides already in
15 the hands of the public, including previously known α 1,3GT cDNA or genomic sequences from other species (e.g., SEQ. ID NO:3, 5, 7, 9 and 11), other glycosyl transferase cDNA and gene sequences, and matching fragments from other published sequence data that are fortuitously identical over the length of the fragment (for example, certain regions of SEQ. ID NO:13). A polynucleotide of this invention can be "distinct" from other polynucleotides
20 because of an internal sequence difference (a substitution, deletion, or insertion), or because it is defined to encompass additional sequence at either end. Also included in the invention are recombinant or synthetic polynucleotides in which an α 1,3GT-like sequence is linked to a heterologous sequence to form: for example, a heterologous promoter in an expression vector, or a selectable marker such as *neo* in a targeting vector.

Particular polynucleotides of this invention are useful for producing polypeptides of interest, as nucleotide probes and primers, and as targeting vectors for genetic knock-outs. Further description of the characteristics of such constructs is provided in a later section.

5 *Preparation:*

The polynucleotides of this invention can be prepared by any suitable technique in the art. Using the data provided in this disclosure or deduced from the deposited plasmids, sequences of less than ~50 base pairs are conveniently prepared by chemical synthesis, either through a commercial service or by a known synthetic method, such as the triester method or
10 the phosphite method. A suitable method is solid phase synthesis using mononucleoside phosphoramidite coupling units (Hirose et al., *Tetra. Lett.* 19:2449-2452, 1978; U.S. Patent No. 4,415,732).

For use in antisense therapy, polynucleotides can be prepared by chemistry that produces compounds suitable stable for the pharmaceutical preparation for which they are
15 intended. Non-limiting examples include thiol-derivatized nucleosides (U.S. Patent 5,578,718), oligonucleotides with modified backbones (U.S. Patent Nos. 5,541,307 and 5,378,825). Also of interest in the context of antisense constructs are peptide nucleic acids. Prototype PNAs have an achiral polyamide backbone consisting of N-(2-aminoethyl)glycine units, to which purine and pyrimidine bases are linked, for example, by way of a methylene
20 carbonyl linker. PNAs are nuclease and protease resistant, and the uncharged nature of the PNA oligomers enhances the stability of PNA-nucleotide duplexes, thereby blocking transcription or translation. Uptake into cells can be enhanced by conjugating to lipophilic groups incorporating into liposomes, and introducing an amino acid side chain into the PNA backbone. See Soomets et al., *Front. Biosci.* 4:D782, 1999; U.S. Patents 5,539,082,
25 5,766,855, 5,786,461, and International Patent Application WO 8/53801.

Polynucleotides of this invention can also be obtained by PCR amplification of a template with the desired sequence. Oligonucleotide primers spanning the desired sequence

are annealed to the template, elongated by a DNA polymerase, and then melted at higher temperature so that the template and elongated oligonucleotides dissociate. The cycle is repeated until the desired amount of amplified polynucleotide is obtained (U.S. Patent Nos. 4,683,195 and 4,683,202). Suitable templates depend on the nucleotide it is desired to obtain.

5 Certain polynucleotides of this invention can be obtained from the deposited plasmids. Polynucleotides transcribed into mRNA can be obtained from the cDNA of a suitable cell in the desired species or a close relative. Cells that express $\alpha 1,3$ GT include fibroblasts and endothelial cells. Intron sequences for $\alpha 1,3$ GT can be obtained from a genomic DNA library of the species of interest.

10 Production scale amounts of large polynucleotides are most conveniently obtained by inserting the desired sequence into a suitable cloning vector and reproducing the clone. Techniques for nucleotide cloning are given in Sambrook, Fritsch & Maniatis (supra) and in U.S. Patent No. 5,552,524. Exemplary cloning and expression methods are illustrated in Examples 1 and 2, below. Polynucleotides can be purified by standard techniques in nucleic
15 acid chemistry, such as phenol-chloroform extraction, agarose gel electrophoresis, and other techniques known in the art, adapted according to the source of the polynucleotide.

Use of the polynucleotides:

Polynucleotides of this invention can be used to identify $\alpha 1,3$ GT nucleotide sequences
20 in a sample of interest for research, diagnostic evaluation, or any other purpose. Generally, this will involve preparing a reaction mixture in which a sample suspected of containing an $\alpha 1,3$ GT-related sequence is contacted with a polynucleotide of this invention under conditions that permit the polynucleotide to hybridize specifically with the compound being tested for, detecting any stable hybrids that form, and correlating the hybrids with the
25 presence of a $\alpha 1,3$ GT related sequence in the sample. The formation of stable hybrids can be detected by any suitable method known in the art. For example, the probe sequence with a detectable label such as a radioisotope, a chromophore, or a hapten such as avidin to which an

signaling reagent can be attached. Alternatively, the reagent polynucleotide can be a primer for an amplification reaction in which the amount of product produced correlates with the formation of specific hybrids.

The specificity of the primer and stringency of hybridization conditions are both
5 chosen with a view to facilitating detection of sequences of interest, while diminishing false positive reactions. Thus, when it is important to distinguish between $\alpha 1,3$ GT sequences of different species, then stringency conditions should be high, and the reagent polynucleotide should be nearly identical to the sequence being tested for. Conditions can be determined empirically so that the reagent polynucleotide will hybridize with the $\alpha 1,3$ GT sequence being
10 tested for but not with $\alpha 1,3$ GT sequences from other species. In a more usual application, the question to be addressed is whether sample taken from an animal of a particular species expresses autologous $\alpha 1,3$ GT, or not.

For example, the polynucleotides of this invention can be used to determine whether a cell or tissue treated to inactivate the endogenous $\alpha 1,3$ GT gene expresses $\alpha 1,3$ GT at the
15 mRNA level. Thus, polynucleotides of this invention are used as probes in mRNA blots or as primers in reverse PCR to detect endogenous $\alpha 1,3$ GT species. False positives will not arise due to expression of $\alpha 1,3$ GT from another species, but could arise from cross-reactivity from another glycosyl transferase sharing homology with $\alpha 1,3$ GT, or with another expressed sequence with a fortuitous sequence match. Again, one of skill in the art will know how to
20 select the reagent sequence and hybridization conditions based on sequence information and empirical testing. Since the degree of sequence identity with other galactosyl transferases is typically less than 60%, the practitioner has more latitude in modifying the reagent sequence to enhance stability, sensitivity, or for any other purpose.

Polynucleotides of this invention can also be used to inhibit the transcription or
25 translation of $\alpha 1,3$ GT in target cells, particularly those of the sheep. Such polynucleotides can be in the form of antisense constructs, which in some embodiments bind to $\alpha 1,3$ GT

mRNA and prevent translation. Other polynucleotides of this invention are ribozymes having a substrate (α 1,3GT mRNA) binding portion, and an enzymatic portion with endonuclease activity that cleaves the substrate. The design and use of ribozymes is described in U.S. Patent Nos. 4,987,071, 5,766,942, 5,998,193, and 6,025,167. Particular use of α 1,3GT sequences for the inhibition of porcine α 1,3GT synthesis is outlined in Strahan et al. (Xenotransplantation 2:143, 1995). The effectiveness of transcription inhibitors can be determined by transfecting a cell expressing α 1,3GT with a test compound, and measuring any alteration of expression by the cell — either at the level of mRNA expression (e.g., by quantitative mRNA blotting or reverse PCR), at the level of protein expression (e.g., by immunoassay using anti- α 1,3GT), or at the level of Gal α (1,3)Gal expression (e.g., by binding of a specific antibody or a specific lectin).

Of particular interest are polynucleotide constructs comprising α 1,3GT sequence of this invention that can be used for altering an endogenous α 1,3GT gene. In general, such constructs have a region of at least about 200 base pairs and more typically at least about 1-kb that are at least about 95% identical to the genomic sequence of interest, to permit specific targeting. The construct will also incorporate a substitution, deletion, or insertion designed to modify the targeted gene.

Also included in this invention are polynucleotides that encode polypeptides of interest. Characteristics of the polypeptides of this invention are described in the section that follows. For polypeptides that are fragments of naturally occurring α 1,3GT, there will be a corresponding naturally occurring polynucleotide encoding sequence. Those skilled in the art will recognize that because of redundancies in the amino acid code, any polynucleotide that encodes a peptide of interest can be used in a translation system to produce the peptide. Except where otherwise required, all possible codon combinations that translate into the peptide sequence of interest are included in the scope of the invention.

The polynucleotides of this invention can be in the form of an expression vector, in which the encoding sequence is operatively linked to control elements for transcription and translation in a prokaryotic or eukaryotic host cell of interest. Further details of expression systems for in vitro peptide production are provided below.

5 Also contemplated in this invention are constructs for introducing a transgene into a eukaryotic cell, for purposes of expressing $\alpha 1,3$ GT, and potentially forming the Gal $\alpha(1,3)$ Gal determinant on cells that would not otherwise present it. Suitable promoters include the endogenous $\alpha 1,3$ GT promoter, predicted to be present in the $\alpha 1,3$ GT genome sequence upstream from the translation start site. Other suitable promoters include constitutive
10 promoters such as those for SV40 and CMV. J.H. White (Adv. Pharmacol. 40:339, 1997) describes modified steroid receptors and steroid-inducible promoters as genetic switches for gene therapy. Walther et al. (J Mol Med. 74:379, 1996) describe cell-type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting.

In particular embodiments, the transgene is inserted into the genome of an embryonic
15 cell (or a nucleus subsequently transferred to an embryonic cell). U.S. Patent No. 4,873,191 describes a process in which genetic material is introduced into a zygote so that it is genetically transformed, then transplanting the embryo into a female so that the embryo develops to term. International Patent Application WO 99/58703 reports a method of preparing transgenic sheep by microinjecting an expression system into a fertilized oosperm,
20 identifying embryonic cells using a nested PCR technique, and then transferring a multicellular embryo into a suitable host. U.S. Patent No. 5,700,671 reports a method for producing mammals with a transgene that encodes a heterologous glycosyltransferase. Other techniques useful in preparing transgenic animals can be found, for example, in U.S. Patent Nos. 4,736,666 5,741,957, and 5,942,435. Individuals with an expressible $\alpha 1,3$ GT transgene, will
25 not have naturally occurring antibodies against Gal $\alpha(1,3)$ Gal, and should accommodate a xenotransplant from other animals expressing $\alpha 1,3$ GT High $\alpha 1,3$ GT activity in a transgenic cell will also decrease the availability of N-acetyl lactosamine acceptor carbohydrate for other

glycosyltransferases using the same acceptor, shifting the balance of synthesized oligosaccharide structures away from the products of other transferases.

Polypeptides

5 The polypeptides of this invention include those that comprise amino acid sequences encoded within any of the polynucleotides of this invention, exemplified by SEQ. ID NO:2 and fragments thereof. Also included in this invention are polypeptides containing α 1,3GT-like sequence that is from naturally occurring allelic variants, synthetic variants, and homologs of α 1,3GT with a percentage of residues identical to the α 1,3GT protein, calculated as
10 described earlier.

It is understood that substitutions, insertions, and deletions can be accommodated within a protein sequence without departing from the spirit of this invention. Conservative substitutions are typically more tolerable, such as the substitution of charged amino acids with amino acids having the same charge, or substituting aromatic or lipophylic amino acids with
15 others having similar features. Certain peptides of this invention are at least 60%, 80% , 90%, 95%, or 100% identical to one of the sequences exemplified in this disclosure; in order of increasing preference. The length of the identical or homologous sequence compared with the prototype polypeptide can be about 7, 10, 15, 20, 30, 50 or 100 residues in order of increasing preference, up to the length of the entire protein.

20 Certain peptides of this invention are distinct from peptides already in the hands of the public, including previously known α 1,3GT proteins and non-functional homologs from other species (e.g., SEQ. ID NOs:4, 6, 8, 10, and 12), and other glycosyl transferases, such as the human A and B blood group transferases. A polypeptide of this invention can be “distinct” from other polypeptides because of an internal sequence difference (a substitution,
25 deletion, or insertion), or because it is defined to encompass additional sequence at either end. Also included in the invention are artificially engineered fusion proteins in which a α 1,3GT-like sequence is linked to a heterologous sequence which modulates α 1,3GT activity, provides

a complementary function, acts as a tag for purposes of labeling or affinity purification, or has any other desirable purpose.

Particular peptides of this invention are useful for their galactose transferase activity, for drug screening, and for raising specific antibody, as described below. mRNA splice
5 variants of mouse $\alpha 1,3$ GT have been observed that omit Exons 5 and 6, and may still produce functional enzyme. If the ovine $\alpha 1,3$ GT is analogous, then the catalytic activity probably resides somewhere else in the molecule. It is predicted that the catalytic activity of $\alpha 1,3$ GT resides further towards the $-COOH$ terminus, probably at least partly in Exon 9.

10 *Preparation:*

Short polypeptides of this invention can be prepared by solid-phase chemical synthesis. The principles of solid phase chemical synthesis can be found in Dugas & Penney, Bioorganic Chemistry, Springer-Verlag NY pp 54-92 (1981), and U.S. Patent No. 4,493,795. Automated solid-phase peptide synthesis can be performed using devices such as a PE-
15 Applied Biosystems 430A peptide synthesizer (commercially available from Applied Biosystems, Foster City CA).

Longer polypeptides are conveniently obtained by translation in an in vitro translation system, or by expression in a suitable host cell. To produce an expression vector, a polynucleotide encoding the desired polypeptide is operably linked to control elements for
20 transcription and translation, and then transfected into a suitable host cell. Expression may be effected in prokaryotes such as E. coli (ATCC Accession No. 31446 or 27325), eukaryotic microorganisms such as the yeast *Saccharomyces cerevisiae*, or higher eukaryotes, such as insect or mammalian cells. Control elements such as the promoter are chosen to permit translation at an acceptable rate under desired conditions. A number of expression systems
25 suitable for producing the peptides of this invention are described in U.S. Patent No. 5,552,524. Expression cloning is available from such commercial services as Lark Technologies, Houston TX.

Following production, the protein is typically purified from the producing host cell by standard methods in protein chemistry in an appropriate combination, which may include ion exchange chromatography, affinity chromatography, and HPLC. Expression products are optionally produced with a sequence tag to facilitate affinity purification, which can
5 subsequently be removed by proteolytic cleavage.

Use of the polypeptides:

Polypeptides of this invention can be used for a number of worthwhile purposes, including but not limited to the production of Gal α (1,3)Gal-containing synthetic
10 oligosaccharides, for drug screening, and for production of antibody.

At least three activities are present in the native α 1,3GT: binding of the substrate UDP-gal, binding of the acceptor oligosaccharide N-acetyl lactosamine, and catalytic activity whereby the acceptor oligosaccharide is galactosylated. The binding site for each acceptor can be determined by contacting a test fragment or homolog with the substrate, or with a
15 competitive inhibitor that would be expected to bind with higher affinity, and determining whether a complex forms by a suitable separation technique, such as HPLC, or by an equilibrium quantitation technique, such as microchip analysis, which will better detect low-affinity reactions.

The site of catalytic activity can be determined by contacting the test peptide with
20 both UDP-galactose and acceptor oligosaccharide, and measuring any Gal α (1,3)Gal formed, for example, by immunoassay. Optionally, a systematic approach can be used to determine functional regions and homologs of α 1,3GT according to any of these assays. For example, the assay system is confirmed on the native α 1,3GT structure; then a series of nested fragments is tested to determine the minimum fragment that provides the same activity.
25 Similarly, substitutions can be introduced into the sequence until the activity is ablated, thereby determining what residues are critical. Henion et al. (Glycobiology 4:193, 1994)

characterized the minimal size for catalytically active α 1,3GT in New World monkeys, finding that ~68 amino acids could be removed from the N-terminal end before losing activity, while removal of only ~3 amino acids from the C-terminal end resulted in loss of activity.

Native α 1,3GT, and fragments and homologs that preserve substrate binding or catalytic activity, can be used to screen for activity inhibitors and enhancers. For example, a reaction mixture can be prepared containing UDP-galactose, a carbohydrate acceptor, a peptide having α 1,3GT activity, and a test compound. The rate of formation of Gal α (1,3)Gal is then measured. When compared to a reaction mixture not containing the test compound, a decrease in activity correlates with inhibitory capacity of the test compound, while an increase in activity correlates with augmentation capacity.

Native α 1,3GT, and fragments and homologs with α 1,3GT activity are also of interest for the artificial production of complex oligosaccharides containing a Gal α (1,3)Gal determinant, or which build upon the Gal α (1,3)Gal linkage. Such structures may be employed for any worthwhile purpose. For example, oligosaccharides that terminate in Gal α (1,3)Gal are of interest for use in the context of minimizing a rejection reaction in an individual xenotransplanted with a Gal α (1,3)Gal-expressing antigen. Substances containing a high density of the determinant can be used as an adsorbant to remove naturally occurring anti-Gal α (1,3)Gal antibodies from plasma by ex vivo recirculation, or by adsorption in situ (see WO 98/42750). Certain Gal α (1,3)Gal polymers, built into structures that have T-cell inhibitory epitopes, are proposed as immunosuppressants for the natural antibody against Gal α (1,3)Gal. Catalytic α 1,3GT peptides can optionally be adapted with amino acid additions, deletions, or substitutions for any worthwhile purpose, such as to improve stability or modify the specificity of the transferase in any way that is desirable.

Peptides of this invention are also of interest for the preparation and testing of antibodies against α 1,3GT. A polyclonal antiserum raised against intact α 1,3GT can be screened to map immunogenic portions of the primary sequence. To do this, sequential

peptides about 12 residues long are synthesized that cover the entire protein (SEQ. ID NO:2), and overlapping by about 8 residues. The peptides can be prepared on a nylon membrane support by standard F-Moc chemistry, using a SPOTS™ kit from Genosys according to manufacturer's directions. Prepared membranes are overlaid with the antiserum, washed, and overlaid with β -galactosidase conjugated anti-immunoglobulin. Positive staining identifies antigenic regions, which, in an appropriate context, may themselves be immunogenic. There will also be antibodies that span different parts of the primary structure, or which rely on a conformational component not displayed in smaller peptides.

Suitable methods for raising and testing α 1,3GT antibodies are described in the following section.

Antibodies

Antibody molecules of this invention include those that are specific for any novel peptide encompassed in this disclosure. These antibodies are useful for a number of purposes, including assaying for the expression of α 1,3GT, and purification of α 1,3GT peptides by affinity purification.

Polyclonal antibodies can be prepared by injecting a vertebrate with a polypeptide of this invention in an immunogenic form. If needed, immunogenicity of a polypeptide can be enhanced by linking to a carrier such as KLH, or combining with an adjuvant, such as Freund's adjuvant. Typically, a priming injection is followed by a booster injection is after about 4 weeks, and antiserum is harvested a week later. If desired, the specific antibody activity can be further purified by a combination of techniques, which may include Protein-A chromatography, ammonium sulfate precipitation, ion exchange chromatography, HPLC, and immunoaffinity chromatography using the immunizing polypeptide coupled to a solid support. Antibody fragments and other derivatives can be prepared by standard immunochemical methods, such as subjecting the antibody to cleavage with enzymes such as papain, pepsin, or trypsin.

Any unwanted cross-reactivity can be removed by treating the polyclonal antibody mixture with adsorbants made of those antigens attached to a solid phase, and collecting the unbound fraction. Contaminating activity against other transferases of the same species, or against $\alpha 1,3$ GT from other species, can all be removed by this technique if such cross-reactivity would interfere with the intended use of the antibody. Specificity of the original antisera can be improved to start with, by immunizing with peptide fragments of $\alpha 1,3$ GT that are substantially distinct from the equivalent region of the homologous protein.

Production of monoclonal antibodies is described in such standard references as Harrow & Lane (1988), U.S. Patent Nos. 4,491,632, 4,472,500 and 4,444,887, and *Methods in Enzymology* 73B:3 (1981). Briefly, a mammal is immunized as described above, and antibody-producing cells (usually splenocytes) are harvested. Cells are immortalized, for example, by fusion with a non-producing myeloma, transfecting with Epstein Barr Virus, or transforming with oncogenic DNA. The treated cells are cloned and cultured, and the clones are selected that produce antibody of the desired specificity.

Other methods of obtaining specific antibody molecules (optimally in the form of single-chain variable regions) involve contacting a library of immunocompetent cells or viral particles with the target antigen, and growing out positively selected clones. Immunocompetent phage can be constructed to express immunoglobulin variable region segments on their surface. See Marks et al., *New Eng. J. Med.* 335:730, 1996, International Patent Applications WO 94/13804, WO 92/01047, WO 90/02809, and McGuinness et al., *Nature Biotechnol.* 14:1449, 1996.

The antibodies of this invention are can be used in immunoassays to detect or quantitate any of the polypeptides of this invention, including $\alpha 1,3$ GT. For example, it may be desirable to measure $\alpha 1,3$ GT in a biological sample to determine whether an individual expresses $\alpha 1,3$ GT (and hence the Gal $\alpha 1,3$ Gal epitope), or whether a cell has been successfully treated to inactivate the $\alpha 1,3$ GT gene. It may also be desirable to measure

α 1,3GT in a biological sample taken from an individual suspected of having a disease that is correlated with altered expression of α 1,3GT,

General techniques of immunoassay can be found in "The Immunoassay Handbook", Stockton Press NY, 1994; and "Methods of Immunological Analysis", Weinheim: VCH

5 Verlags gesellschaft mbH, 1993). The antibody is combined with a test sample under conditions where the antibody will bind specifically to any modulator that might be present, but not any other proteins liable to be in the sample. The complex formed can be measured in situ (U.S. Patent Nos. 4,208,479 and 4,708,929), or by physically separating it from unreacted reagents (U.S. Patent No. 3,646,346). Separation assays typically involve labeled
10 α 1,3GT reagent (competition assay), or labeled antibody (sandwich assay) to facilitate detection and quantitation of the complex. Suitable labels are radioisotopes such as ^{125}I , enzymes such as β -galactosidase, and fluorescent labels such as fluorescein. Antibodies of this invention can also be used to detect α 1,3GT in tissue sections by such techniques as immunohistology or flow cytometry. The antibody is contacted with the tissue, unreacted
15 antibody is washed away, and then bound antibody is detected — either directly, or by using a labeled anti-immunoglobulin reagent.

Assays of this nature can also be used in a competitive format to identify antibodies that bind to the same epitope on a target compound. In one such format, the reference antibody is labeled, and tested for binding to α 1,3GT or a related peptide under conditions
20 that permit specific antibody-peptide complexes to form. In parallel, the α 1,3GT peptide is first reacted with the test antibody, and the labeled reference antibody is added subsequently. The assay is read by separating free antibody from peptide-antibody complexes (e.g., by gel filtration or precipitation), and then determining the proportion of label associated with the complexes. If the bound proportion decreases as a result of preincubating with the test
25 antibody, then the test antibody and the reference antibody share overlapping or conformationally related epitopes. Epitope sharing can also be evaluated by mapping the

binding site of each antibody using peptide fragments, described earlier. Antibodies can also be screened to identify those with catalytic inhibitory capacity, according to the inhibition screening assay described in the preceding section

5 Inactivation of the $\alpha(1,3)$ Galactosyltransferase gene

This invention provides cells and cell nuclei, in which a preexisting gene for $\alpha 1,3$ GT has been inactivated. This means that synthesis of the $\text{Gal}\alpha(1,3)\text{Gal}$ epitope by at least one $\alpha 1,3$ GT allele has been suppressed.

10 A gene for $\alpha 1,3$ GT can be inactivated by any one of a number of transformations. For example, the gene may be adapted so that no mRNA transcript is produced; for example, by deleting or altering a transcription control element, such as a promoter or a transcription start sequence. Alternatively, the gene may be adapted so that any mRNA that is produced is not transcribable into the protein product. This can be effected, for example, by deleting or
15 altering a translation control element, such as a ribosomal binding site or a translation initiation codon. Alternatively, the gene may be adapted so that any protein that is produced lacks the essential features of a glycosyl transferase. For example, the encoding region can be interrupted with stop codons, the encoding region can be placed out-of-phase, or critical portions of the protein may be missing, such as a structural component or a signal peptide for secretion. In a related alternative, the gene may be adapted so that the protein product lacks
20 the specificity of $\alpha 1,3$ GT — either because the catalytic site is removed, or because substrate binding specificity has been sufficiently altered so that the enzyme is incapable of synthesizing the $\text{Gal}\alpha(1,3)\text{Gal}$ linkage.

A principle method for inactivating the $\alpha 1,3$ GT gene is to actually change the genetic structure, making the inactivation inheritable by progeny of the cell. Changes of this nature
25 can be effected by disrupting the genome with an integrating vector or mutating the genome by chemical or biological treatment. Treated cells are then cloned, and tested to determine if

α 1,3GT expression has been affected. Suitable means of testing include determination of mRNA expression by probe or amplification based assays, or determination of α 1,3GT protein expression by immunoassay of cell lysates or immunohistochemical staining of fixed cells.

5 Efficient targeting of the α 1,3GT gene generally requires a targeting vector, comprising nucleotide sequence identical or nearly identical to a portion of the gene of interest, linked to another structure capable of introducing the alteration. One such method uses homologous recombination, in which a DNA vector comprising homologous regions recombines at the targeted site, substituting its DNA sequence for that of the target. Cloned cells that have been
10 selectively targeted can be identified by PCR amplification of a sequence exclusive to the targeting vector, restriction analysis of the recombination site, or expression phenotype.

Generally it is more convenient to include a selectable marker in the targeting construct, so that targeted cells can rapidly be separated from untargeted cells. U.S. Patent 5,614,396 describes a method for obtaining a cell containing a desired sequence in the cell's genome, by
15 using a targeting vector having two regions homologous to the targeting sequence, flanking the sequence which is to be inserted, and also having a selectable marker. The DNA undergoes homologous recombination at the target site, and recombined cells are recovered under selective culture conditions. Positive selection markers include the *neo* gene, selectable using G418 or kanamycin; the *hyg* gene, selectable using hygomycin the *gpt* gene, selectable using xanthine,
20 and hypoxanthine-phosphoribosyltransferase (HPRT), selectable using hypoxanthine. Negative selection markers include thymidine kinase(TK), selectable using acyclovir or gancyclovir; and HPRT, selectable using 6-thioguanine; and cytosine deaminase, selectable using 5-fluoro-cytosine. Markers can also be labels like green fluorescent protein or β -galactosidase, which permit clones of targeted cells to be identified and selected. In certain
25 contexts, it is advantageous to use markers with reduced potential for antigenicity in humans. For example, U.S. Patent No. 6,020,192 illustrates a humanized green fluorescent protein.

For effecting homologous recombination, U.S. Patent Nos. 5,464,764 and 5,631,153 describe a double-selection strategy, in which two sequences homologous to the gene target flank a positive selection marker, and a negative selection marker is attached to the 3' terminal of the second flanking region. Homologous integration retains the positive selection marker, but eliminates the negative selection marker, whereas random integration usually retains both markers. Thus, by screening for both markers sequentially or together, cells that have been correctly targeted will be positively selected, and those that have been incorrectly targeted are selected out. U.S. Patent 5,789,215 reports the use of homologous recombination targeting vectors for modifying the cell genome of mouse embryonic stem cells. Other information of interest for homologous recombination targeting can be found in U.S. Patent Nos. 5,589,369 and 5,776,774.

Example 3 describes illustrative targeting vectors according to this invention. They are capable of inactivating the sheep $\alpha 1,3$ GT gene by eliminating part of the protein coding region via homologous recombination. The vectors comprise flanking regions identical to the targeted $\alpha 1,3$ GT sequence, one side being about 1-kb, the other being at least 1 or 2-kb, in either order. In between the flanking regions is a selectable marker such as *neo*, designed to replace one of the Exons in the $\alpha 1,3$ GT coding sequence. The selectable marker genes are not provided with their own promoter, and require continued translation through the upstream $\alpha 1,3$ GT sequence in order to be expressed. This helps the marker select for properly integrated vector, because vector inserted at a random site will probably not link the marker gene to a suitable promoter, and resistance to the selector drug will not be conferred. This strategy is particularly effective for cell types that normally express a high level of $\alpha 1,3$ GT and the Gal $\alpha(1,3)$ Gal epitope. In these cells, the $\alpha 1,3$ GT promoter will be highly active and the drug resistance marker will be strongly expressed. Thus, a higher concentration of selector drug can be used to select out cells that have the vector inserted elsewhere.

Vectors p0054, p0079, and p0063 (Figures 9, 10, and 11) are targeted to eliminate Exon 4, which contains the $\alpha 1,3$ GT translation start codon. Vector p0078 (Figure 12) is targeted to eliminate Exon 8, and contains an additional feature of interest. The sequence replacing Exon 8 has an encoding region for a poly-glycine linker, followed by the *neo* gene.

5 Since *neo* is translated within the sequence of the rest of the $\alpha 1,3$ GT protein, the linker should improve the flexibility or accessibility of the *neo* gene product and enhance the neomycin resistance conferred. Vector p0047 and p0046 are designed to replace Exon 9, which is thought to contain at least part of the $\alpha 1,3$ GT catalytic site.

10 All these vectors, and other designs that would be effective in inactivating ovine $\alpha 1,3$ GT, can be constructed using the sequence data provided in this disclosure and optionally the deposited phage plasmids, according to standard protocols of genetic engineering. Also suitable are insertion vectors (the general structure of which is reported, for example, by Hasty et al., Mol. Cell Biol. 11: 4509, 1991). In this case, homologous recombination results in insertion of the linearized vector sequence, thereby disrupting the gene. Also suitable are
15 shorter oligonucleotides, such as chimeroplasts (A. Cole-Strauss et al., Science 273:1386, 1996), which can direct single base pair changes to a specific gene sequence.

The targeting vectors can be used to inactivate $\alpha 1,3$ GT in sheep cells, or the cells of other phylogenetically related species that have sufficient identity through the targeted area that homologous recombination will take place. Of particular interest are ruminants of the
20 subfamily caprinae, especially ovids and pseudois, exemplified by the sheep of any domestic breed.

Example 4 provides a non-limiting illustration of the use of such vectors. A suitable cell line is combined with the vectors in a culture medium, and the vectors are introduced into the cell. In the illustration, the vectors are introduced by optimized conditions of
25 electroporation. The cells are then cultured for a time in an appropriate medium for maintenance of the cells, during which time the recombination event should occur. The cells

are then subjected to culture conditions that permit outgrowth of cells bearing the selectable marker as a result of successful recombination.

Those skilled in the art will recognize that other means of introducing the targeting vector into the cell are also acceptable. For example, International Patent Application

5 WO 29/48005 reports a strategy for modifying a gene in a cell by introducing a parvoviral vector comprising a sequence substantially identical to the target except for the modification being introduced, and permitting the viral vector to effect homologous recombination, thereby modifying the gene sequence. Figure 12 shows targeting constructs based on vectors p0054 and p0079, modified to ~4-kb, so that they will fit within the genome of adeno-associated
10 virus. U.S. Patent No. 5,932,241 describes cationic lipid DNA complexes for gene targeting. U.S. Patent No. 5,804,413 describes herpes simplex virus strains for gene transfer.

After genetic manipulation has been completed and altered cells have been selected, inactivation of the $\alpha 1,3$ GT gene can be confirmed by suitable testing. Assays for expression of $\alpha 1,3$ GT at the mRNA level and at the protein level have already been described. The
15 nature of the genetic alteration can be determined by PCR amplification using primers bracketing the targeted recombination site, and characterizing the amplification product, or by Southern analysis. If the targeting vector contains a unique sequence, then correct integration can be confirmed using a primer specific for the inserted sequence and a primer specific for neighboring $\alpha 1,3$ GT sequence. Sequence information disclosed in this application relating to
20 $\alpha 1,3$ GT unencoding and intron regions (SEQ. ID NOs:15-25) can be used to develop such primers. As illustrated in Example 4, production of amplification product of the predicted size confirms correct integration.

Animals and cells that are homozygous for inactivated $\alpha(1,3)$ Galactosyltransferase

25 Certain aspects of this invention relate to animals and tissues in which the $\alpha 1,3$ GT gene of at least one haplotype is inactivated. To produce such animals, a cell with this

characteristic is provided that has the potential to develop into a fertile embryo. In mice, it is possible to inactivate $\alpha 1,3$ GT in embryonic stem cells, inject the cells into a blastocyst in culture, and then engraft the blastocyst into a female which acts as a surrogate to bring the genetically altered embryo to term (U.S. Patent No. 5,849,991).

5 In ungulate animals, a different procedure has been developed. First, an $\alpha 1,3$ GT gene is inactivated in cultured cells, and then the nucleus of such donor cells is transferred into an enucleated recipient cell, such as an oocyte or other pluripotent cell, that is capable of developing into a fertile embryo after the nucleus has been transferred.

10 International Patent Application WO 97/07669 (Roslin Institute) describes quiescent cell populations for nuclear transfer. International Patent Application WO 97/07668 (Roslin Institute) describes inactivated oocytes as cytoplasm recipients for nuclear transfer. International Patent Application WO 99/01164 (University of Massachusetts) relates to cloning pigs using donor nuclei from differentiated cells. U.S. Patent No. 5,994,619 (University of Massachusetts) reports production of chimeric bovine or porcine animals using
15 cultured inner cell mass cells. U.S. Patent No. 6,011,197 (Infigen) relates to a method for cloning bovines, by reprogramming non-embryonic bovine cells using leukocyte inhibitory factor (LIF) and fibroblast growth factor (FGF), then transferring the nucleus into an enucleated oocyte. International Patent Application WO 99/21415 (Stem Cell Sciences) reports nuclear transfer for production of transgenic animal embryos. Loi et al. (Reprod. Nutr.
20 Dev. 38:615, 1998) discuss embryo transfer and related technologies in sheep reproduction. Wells et al. (Biol. Reprod. 57:385, 1997) report production of cloned lambs from an established embryonic cell line. Liu et al. (Mol. Reprod. Dev. 47:255, 1997) discuss the effect of cell cycle coordination between nucleus and cytoplasm and the use of in vitro matured oocytes in nuclear transfer in sheep embryos. Campbell et al. (Nature 380:65, 1996) report
25 sheep cloned by nuclear transfer from an established cell line.

In the practice of this invention, donor cells are typically nucleated cells of the desired species that can be maintained easily in culture conditions. An illustrative example is a

primary fibroblast line, although other types of cells (such as a stable endothelial cell culture) may also be suitable. For the production of $\alpha 1,3$ GT inactivated sheep, suitable donor cells can be taken from fetal tissue of the Black Welsh Mountain or Finn Dorset line. The selected breed need not be isogenic for the particular vector constructs illustrated in this disclosure, because there will be sufficient identity within the $\alpha 1,3$ GT gene to be successfully targeted. Primary fibroblast cultures can readily produced from fetuses collected at about 35 days of gestation, and subjected to a mild trypsin/EDTA solution. Cells are then introduced with the targeting vector, cultured long enough to permit genetic alteration to take place, and then selected for proper recombination, as described in the previous section.

Nuclear transfer is particularly effective if the nucleus of the donor cell is quiescent, which can be achieved by culturing the donor cell in a serum-free medium (WO 97/07669). In an exemplary method, the nucleus of a donor cell is transferred into an oocyte that is arrested in the metaphase of the second meiotic division, and subsequently activating the reconstituted cell. Briefly, unfertilized metaphase II oocytes are collected as follows: Female animals are synchronized using progestagen sponges for ~14 days, and induced to superovulate with single injections of follicle-stimulating hormone on two successive days. Ovulation is induced with a suitable dose of gonadotrophin-releasing hormone or an analog thereof (e.g., ~8 mg GnRH Receptal™, Hoechst, UK) on the following day. The oocytes are recovered by flushing from the oviduct one day later, washed, and enucleated by treating with cytochalasin B and aspirating the nucleus using a glass pipette. Enucleated oocytes are then placed into contact with a single cell that acts as the nucleus donor.

Fusion of the donor nucleus into the enucleated recipient cell is effected by placing the couplet in a fusion chamber and aligning it between the electrodes. Electrical pulses are then applied to induce fusion, typically a low-voltage AC pulse for several seconds, followed by a plurality of very short high-voltage DC pulses. Following an incubation period, activation is induced by application of an additional electrical pulse. The reconstructed zygote is then

cultured for a time before engrafting into a surrogate female. Further details and alternative procedures are described in the patent publications cited above.

Estrus in the surrogate female is typically synchronized artificially using a suitable combination of inducing agents. Cameron et al. (Aust. Vet. J. 66:314, 1989) discuss
5 synchronization methods and other practical aspects for commercial embryo transfer in pigs. Blum-Reckow et al. (J. Anim. Sci. 69:3335, 1991) report experiments relating to transfer of pig embryos after long-term in vitro culture. Replacing medium every 12 h during culture improved survival, and pregnancy rate improved if the sexual cycle of recipients was 24 h behind that of the donor.

10 The embryos are introduced into the uterus of the recipient female using any suitable technique, including devices adapted for the purpose, or appropriate surgical methods. For example, U.S. Patent No. 4,326,505 describes surgical procedures for embryo transplants in animals, in which the uterine horn is positioned in the peritoneal cavity proximate to the vaginal wall, a cannula is inserted through the vaginal wall and into the uterine horn, and the
15 embryo is introduced through the cannula. Non-surgical methods include using a suitable device to manipulate the injection port through the folds of the cervix to the bifurcation of the uterus. For example, devices and techniques for porcine non-surgical embryo transfer are reported by Li et al. (J. Anim. Sci. 74:2263, 1996). Wallenhorst et al. (J. Anim. Sci. 77:2327, 1999) describe the effect of transferring pig embryos to different uterine sites.

20 The expression of the Gal α (1,3)Gal epitope is autosomal dominant, and prevention of Gal α (1,3)Gal mediated xenograft rejection is improved with homozygous inactivation of α 1,3GT. One option is to select cells for production of embryos that are already homozygously inactivated. For example, the α 1,3GT gene can be targeted for homologous recombination with a construct that incorporates a drug resistance gene, such as *neo*. Targeted
25 cells are first cultured with neomycin at a level that will select for recombination of at least one haplotype. Selected cells are then cultured at a higher level of neomycin to select double recombinants (U.S. Patent No. 5,589,369). In another example, the α 1,3GT gene is targeted

simultaneously or sequentially with two different constructs for the same region, each having a different drug resistance gene. The Exon 4 targeting vectors p0054 (*neo*) (Figure 9) and p0063 (*pac*) (Figure 11) can be used in this capacity. Cells are then selected by culturing with the two selection drugs simultaneously or sequentially to select double recombinants. In yet another example, targeting vectors are used that delete part of the α 1,3GT gene sequence, targeted cells are cloned, and their genomic DNA is subjected to Southern or PCR analysis to determine whether the sequence has been deleted from both haplotypes. In a further example, the vectors are used to target cells that actively synthesize and present on the plasma membrane a high density of Gal α (1,3)Gal (such as endothelial cells). After targeting, the cells are subject to multiple rounds of proliferation and selection using specific antibody to the determinant, for example, by flow cytometry or complement-mediated lysis. The cell population surviving repeated selection will be incapable of synthesizing the xenogeneic oligosaccharide, and will be enriched for cells having homozygous inactivation of α 1,3GT.

Animals homozygous for inactivated α 1,3GT can also be obtained by first producing animals heterozygous for inactivated α 1,3GT according to this disclosure — and then mating the heterozygous knockouts once they reach sexual maturity, to obtain progeny that have inherited inactivated α 1,3GT from both parents. Alternatively, cells from a heterozygous knockout can be targeted with an inactivation vector according to this invention to inactivate α 1,3GT on the other haplotype, and used to produce an embryo with homozygously inactivated α 1,3GT.

Tissue devoid of Gal α (1,3)Gal determinants

Tissue samples can be tested to determine whether α 1,3GT has been successfully inactivated. As described elsewhere in this disclosure, changes to the α 1,3GT gene can be determined by Southern analysis or PCR amplification of genomic DNA; mRNA expression can be determined by Northern analysis or reverse PCR, and protein expression can be

determined by immunoassay or immunohistochemistry. Elimination of mRNA or protein expression correlates with homozygous inactivation of $\alpha 1,3$ GT, whereas quantitative reduction in mRNA or protein expression correlates with inactivation of $\alpha 1,3$ GT on one haplotype. If inactivation of $\alpha 1,3$ GT has been effected at the level of protein catalytic activity, then mRNA and protein levels may appear normal.

A useful test for successful $\alpha 1,3$ GT inactivation is expression of the $\text{Gal}\alpha(1,3)\text{Gal}$ epitope. This can be determined using an antibody or lectin specific for $\text{Gal}\alpha(1,3)\text{Gal}$. Since it is a self-antigen in most mammals, specific antibodies cannot easily be obtained by immunizing the usual source animals. However, purified antibody can be obtained from pooled human serum by adsorbing on an affinity column of Synsorb 115 (ChembioMed, Alberta, Canada) or D(+) melibiose (Sigma). An alternative is the "IB4" lectin from *Bandeiraea (Griffonia) simplicifolia* (Sigma Cat. L 3019) which is specific for α -D-galactosyl residues (Hayes et al., J Biol Chem. 25:1904, 1976), and binds both the $\text{Gal}\alpha(1,3)\text{Gal}$ epitope, and B blood group substance. In most mammals, $\text{Gal}\alpha(1,3)\text{Gal}$ is expressed on red blood cells, and can be detected in a simple agglutination reaction. The antibody or lectin can be used to stain for $\text{Gal}\alpha(1,3)\text{Gal}$ in fixed tissue or in flow cytometry analysis.

Density of $\text{Gal}\alpha(1,3)\text{Gal}$ in a particular tissue of interest can be quantitated using a complement lysis assay. Briefly, tissue cells are suspended (by treating with trypsin or collagenase, if necessary), washed, incubated in a medium containing ^{51}Cr for a few hours to incorporate the label, and then washed again. The labeled targets are then combined with diluted human serum as a source of both antibody and complement, and then incubated for several hours at 37°C . Release of the label correlates with density of $\text{Gal}\alpha(1,3)\text{Gal}$ on the surface of the target cells. For further details of assays for $\alpha 1,3$ GT inactivation and $\text{Gal}\alpha(1,3)\text{Gal}$ determination, the reader can consult U.S. Patent No. 5,849,991.

Once an animal has been produced with homozygously inactivated $\alpha 1,3$ GT, there should be no synthesis of Gal $\alpha(1,3)$ Gal by the $\alpha 1,3$ GT gene, and the phenotype should breed true. The animal or any progeny bearing the same phenotype can be used as a source of any tissue type that is desired for xenotransplantation. Possible harvest tissue includes but is not limited to any of the following: whole organs, such as kidney, liver, heart, lung, eyes, and pancreas; solid tissue, such as skin, cartilage, pancreatic islets, and vasculature of various types; and cell suspensions, such as progenitor cells for regeneration of neural tissue, hepatocytes, or other cell types.

The following examples provided as further non-limiting illustrations of particular embodiments of the invention.

EXAMPLES

Example 1: Cloning and characterization of the ovine $\alpha(1,3)$ -galactosyl transferase cDNA

The cDNA encoding ovine $\alpha(1,3)$ -galactosyl transferase (GT) was cloned using the reverse transcriptase polymerase chain reaction (PCR) amplification technique.

Two oligonucleotide primers were prepared. The sense oligonucleotide, 698007 (5'-GAGAAAATAA TGAATGTCAA AGGA-3'; SEQ. ID NO:26), included 5' untranslated sequence and the first five codons that encode mature $\alpha 1,3$ GT. The antisense oligonucleotide, 698006 (5'-TGATAATCCC AGCAGTATTC-3'; SEQ. ID NO:27), encoded about amino acids 336 to 342. These primers were used in combination with a Titan rt. PCR kit (Boehringer Mannheim) and total RNA (TriPure™ RNA extraction kit, Boehringer Mannheim) from Black Welsh Mountain (BW) fetal fibroblasts.

The 1035bp PCR product was cloned into pCR-BluntII-TOPO vector (Invitrogen) and the resulting plasmid propagated by transforming TOP10 competent cells. One colony with plasmid containing the correct fragment was selected. Plasmid p0010 was isolated and

the partial cDNA insert sequenced. The final 75 nucleotides of the coding sequence were obtained from phage G (see Example 3), giving a complete sequence of 1110 base pairs.

The 5' untranslated region (UTR) of the ovine $\alpha 1,3$ GT gene was cloned by rapid amplification of cDNA ends (RACE) PCR. A 5' race kit (Boehringer Mannheim) was used in accordance with the manufacturer's instructions. Total RNA was isolated from Black Welsh Mountain fetal fibroblasts and a reverse transcriptase reaction carried out. An anchor of known sequence was linked to the 5' termini of the cDNA molecules produced. First round PCR was performed with sense (supplied) and antisense 798006 (5'-CTTGATGGGT TTATCCAGAA CA-3'; SEQ. ID NO:28) primers. Second round PCR product, produced with the same sense primer but a nested antisense primer (798005, 5'-CTGTGGATAT ATTCCCAAAA CAC-3'; SEQ. ID NO:29), was cloned into pCR-BluntII-TOPO vector. Colonies that contained plasmid with insert were selected. One clone was sequenced and extended the ovine sequence by 193bp into the 5' UTR (SEQ ID NO:14).

Figure 1 shows the nucleotide sequence of the cDNA (SEQ. ID NO:1). There are 193bp at the 5' end that are untranslated. Also shown is the 369 amino acid sequence of the predicted protein product (SEQ. ID NO:2). The encoding region is residues 194 to 1300 of SEQ. ID NO:1.

Figures 2 and 3 compare the polynucleotide and amino acid sequences with those of the bovine $\alpha 1,3$ GT (SEQ. ID NOs:3 and 4). Identical residues are marked below with an asterisk.

The sheep $\alpha 1,3$ GT encoding sequence and translation product were compared with SEQ. ID NOs 3-11 using version 2.0 of the BLASTN, BLASTP, and TBLASTN algorithms (National Center for Biotechnology Information; Altschul et al., Nucleic Acids Res. 25:3389, 1997). Comparison of ovine $\alpha 1,3$ GT protein encoding sequence across the whole length of the murine sequence (Jozaisse et al, 1992. J Biol Chem 267:5534-5541) and bovine sequence (Joziasse et al, 1989. J Biol. Chem 264:14290-14297) showed homologies of 78% or 95% respectively. A more detailed comparison is shown in Table 1.

TABLE 1: Comparison of Sheep α 1,3GT with other α 1,3GT sequences

Comparison with:		Sheep α 1,3GT residues matched	Percent identity in matched sequence
NUCLEOTIDES			
bovine α 1,3GT	SEQ. ID NO:3	194-1303	95 %
marmoset α 1,3GT	SEQ. ID NO:5	448-1303	87 %
pig α 1,3GT	SEQ. ID NO:7	503-1303	90 %
mouse α 1,3GT	SEQ. ID NO:9	657-1303	83 %
human α 1,3GT pseudogene	SEQ. ID NO:11	620-1303	87 %
AMINO ACIDS			
bovine α 1,3GT	SEQ. ID NO:4	1-369	94 %
marmoset α 1,3GT	SEQ. ID NO:6	1-369	82 %
pig α 1,3GT	SEQ. ID NO:8	1-369	82 %
mouse α 1,3GT	SEQ. ID NO:10	1-369	72 %
human α 1,3GT pseudogene	SEQ. ID NO:12	139-249	81 %

Example 2: Expression and Southern blot analysis of the Galactosyl Transferase gene

Based on the comparison of the ovine cDNA sequence with the genome and mouse sequence, predictions were made about the organization of the ovine α 1,3GT gene.

Hybridization probes for the α 1,3GT gene outside the coding region were designed as follows:

A partial cDNA probe, produced by excising a 1035bp fragment from plasmid p0010

(Example 1); an Exon 4 probe, produced by concatamerizing 95bp synthetic oligonucleotides

(sense 998003, antisense 998004; SEQ. ID NOs:30 and 31); a 700bp fragment spanning from Exon 6 to 7, derived by PCR from phage G (Example 3) using primers 898003

(5'-GGTGGTTTCC GAGATGGTTT AACAA-3'; SEQ. ID NO:32) and 898005

(5'-GGGTTGAACC AGTCCGATAG CTTA-3'; SEQ. ID NO:33); a 513bp fragment from

Exon 9, produced by PCR using primers 698001 (5'-TCCAGGATGC CTTTGATAGA G-3'; SEQ. ID NO:34) and 698006 (5'-TGATAATCCC AGCAGTATTC-3'; SEQ. ID NO:27). These probes were used for the analysis in this example, and for library screening (Example 3).

5 **Figure 4** shows Southern blot analysis to determine the copy number of $\alpha 1,3$ GT in sheep. Ovine genomic DNA was digested with ApaI, AseI, BamHI, BsmI, EcoRI or EcoRV, then transferred to nitrocellulose membrane, using standard techniques (Sambrook et al, 1989). Probing with Exon 4 or Exon 6-7 probes revealed a single band in each lane. The likelihood of achieving disruption of the ovine $\alpha 1,3$ GT gene using the targeting strategies in Example 3 is greater if the gene is transcribed and exists as a single copy in the genome.

10 **Figure 5** shows Northern blot analysis for gene expression. Northern analysis was performed using 8 μ g of Black Welsh Mountain (BW) fetal fibroblast-derived poly-A RNA, which was isolated using standard techniques (Sambrook et al, 1989). Probing with the $\alpha 1,3$ GT partial cDNA fragment revealed a single band of approximately 3-kb, similar to that previously reported in the mouse (Jozaisse et al, 1992. J Biol Chem 267:5534-5541).

15 Together, these data provide evidence that the $\alpha 1,3$ GT gene is single copy and is expressed in Black Welsh Mountain fetal fibroblasts.

Example 3: Construction of targeting vectors from genomic Galactosyl Transferase DNA

20 Construction of vectors to disrupt the $\alpha 1,3$ GT gene by homologous recombination requires isolation of genomic sequences, isogenic (or at least sufficiently identical) to sequences in the target cells. To facilitate this, genomic DNA was isolated from Black Welsh Mountain fetal fibroblasts and a λ DASHII phage library constructed. Briefly, Sau3A partially digested genomic DNA was dephosphorylated and ligated to compatible BamHI
25 vector arms (Stratagene). The ligation products were packaged to produce recombinant phage,

which were propagated on *spi* selective XL1-Blue-MRA(P2) bacterial cells. The resulting library had a complexity of 1.4×10^6 recombinants and was subsequently amplified once.

Using the $\alpha 1,3$ GT Exon-4, Exon-6-7 and Exon-9 probes described in Example 2, phage clones spanning these regions were isolated according to standard methods (Sambrook et al,
5 1989). Six useful clones were isolated.

Figure 6 shows the restriction map of the $\alpha 1,3$ GT gene, and the regions included in Phage $\alpha 1,3$ GT clones. The clones designated **B** and **D** contain the 5' UTR of the $\alpha 1,3$ GT gene and Exon 4, which contains the start codon. The clones designated **C** and **N** contain Exons 4, 5, 6 and 7. The clone **G** spans Exon 6, 7, 8 and 9. Clone **Q** contains part of Exon 9
10 and the 3' UTR. These phage DNAs reflect the endogenous $\alpha 1,3$ GT gene. They were characterized by inter-exon PCR, sequencing and restriction analysis combined with exon-specific probing.

Recombinant phage **B**, **C** and **G** have been deposited as a pooled sample, which can be separated using the oligonucleotide probes 1198001 (5'-GGGAGGAAGC
15 GAAGGTGCA-3'; SEQ. ID NO:35), 798006 (5'-CTTGATGGGT TTATCCAGAA CA-3'; SEQ. ID NO:28) and 698006 (5'-TGATAATCCC AGCAGTATTC-3'; SEQ. ID NO:27), that recognize 5'UTR, Exon 5 and Exon 9 sequence, respectively.

Figure 7 maps the sequenced intron regions of $\alpha 1,3$ GT to their positions in the gene. The areas numbered 1 to 9 in the figure correspond to SEQ. ID NOs:15, 16, 19, 20, 21, 22, 23,
20 24, and 25, respectively.

Figure 8 shows the position of exemplary targeting vectors designed for use in homologous recombination to disrupt gene expression by excising Exons 4 and 9. These and a number of other vectors are described below.

Figure 9 shows in more detail the promoterless targeting vector designated plasmid
25 p0054, directed towards Exon 4. The vector comprises two regions that are complementary to genomic sequence; a 1.2-kb 5' arm, which includes sequence from Intron 3 leading up to and

including the start codon of the $\alpha 1,3$ GT gene in Exon 4, and a ~9-kb 3' arm that initiates 1.5-kb into Intron 4, continuing to Intron 5. Separating these regions is *neo*^R-polyA sequence. After homologous recombination the vector confers neomycin phosphotransferase resistance to the cells and deletes 1.5-kb of genomic sequence, including the first coding exon of $\alpha 1,3$ GT gene. The entire cassette was cloned into pBlueScriptTM for propagation in DH5 α bacterial cells.

The p0054 vector was constructed by amplifying a truncated left arm (300bp, includes EcoRI site) (using primers 199001, 5'-ACGTGGCTCC AAGAATTCTC CAGGCAAGAG TACTGG-3', SEQ. ID NO:36; and 199006, 5'-CATCTTGTTT AATGGCCGAT CCCATTATTT TCTCCTGGGA AAAGAAAAG-3', with tail complementary to the start of *neo* coding sequence, SEQ. ID NO:137), and a *neo*-polyA sequence obtained from Stratagene (using primers 199005, 5'-CTTTTCTTTT CCCAGGAGAA AATAATGGGA TCGGCCATTG AACAAGATG-3', SEQ. ID NO:38, with tail complementary to left arm; and 199004, 5'-CAGGTCGACG GATCCGAACA AAC-3', SEQ. ID NO:39). These fragments were used to prime from each other to give a 1.2-kb fusion product. This was ligated to Intron 3 sequence, to extend the left arm, and to ~9-kb of 3' sequence to create the right arm, which initiates 1.5-kb into Intron 4, continuing to Intron 5.

Figure 10 shows the promoterless *neo*-polyA insertion vector designated plasmid p0079, also directed towards Exon 4. This vector contains the same left arm-*neo*-polyA fusion as in vector p0054, but with a modified right arm of 3.9-kb. The 3' region comprises a 1.5-kb fragment, generated by PCR (using primers 200011, 5'-CAGATCTAAC GAGGATTCAA TGTCAAAGGA AAAGTGATTC TGTCAT-3', SEQ. ID NO:40; and 499006, 5'-CTGAACTGAA TGTTTATCCA GGCCATC-3', SEQ. ID NO:41), which extends from the second codon in Exon 4 into Intron 4, replacing the sequence deleted in p0054. The 3' arm was extended by ligation to a 2.4-kb EcoRV downstream fragment.

Figure 11 shows the promoterless *pac*-polyA replacement vector designated plasmid p0063, also directed towards Exon 4. Construction of this vector was similar as for p0054,

except that it contains the *pac* gene, which codes for puromycin N-acetyltransferase, rather than the *neo* gene. The *pac* sequence is available in plasmid pPUR from Clontech. The oligonucleotide primers used to generate the 5'-*pac*-polyA fusion were, for the 5' region, 199001 (SEQ. ID NO:36) and 699002 (5'-GCGCACCGTG GGCTTGTACT

5 CGGTCATTAT TTTCTCCTGG GAAAAGAAAA G-3', SEQ. ID NO:42), with tail complementary to the start of *pac* coding sequence; and, for *pac*-polyA, 699004 (5'-GAGAAAATAA TGACCGAGTA CAAGCCCACG GTGC-3' SEQ. ID NO:43), with tail complementary to left arm, and 699005 (5'-CTGGGGATCC AGACATGATA AGATAC-3' SEQ. ID NO:44).

10 **Figure 12** shows restriction fragments of the Exon 4 directed targeting vectors (3.9-kb NsiI / BglIII, from p0054; 3.6-kb NsiI / ClaI, from p0079; Figure 10). These fragments are of appropriate size for insertion into recombinant adeno-associated virus (AAV) for gene targeting according to the general approach outlined in International Patent Application WO 98/48005.

15 **Figure 13** shows the promoterless *neo*-polyA replacement vector designated plasmid p0078, directed towards Exon 8. The vector comprises a 1.3-kb left arm, which is complementary to sequence from Intron 7 up to and including the first nucleotide of Exon 8, fused in frame to 5 × GGA (glycine) repeats, then to *neo*-polyA sequence (obtained from Stratagene). The glycine linker is designed to permit more independent rotation of each
20 functional domain (the remaining fragment of $\alpha 1,3$ GT, and *neo*), allowing *neo* to perform its function. The vector was constructed by amplifying the left arm (using primers 200-005, 5'-CTGGTTGGTT CTAGAACAGG AGGA-3', SEQ. ID NO:45; and 200-007, 5'-CATCTTGTTT AATGGCCGAT CCCATTCCTC CTCCTCCTCC ACTGGTGACA AACAGAGTC CATGAG -3' SEQ. ID NO:46, with tail complementary to the start of *neo*
25 coding sequence) and *neo*-polyA sequence (using primers 200-006, 5'-CTCATGGACT CTGTTTTGTC ACCAGTGGAG GAGGAGGAGG AATGGGATCG GCCATTGAAC AAGATG -3', SEQ. ID NO:47, with tail complementary to left arm; and 200-008,

5'-CAGGTCGACG GATCCGAACA AAC -3', SEQ. ID NO:48). These fragments were then used to prime from each other, giving a 2.2-kb fusion product. To complete the targeting vector, this product was ligated to a ~9-kb right arm, which initiates 0.7-kb into Intron 8, continuing to the 3'UTR.

5 **Figure 14** shows the targeting vector designated plasmid p0047, designed to disrupt Exon 9 of the $\alpha 1,3$ GT gene. The pMC1-*neo*-polyA replacement vector comprises (from left to right) 1.8-kb of Intron 8 sequence, located 0.4-kb prior to Exon 9; pMC1-*neo*-polyA sequence (Stratagene); and a ~7-kb right arm (HindIII restriction sites blunt ended using T4 DNA polymerase obtained from Promega), initiating 60bp upstream of the stop codon of Exon 9, and continuing into the 3'UTR.

10 **Figure 15** shows the targeting vector designated plasmid p0046, also directed towards Exon 9. The pIRES- β geo-polyA vector (obtained from Austin Smith, Centre for Genome Research, Edinburgh UK) contains the same right arm as p0047 extended to include the remainder of Intron 8 and the first ~120bp of Exon 9, which allows expression of the inserted selectable cassette: the internal ribosome entry site- β -galactosidase-*neo*^R-polyA.

15 After homologous recombination, the selectable marker in both p0047 and p0046 are designed to replace >80% of Exon 9, which is hypothesized to comprise at least part of the catalytic domain of $\alpha 1,3$ GT.

20 Example 4: Disruption of the Galactosyl Transferase gene by homologous recombination

Black Welsh Mountain fetal fibroblasts have previously been used in nuclear transfer experiments, creating live offspring (GB Patents 2318578 and 2331751). For the purposes of the present experiment, electroporation conditions were optimized using the β -galactosidase marker plasmid, pCMV-Sport- β gal (obtained from Gibco). Using a 0.4cm cuvette with 3 x 10⁵ cells (0.8ml, 6 μ g plasmid DNA) and a setting of 250 μ F:400Volts (Gene Pulser, BioRad), 25 10-30% of the surviving fibroblasts stained positive for β -gal expression.

For targeting electroporations 10, 25 or 100 μ g of NotI linearized p0054 vector was mixed with 1×10^7 early passage Black Welsh Mountain fetal fibroblasts and pulsed as described above. Cells were grown on tissue culture plastic for 24 hours before G418 (300 μ g/ml) was applied. After 10-14 days colonies were isolated. Half the colony cell population was expanded for analysis, while the remainder was cryopreserved for later recovery.

Figure 16 shows the results of site specific recombination detected by PCR amplification. Wild type and targeted $\alpha 1,3$ GT alleles were detected using sense (399010, 5'-CAGCTGTGTG GGTATGGGAG GG-3'; SEQ. ID NO:49) and antisense (499006, 5'-CTGAACTGAA TGTTTATCCA GGCCATC-3'; SEQ. ID NO:50) PCR primers, yielding products of 2.8-kb and 2.2-kb, respectively. A second PCR screen with primers 399010 (SEQ. ID NO:49) and 399005 (5'-AGCCGATTGT CTGTTGTGCC CAGTCAT-3'; SEQ. ID NO:51) produced a fragment of 1.5-kb only in clones that were correctly targeted. The frequency of site-specific recombination was 1 in 52 (6 in 312) clones in the 10 μ g experiment or 1 in 88 (10 in 877) from all electroporations.

The *neo*^R gene was tested in one sample by Southern blot analysis. DNA was digested with the restriction enzyme BsmI, and the blot was probed with *neo* coding sequence, producing a diagnostic band at 5.5-kb. However, all cryopreserved samples of targeted Black Welsh Mountain cells failed to grow after resuscitation. Analysis other than PCR was not possible due to inadequate amounts of DNA. The PCR data demonstrate successful gene disruption by homologous recombination in sheep somatic cells.

Additional vectors were constructed for targeting Exon 8 or 9, using the *pac* gene as a resistance marker. Transfection of Black Welsh Mountain fetal fibroblasts with the pIRES- β geo-polyA replacement vector failed to produce successful targeting in the 250 clones examined. Apparently, the efficiency of this vector was lower than the promoterless neo-polyA vector.

Example 5: Gene targeting of the α 1,3GT gene in other breeds

In this experiment, targeting vectors were used to affect the α 1,3GT gene in cells of a different breed.

Cell lines were created as follows. Finn Dorset (FD) day 35 fetuses were decapitated and eviscerated. The carcasses were dissociated manually, and then treated with trypsin/EDTA solution (Sigma). Primary cultures of fibroblasts were grown in GMEM media (Sigma), supplemented with 10% FCS (Globe Farm), on tissue culture plastic coated with 0.1% gelatin. Cells were exposed to gentamycin (Gibco) for the first 24 hours to prevent bacterial contamination. Once confluent, cells were cryopreserved in aliquots of $\sim 1 \times 10^6$ per vial. Euploid lines of male genotype were used for gene targeting.

Cell suspensions were targeted with 10 μ g of linearized promoterless neo-polyA replacement vector p0054. Electroporation was conducted by applying an electrical pulse of 125 μ F, 350 Volts. A total of 568 clones were derived from one electroporated primary culture, designated 7G65F4. Colonies were screened for successful targeting as described in Example 4. Eighteen colonies (3.2%) showed patterns consistent with homogeneous cell populations in which one α 1,3GT allele was deleted. A further 17 colonies containing mixed populations of targeted and non-targeted cells were detected. Surprisingly, even though the DNA of the targeting vectors is not isogenic with Finn Dorset gene sequences the targeting frequency was higher than in the experiments with Black Welsh Mountain cells (Example 4).

Homogeneous colonies of targeted FD cells stored in liquid N₂ were thawed rapidly and collected by centrifugation. Three clones (3C6, 5E1 and 4H2) from culture 7G65F4 retained a normal karyotype and fibroblast morphology, and grew successfully. Cells were grown for up to five days in normal medium containing 10% FBS, replacing the medium every 48 hours. The cells were then stressed for up to five days, in medium containing only 0.5% FBS, replacing the medium every 48 hours. Thereafter, culturing continued in 10% FBS and karyotyped. The 4H2 clone was unstable in longer periods of culture, but clones 3C6 and 5E1 grew in a slow, stable fashion, and thus suitable for nuclear donors.

Example 6: Animals in which an $\alpha 1,3$ GT gene is inactivated

Successfully targeted fibroblast cell lines 3C6 and 5E1 are used as donors for nuclear transfer. The cells are grown for up to five days in 10% FBS, and then starved for up to five days in 0.5% FBS, as described in Example 5. Prepared cells are trypsinized for ~5 min, and collected by low-speed centrifugation (800 rpm for 3 min). They are then resuspended in < 100 μ L 10% FCS medium, and used immediately for nuclear transfer.

Six weeks before the transfer, adult female breeding sheep are selected, and brought in to the facility to acclimatize to the surroundings. For each nuclear transfer experiment, about 8 animals are used as oocyte donors, 2 as temporary recipients, and 10 as final recipients.

Oocytes are collected as follows. Time of estrus is controlled in donor animals by treatment with an intravaginal progestagen sponge for 11 to 16 days, replacing once if necessary. Ovine follicular growth is promoted by injection of gonadotrophin, with or without subcutaneous or intramuscular injection of 0.6 mg (2 mL) follicle stimulating hormone (FSH) twice daily over 4 consecutive days, followed by a single injection of 500 i.u. (2.5 mL) pregnant mare's serum gonadotropin (PMSG) on the day of sponge removal. Time of ovulation is controlled by subcutaneous or intramuscular injection of an analogue of gonadotropin releasing hormone (e.g. BuserelinTM, given 24 h after sponge removal). Between one and twelve days after the onset of estrus, general anesthesia is induced by an intravenous injection of a barbiturate, followed by intubation and maintenance with gaseous anesthetics. The reproductive tract is exposed by mid-ventral laparotomy, and the oviduct or uterus is temporarily cannulated as a passageway for sterile medium. Three small puncture incisions made at sites anterior to the udder, through which a laparoscope, manipulating forceps and a needle are used to manipulate the uterus. After oocytes are collected, the incision is sutured closed, and the donor animal is allowed to recover from anaesthetic.

Nuclear transfer is conducted as follows. First, the oocytes are stripped of cumulus cells by triturating with a pipette and incubating with hyaluronidase. They are then

enucleated by removing the first polar body and metaphase plate. A single 3C6 or 5E1 targeted cell is introduced under the zona of each oocyte. The cell combination is subject to simultaneous electrofusion and activation (0.25 kV cm^{-1} AC for 5 sec. to align oocyte and donor cell, followed by 3 pulses of 1.25 kV cm^{-1} DC for 80 μsec to fuse and activate the reconstructed embryo). The activated cell is maintained in culture overnight at 39°C . Next day, the cells are embedded in agar chips to protect from macrophages, and then transferred to the ligated oviduct of a temporary recipient.

For the temporary recipient, estrous is controlled by treatment with intravaginal progestagen sponge for 11 to 16 days, with or with subcutaneous or intramuscular injection of 500 i.u. of PMSG. The timing brings the temporary recipients to estrus ~3 days before the oocyte donors. Cells are collected under general anesthesia using barbiturate followed by gaseous anesthetics. The reproductive tract is exposed by midventral laparotomy; placing ligatures of silk at each uterotubal junction, and embryos are transferred through the fimbriated end of the oviduct. The laparotomy is then closed, and a long-acting antibiotic is administered. Blood samples of < 20 mL (< 5% of blood volume may be taken weekly for monitoring purposes. The embryo are flushed from the temporary recipient after 6 days, and developing embryos are removed from the agar chip.

Blastocysts and morula are then transferred into the recipients that will carry the embryo to term. Estrus is controlled by treatment with an intravaginal progestagen sponge for 11 to 16 days, bringing the final recipients to estrus simultaneously with the oocyte donor. The permanent recipients are anesthetized by intravenous barbiturate and gaseous anesthetics, the reproductive tract is exposed by mid-ventral laparotomy, and the oviduct or uterus is temporarily cannulated for transfer of the embryos. Alternatively, three small puncture incisions are made anterior to the udder, and a laparoscope, manipulating forceps and needle are inserted for manipulation of the uterus. The oviduct or uterus is temporarily cannulated for transfer of the embryos, and the incision is sutured closed.

Recipients of oocytes with a targeted nucleus, engrafted in the manner outlined, were monitored for the status of their pregnancy by subcutaneous ultrasonic scanning on a weekly basis. Ten recipients were determined to be pregnant 35 days after engraftment. At the time these observations were recorded, insufficient time had passed for any engrafted pregnancies to reach term. Some of the pregnancies were stable, and some started to regress. A fetus and umbilical cord were recovered from one of the regressing pregnancies for analysis.

Figure 17 shows the results of PCR analysis of the tissue from the umbilical cord. Using primers for the 5' untranslated region and the neo gene, a band corresponding to 1.5 kb was detected, which should only be present in progeny from a cell successfully targeted with a neo-containing deletion vector. Using primers for the 5' and 3' untranslated regions, two bands were observed: 2.8 kb, corresponding to the wild type $\alpha 1,3\text{GT}$ gene, and 2.2 kb, appropriate for a targeted $\alpha 1,3\text{GT}$ gene. These results are consistent with inactivation of the $\alpha 1,3\text{GT}$ gene on one haplotype.

For animals maintaining their pregnancy, the progress of the fetus is monitored regularly by ultrasound, and brought to term. Blood cells are collected after birth, to verify that at least one $\alpha 1,3\text{GT}$ allele has been inactivated.

BIOLOGICAL DEPOSIT

The recombinant phage designated **B**, **C** and **G**, have been deposited with the National Collections of Industrial and Marine Bacteria Limited (NCIMB), 23 St. Machar Drive, Aberdeen AB2 1RY, Scotland, United Kingdom (Tel: +44 (0)1224 273332; Fax: +44 (0)1224 272461).

A deposit comprising equal concentrations of each phage was received on April 25, 2000, and is catalogued under Accession No. NCIMB 41056. The concentration is 0.8×10^8

pfu/mL for each of the three phage, for a total of 2.4×10^8 pfu/mL. Each phage can be separated from the mixture using the following probes:

- Phage **B**: probe GGGAGGAAGCGAAGGTGCA (SEQ. ID NO:35), 5'UTR
- Phage **C**: probe CTTGATGGGTTTATCCAGAACA (SEQ. ID NO:28), Exon 5
- Phage **G**: probe TGATAATCCCAGCAGTATTC (SEQ. ID NO:27), Exon 9

Each recombinant phage was deposited with the MCIMB separately on May 30, 2000. Accession numbers are: Clone **B**, No. 41059; Clone **C**, No. 41060; and Clone **G**, No. 41061. Each deposit has a concentration of 2×10^8 pfu/mL.

The phage are useful for obtaining sequence information about the sheep $\alpha 1,3$ Galactosyltransferase gene (described in Example 3) and as an amplification template for preparing certain polynucleotides of this invention.

The deposits are made under terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. For purposes of prosecution of this and any related application in the United States, the deposit is made under terms and with the undertakings of 37 CFR §§ 1.801-1.808. Subject to 37 CFR § 1.808(b), all restrictions imposed on the availability to the public of the deposited material will be irrevocably removed upon the granting of a U.S. patent thereto.

SEQUENCE DATA

TABLE 2: Sequences listed in this Disclosure

SEQ. ID NO:	Designation	Reference
1	Sheep α 1,3-GT cDNA sequence	This Invention.
2	Sheep α 1,3-GT amino acid sequence	This Invention.
3	Bovine α 1,3-GT cDNA sequence	GenBank Accession J04989 Joziassse et al. "Bovine α 1- \rightarrow 3-galactosyltransferase" J. Biol. Chem. 264, 14290 (1989)
4	Bovine α 1,3-GT amino acid sequence	GenBank Accession P14769 Joziassse et al. (1989), supra.
5	Mermoset α 1,3-GT cDNA sequence	GenBank Accession S71333 lymphoid cell line B95.8, mRNA Partial Macher et al. "Defining the minimal size of catalytically active primate α 1,3 galactosyltransferase" Glycobiology 4,193 (1994)
6	Mermoset α 1,3-GT amino acid sequence	GenBank Accession S71333 Macher et al., supra.
7	Pig α 1,3-GT cDNA sequence	GenBank Accession L36152 Sus scrofa alpha-1,3-galactosyltransferase mRNA. Strahan et al. "cDNA sequence and chromosome localization of pig α 1,3 galactosyltransferase" Immunogenetics 41, 101 (1995) See also GenBank Accession L36535 Sandrin et al. "Characterization of cDNA clones for porcine a(1,3)galactosyl transferase" Xenotransplantation (1994)
8	Pig α 1,3-GT amino acid sequence	GenBank Accession L36152 Strahan et al., supra.
9	Mouse α 1,3-GT cDNA sequence	GenBank Accession M26925 Larsen et al. "Isolation of a cDNA encoding a murine UDPgalactose: β -D-galactosyl-1,4-N-acetyl-D-glucosaminide alpha-1,3-galactosyltransferase" Proc. Natl. Acad. Sci. USA 86, 8227 (1989) See also GenBank Accession IM85153 Joziassse et al. "Murine alpha-1,3-galactosyltransferase: A single gene locus specifies four isoforms of the enzyme by alternative splicing" J. Biol. Chem. 267, 5534 (1992)
10	Mouse α 1,3-GT amino acid sequence	GenBank Accession M26925 Larsen et al., supra.

TABLE 2: Sequences listed in this Disclosure

SEQ. ID NO:	Designation	Reference
11	Human α 1,3-GT pseudogene DNA sequence	GenBank Accession M60263 Joziassse et al. "Characterization of an alpha-1->3-galactosyltransferase homologue on human chromosome 12 that is organized as a processed pseudogene" J. Biol. Chem. 266, 6991 (1991)
12	Human α 1,3-GT pseudogene open reading frame amino acid sequence	calculated from GenBank Accession M60263 Joziassse et al., supra.
13	Bovine γ globin gene and globin pseudogene	GenBank Accession M63452 C.H. Duncan (direct submission)
14	Exon 4 of the sheep α 1,3-GT gene	This Invention.
15	Pre-Exon 4 sequence (Phage B and C)	This Invention. Region 1 of Figure 7
16	Post-Exon 4 sequence Exon 4 / intron 4 boundary	This Invention. Region 2 of Figure 7
17	Post-Exon 4 sequence	This Invention.
18	Post-Exon 4 sequence	This Invention.
19	Post-Exon 4 sequence	This Invention. Region 3 of Figure 7
20	Pre-Exon 8 sequence	This Invention. Region 4 of Figure 7
21	Intron sequence approx -4kb to -2kb from Exon 9	This Invention. Region 5 of Figure 7
22	Intron sequence approx -2kb to -1kb from Exon 9	This Invention. Region 6 of Figure 7
23	Intron sequence 5' to Exon 9	This Invention. Region 7 of Figure 7
24	Intron sequence 3' to Exon 9	This Invention. Region 8 of Figure 7
25	Intron sequence approx -2kb to -1kb from Exon 9	This Invention. Region 9 of Figure 7
26 to 51	Probes and PCR primers	This Invention.

Sequence Listing

<110> Clark Mr., John
Denning, Chris

<120> Animal Tissue For Xenotransplantation

<130> 730/002

<140> [filed herewith]

<141> 2000-06-13

<150> 60/204,148

<151> 2000-05-15

<160> 51

<170> PatentIn Ver. 2.1

<210> 1

<211> 1303

<212> DNA

<213> Ovis sp.

<220>

<221> CDS

<222> (194)..(1303)

<400> 1

agccgaggac gccgccgggg agccgaggct ccggccagcc cccagcgcgc ccagcttctg 60

cagatcagga gtcagaacgc tgcaccttcg ctctctccca gccctgcctc cttctgcaaa 120

acggagctca atagaacttg gtacttttgc cttttactct gggaggagag aagcagacga 180

tgaggagaaa ata atg aat gtc aaa gga aaa gtg att ctg tca atg ctg 229

Met Asn Val Lys Gly Lys Val Ile Leu Ser Met Leu

1 5 10

gtt gtc tca act gtc att gtt gtg ttt tgg gaa tat atc cac agc cca 277

Val Val Ser Thr Val Ile Val Val Phe Trp Glu Tyr Ile His Ser Pro

15 20 25

gaa ggc tct ttg ttc tgg ata aac cca tca aga aac cca gaa gtc agt 325

Glu Gly Ser Leu Phe Trp Ile Asn Pro Ser Arg Asn Pro Glu Val Ser

30 35 40

ggc ggc agc agc att cag aag ggc tgg tgg ttt ccg aga tgg ttt aac 373

Gly Gly Ser Ser Ile Gln Lys Gly Trp Trp Phe Pro Arg Trp Phe Asn

45 50 55 60

aat ggt tac caa gaa gaa gat gaa gac gta gac gaa gaa aag gaa caa 421

Asn Gly Tyr Gln Glu Glu Asp Glu Asp Val Asp Glu Glu Lys Glu Gln

65 70 75

aga aag gaa gac aaa agc aag ctt aag cta tcg gac tgg ttc aac cca 469

Arg Lys Glu Asp Lys Ser Lys Leu Lys Leu Ser Asp Trp Phe Asn Pro

80 85 90

ttt aaa cgc cct gag gtt gtg act atg aca gat tgg aag gca ccc gtg 517

Phe Lys Arg Pro Glu Val Val Thr Met Thr Asp Trp Lys Ala Pro Val

95 100 105

gtg tgg gaa ggc act tac aac aga gcc gtc tta gac gat tac tac gcc 565

Val Trp Glu Gly Thr Tyr Asn Arg Ala Val Leu Asp Asp Tyr Tyr Ala

110 115 120

aag cag aaa att acc gtc ggc ctg acg gtt ttc gcc gtc gga aga tac 613

Lys Gln Lys Ile Thr Val Gly Leu Thr Val Phe Ala Val Gly Arg Tyr

125 130 135 140

att gag cat tac ttg gag gag ttc tta acg tct gct aat aag cac ttc 661

Ile Glu His Tyr Leu Glu Glu Phe Leu Thr Ser Ala Asn Lys His Phe

145 150 155

atg gtt ggc cac cga gtc atc ttt tac gtc atg gtg gac gac gtc tcc 709
 Met Val Gly His Arg Val Ile Phe Tyr Val Met Val Asp Asp Val Ser
 160 165 170

agg atg cct ttg ata gag ctg ggc cct ctg cgc tcc ttc aaa/ gtg ttt 757
 Arg Met Pro Leu Ile Glu Leu Gly Pro Leu Arg Ser Phe Lys Val Phe
 175 180 185

gag gtc aag cct gag agg agg tgg cag gac gtc agc atg gtg cgc atg 805
 Glu Val Lys Pro Glu Arg Arg Trp Gln Asp Val Ser Met Val Arg Met
 190 195 200

aag acc atc ggg gag cac atc gtg gcc cac atc cag cgt gag gtt gac 853
 Lys Thr Ile Gly Glu His Ile Val Ala His Ile Gln Arg Glu Val Asp
 205 210 215 220

ttc ctc ttc tgc atg gac gtg gac cag gtc ttc caa gac gag ttc ggg 901
 Phe Leu Phe Cys Met Asp Val Asp Gln Val Phe Gln Asp Glu Phe Gly
 225 230 235

gtg gag acc ctg ggt gag tcg gtg gcc cag cta cag gcc tgg tgg tac 949
 Val Glu Thr Leu Gly Glu Ser Val Ala Gln Leu Gln Ala Trp Trp Tyr
 240 245 250

aag gca gat ccc gat gag ttt acc tac gag agg cgc aag gag tct gca 997
 Lys Ala Asp Pro Asp Glu Phe Thr Tyr Glu Arg Arg Lys Glu Ser Ala
 255 260 265

gca tac att ccc ttc ggc gaa ggg gat ttt tat tac cac gca gcc att 1045
 Ala Tyr Ile Pro Phe Gly Glu Gly Asp Phe Tyr Tyr His Ala Ala Ile
 270 275 280

ttt ggg gga aca ccc act cag gtc ctt aac atc acc cag gaa tgc ttc 1093
 Phe Gly Gly Thr Pro Thr Gln Val Leu Asn Ile Thr Gln Glu Cys Phe
 285 290 295 300

aaa gga atc ctc aag gac aag aaa aat gac ata gaa gcc caa tgg cat 1141
 Lys Gly Ile Leu Lys Asp Lys Lys Asn Asp Ile Glu Ala Gln Trp His
 305 310 315

gat gag agc cat cta aac aag tat ttc ctt ctc aac aaa ccc act aaa 1189
 Asp Glu Ser His Leu Asn Lys Tyr Phe Leu Leu Asn Lys Pro Thr Lys
 320 325 330

atc tta tcc ccg gaa tac tgc tgg gat tat cat ata ggc cta cct gcg 1237
 Ile Leu Ser Pro Glu Tyr Cys Trp Asp Tyr His Ile Gly Leu Pro Ala
 335 340 345

gat att aag ctt gtc aag atg tct tgg cag aca aaa gag tat aat gtg 1285
 Asp Ile Lys Leu Val Lys Met Ser Trp Gln Thr Lys Glu Tyr Asn Val
 350 355 360

gtt aga aat aac gtc tga 1303
 Val Arg Asn Asn Val 370

<210> 2
 <211> 369
 <212> PRT
 <213> Ovis sp.

<400> 2
 Met Asn Val Lys Gly Lys Val Ile Leu Ser Met Leu Val Val Ser Thr
 1 5 10 15
 Val Ile Val Val Phe Trp Glu Tyr Ile His Ser Pro Glu Gly Ser Leu
 20 25 30
 Phe Trp Ile Asn Pro Ser Arg Asn Pro Glu Val Ser Gly Gly Ser Ser
 35 40 45
 Ile Gln Lys Gly Trp Trp Phe Pro Arg Trp Phe Asn Asn Gly Tyr Gln
 50 55 60
 Glu Glu Asp Glu Asp Val Asp Glu Glu Lys Glu Gln Arg Lys Glu Asp
 65 70 75 80
 Lys Ser Lys Leu Lys Leu Ser Asp Trp Phe Asn Pro Phe Lys Arg Pro
 85 90 95
 Glu Val Val Thr Met Thr Asp Trp Lys Ala Pro Val Val Trp Glu Gly
 100 105 110
 Thr Tyr Asn Arg Ala Val Leu Asp Asp Tyr Tyr Ala Lys Gln Lys Ile

Thr Val Gly Leu Thr Val Phe Ala Val Gly Arg Tyr Ile Glu His Tyr
130 135 140
Leu Glu Glu Phe Leu Thr Ser Ala Asn Lys His Phe Met Val Gly His
145 150 155 160
Arg Val Ile Phe Tyr Val Met Val Asp Asp Val Ser Arg Met Pro Leu
165 170 175
Ile Glu Leu Gly Pro Leu Arg Ser Phe Lys Val Phe Glu Val Lys Pro
180 185 190
Glu Arg Arg Trp Gln Asp Val Ser Met Val Arg Met Lys Thr Ile Gly
195 200 205
Glu His Ile Val Ala His Ile Gln Arg Glu Val Asp Phe Leu Phe Cys
210 215 220
Met Asp Val Asp Gln Val Phe Gln Asp Glu Phe Gly Val Glu Thr Leu
225 230 235 240
Gly Glu Ser Val Ala Gln Leu Gln Ala Trp Trp Tyr Lys Ala Asp Pro
245 250 255
Asp Glu Phe Thr Tyr Glu Arg Arg Lys Glu Ser Ala Ala Tyr Ile Pro
260 265 270
Phe Gly Glu Gly Asp Phe Tyr Tyr His Ala Ala Ile Phe Gly Gly Thr
275 280 285
Pro Thr Gln Val Leu Asn Ile Thr Gln Glu Cys Phe Lys Gly Ile Leu
290 295 300
Lys Asp Lys Lys Asn Asp Ile Glu Ala Gln Trp His Asp Glu Ser His
305 310 315 320
Leu Asn Lys Tyr Phe Leu Leu Asn Lys Pro Thr Lys Ile Leu Ser Pro
325 330 335
Glu Tyr Cys Trp Asp Tyr His Ile Gly Leu Pro Ala Asp Ile Lys Leu
340 345 350
Val Lys Met Ser Trp Gln Thr Lys Glu Tyr Asn Val Val Arg Asn Asn
355 360 365
Val

<210> 3
<211> 1617
<212> DNA
<213> BOVINE

<220>
<221> CDS
<222> (469)..(1575)

<400> 3
ccggggggccg ggccgagctg ggagcgtcga gcccgctgcc cagcgcccgcc cggtccctc 60
gcgccccctgc ccgcccgcgc ggaggagcgc ccggcggccg gccgacggga gcgcagcggc 120
acacccccgcc ccggcacgcc cgcgggggctc gggaggaggc agcgcgccga ctgttccggc 180
agccgaggac gccgcggggg agccgaggcg ccggccagcc cccagcgccg ccagcttctg 240
cggatcaggg aaaccacgtg tcctcaagtg gccagccagc tgtccccaag aggaacttgc 300
ctggcatttg cacggaaaga cgagacactt cacaaaatca acggagtcag aaggctgcac 360
cttcgcttcc tccagccct gcctccttct gcagaacgga gctcagtaga acttggtact 420
tttgctttt actctaggag gagagaagca gacgatgagg agaaaata atg aat gtc 477
Met Asn Val
1
aaa gga aaa gtg att ctg tca atg ctg gtt gtc tca act gtc att gtt 525
Lys Gly Lys Val Ile Leu Ser Met Leu Val Val Ser Thr Val Ile Val
5 10 15
gtg ttt tgg gaa tat atc cac agc cca gaa ggc tct ttg ttc tgg ata 573
Val Phe Trp Glu Tyr Ile His Ser Pro Glu Gly Ser Leu Phe Trp Ile
20 25 30 35
aac cca tca aga aac cca gaa gtt ggt ggc agc agc att cag aag ggc 621
Asn Pro Ser Arg Asn Pro Glu Val Gly Gly Ser Ser Ile Gln Lys Gly
40 45 50
tgg tgg ctt ccg aga tgg ttt aac aat ggt tac cat gaa gaa gat gga 669
Trp Trp Leu Pro Arg Trp Phe Asn Asn Gly Tyr His Glu Glu Asp Gly
55 60 65

gac ata aac gaa gaa aag gaa caa aga aac gaa gac gaa agc aag ctt Asp Ile Asn Glu Glu Lys Glu Gln Arg Asn Glu Asp Glu Ser Lys Leu 70 75 80	717
aag cta tcg gac tgg ttc aac cca ttt aaa cgc ccc gag gtt gtg acc Lys Leu Ser Asp Trp Phe Asn Pro Phe Lys Arg Pro Glu Val Val Thr 85 90 95	765
atg acg aag tgg aag gct cca gtg gtg tgg gaa ggc act tac aac aga Met Thr Lys Trp Lys Ala Pro Val Val Trp Glu Gly Thr Tyr Asn Arg 100 105 110 115	813
gcc gtc tta gac aat tat tat gcc aag cag aaa att acc gtc ggc ctg Ala Val Leu Asp Asn Tyr Tyr Ala Lys Gln Lys Ile Thr Val Gly Leu 120 125 130	861
acg gtt ttc gcc gtc gga aga tac att gag cat tac ttg gag gag ttc Thr Val Phe Ala Val Gly Arg Tyr Ile Glu His Tyr Leu Glu Glu Phe 135 140 145	909
tta acg tct gct aat aag cac ttc atg gtg ggc cac cca gtc atc ttt Leu Thr Ser Ala Asn Lys His Phe Met Val Gly His Pro Val Ile Phe 150 155 160	957
tat atc atg gta gat gat gtc tcc agg atg cct ttg ata gag ttg ggt Tyr Ile Met Val Asp Asp Val Ser Arg Met Pro Leu Ile Glu Leu Gly 165 170 175	1005
cct ctg cgc tcc ttc aaa gtg ttt aag atc aag cct gag aag agg tgg Pro Leu Arg Ser Phe Lys Val Phe Lys Ile Lys Pro Glu Lys Arg Trp 180 185 190 195	1053
cag gac atc agc atg atg cgc atg aag act atc ggg gag cac att gtg Gln Asp Ile Ser Met Met Arg Met Lys Thr Ile Gly Glu His Ile Val 200 205 210	1101
gcc cac atc cag cat gag gtt gac ttc ctt ttc tgc atg gat gtg gac Ala His Ile Gln His Glu Val Asp Phe Leu Phe Cys Met Asp Val Asp 215 220 225	1149
cag gtc ttc caa gac aag ttt ggg gtg gag acc ctg ggc gag tcg gtg Gln Val Phe Gln Asp Lys Phe Gly Val Glu Thr Leu Gly Glu Ser Val 230 235 240	1197
gcc cag cta caa gcc tgg tgg tac aag gca gat ccc aat gac ttc acc Ala Gln Leu Gln Ala Trp Trp Tyr Lys Ala Asp Pro Asn Asp Phe Thr 245 250 255	1245
tac gag agg cgg aag gag tct gca gca tac att ccc ttc ggc gaa ggg Tyr Glu Arg Arg Lys Glu Ser Ala Ala Tyr Ile Pro Phe Gly Glu Gly 260 265 270 275	1293
gat ttt tat tac cat gca gcc att ttt ggg gga aca ccc act cag gtc Asp Phe Tyr Tyr His Ala Ala Ile Phe Gly Gly Thr Pro Thr Gln Val 280 285 290	1341
ctt aac atc acc cag gaa tgc ttc aaa gga atc ctc aag gac aag aaa Leu Asn Ile Thr Gln Glu Cys Phe Lys Gly Ile Leu Lys Asp Lys Lys 295 300 305	1389
aat gac ata gaa gcc caa tgg cat gat gaa agc cat cta aac aag tat Asn Asp Ile Glu Ala Gln Trp His Asp Glu Ser His Leu Asn Lys Tyr 310 315 320	1437
ttc ctt ctc aac aaa cct act aaa atc tta tcc ccg gaa tac tgc tgg Phe Leu Leu Asn Lys Pro Thr Lys Ile Leu Ser Pro Glu Tyr Cys Trp 325 330 335	1485
gat tat cac ata ggc cta cct gcg gat att aag ctt gtc aag atg tct Asp Tyr His Ile Gly Leu Pro Ala Asp Ile Lys Leu Val Lys Met Ser 340 345 350 355	1533
tgg cag aca aaa gag tat aat gtg gtt aga aat aat gtc tga Trp Gln Thr Lys Glu Tyr Asn Val Val Arg Asn Asn Val 360 365	1575
ctttgtgccg gtacatttct gaatttgaga gagtattatt ct	1617

<210> 4
<211> 368
<212> PRT
<213> BOVINE

<400> 4
Met Asn Val Lys Gly Lys Val Ile Leu Ser Met Leu Val Val Ser Thr
1 5 10 15
Val Ile Val Val Phe Trp Glu Tyr Ile His Ser Pro Glu Gly Ser Leu
20 25 30
Phe Trp Ile Asn Pro Ser Arg Asn Pro Glu Val Gly Gly Ser Ser Ile
35 40 45
Gln Lys Gly Trp Trp Leu Pro Arg Trp Phe Asn Asn Gly Tyr His Glu
50 55 60
Glu Asp Gly Asp Ile Asn Glu Glu Lys Glu Gln Arg Asn Glu Asp Glu
65 70 75 80
Ser Lys Leu Lys Leu Ser Asp Trp Phe Asn Pro Phe Lys Arg Pro Glu
85 90 95
Val Val Thr Met Thr Lys Trp Lys Ala Pro Val Val Trp Glu Gly Thr
100 105 110
Tyr Asn Arg Ala Val Leu Asp Asn Tyr Tyr Ala Lys Gln Lys Ile Thr
115 120 125
Val Gly Leu Thr Val Phe Ala Val Gly Arg Tyr Ile Glu His Tyr Leu
130 135 140
Glu Glu Phe Leu Thr Ser Ala Asn Lys His Phe Met Val Gly His Pro
145 150 155 160
Val Ile Phe Tyr Ile Met Val Asp Asp Val Ser Arg Met Pro Leu Ile
165 170 175
Glu Leu Gly Pro Leu Arg Ser Phe Lys Val Phe Lys Ile Lys Pro Glu
180 185 190
Lys Arg Trp Gln Asp Ile Ser Met Met Arg Met Lys Thr Ile Gly Glu
195 200 205
His Ile Val Ala His Ile Gln His Glu Val Asp Phe Leu Phe Cys Met
210 215 220
Asp Val Asp Gln Val Phe Gln Asp Lys Phe Gly Val Glu Thr Leu Gly
225 230 235 240
Glu Ser Val Ala Gln Leu Gln Ala Trp Trp Tyr Lys Ala Asp Pro Asn
245 250 255
Asp Phe Thr Tyr Glu Arg Arg Lys Glu Ser Ala Ala Tyr Ile Pro Phe
260 265 270
Gly Glu Gly Asp Phe Tyr Tyr His Ala Ala Ile Phe Gly Gly Thr Pro
275 280 285
Thr Gln Val Leu Asn Ile Thr Gln Glu Cys Phe Lys Gly Ile Leu Lys
290 295 300
Asp Lys Lys Asn Asp Ile Glu Ala Gln Trp His Asp Glu Ser His Leu
305 310 315 320
Asn Lys Tyr Phe Leu Leu Asn Lys Pro Thr Lys Ile Leu Ser Pro Glu
325 330 335
Tyr Cys Trp Asp Tyr His Ile Gly Leu Pro Ala Asp Ile Lys Leu Val
340 345 350
Lys Met Ser Trp Gln Thr Lys Glu Tyr Asn Val Val Arg Asn Asn Val
355 360 365

<210> 5
<211> 1131
<212> DNA
<213> Mermoset alpha 1,3-GT

<220>
<221> CDS
<222> (1)..(1131)

<400> 5
atg aat gtc aaa gga aaa gta att ctg tcg atg ctg gtt gtc tca act 48
Met Asn Val Lys Gly Lys Val Ile Leu Ser Met Leu Val Val Ser Thr
1 5 10 15

gtg att gtt gtg ttt tgg gaa tat atc aac agc cca gaa ggc tct ttc 96
Val Ile Val Val Phe Trp Glu Tyr Ile Asn Ser Pro Glu Gly Ser Phe
20 25 30

ttg tgg ata tat cac tca aag aac cca gaa gtt gat gac agc agt gct 144
Leu Trp Ile Tyr His Ser Lys Asn Pro Glu Val Asp Asp Ser Ser Ala
35 40 45

cag aag gac tgg tgg ttt cct ggc tgg ttt aac aat ggg atc cac aat Gln Lys Asp Trp Trp Phe Pro Gly Trp Phe Asn Asn Gly Ile His Asn 50 55 60	192
tat caa caa gag gaa gaa gac aca gac aaa gaa aaa gga aga gag gag Tyr Gln Gln Glu Glu Glu Asp Thr Asp Lys Glu Lys Gly Arg Glu Glu 65 70 75 80	240
gaa caa aaa aag gaa gat gac aca aca gag ctt cgg cta tgg gac tgg Glu Gln Lys Lys Glu Asp Asp Thr Thr Glu Leu Arg Leu Trp Asp Trp 85 90 95	288
ttt aat cca aag aaa cgc cca gag gtt atg aca gtg acc caa tgg aag Phe Asn Pro Lys Lys Arg Pro Glu Val Met Thr Val Thr Gln Trp Lys 100 105 110	336
gcg ccg gtt gtg tgg gaa ggc act tac aac aaa gcc atc cta gaa aat Ala Pro Val Val Trp Glu Gly Thr Tyr Asn Lys Ala Ile Leu Glu Asn 115 120 125	384
tat tat gcc aaa cag aaa att acc gtg ggg ttg acg gtt ttt gct att Tyr Tyr Ala Lys Gln Lys Ile Thr Val Gly Leu Thr Val Phe Ala Ile 130 135 140	432
gga aga tat att gag cat tac ttg gag gag ttc gta aca tct gct aat Gly Arg Tyr Ile Glu His Tyr Leu Glu Glu Phe Val Thr Ser Ala Asn 145 150 155 160	480
agg tac ttc atg gtc ggc cac aaa gtc ata ttt tat gtc atg gtg gat Arg Tyr Phe Met Val Gly His Lys Val Ile Phe Tyr Val Met Val Asp 165 170 175	528
gat gtc tcc aag gcg ccg ttt ata gag ctg ggt cct ctg cgt tcc ttc Asp Val Ser Lys Ala Pro Phe Ile Glu Leu Gly Pro Leu Arg Ser Phe 180 185 190	576
aaa gtg ttt gag gtc aag cca gag aag agg tgg caa gac atc agc atg Lys Val Phe Glu Val Lys Pro Glu Lys Arg Trp Gln Asp Ile Ser Met 195 200 205	624
atg cgt atg aag acc atc ggg gag cac atc ttg gcc cac atc caa cac Met Arg Met Lys Thr Ile Gly Glu His Ile Leu Ala His Ile Gln His 210 215 220	672
gag gtt gac ttc ctc ttc tgc atg gat gtg gac cag gtc ttc caa gac Glu Val Asp Phe Leu Phe Cys Met Asp Val Asp Gln Val Phe Gln Asp 225 230 235 240	720
cat ttt ggg gta gag acc ctg ggc cag tcg gtg gct cag cta cag gcc His Phe Gly Val Glu Thr Leu Gly Gln Ser Val Ala Gln Leu Gln Ala 245 250 255	768
tgg tgg tac aag gca gat cct gat gac ttt acc tat gag agg cgg aaa Trp Trp Tyr Lys Ala Asp Pro Asp Phe Thr Tyr Glu Arg Arg Lys 260 265 270	816
gag tcg gca gca tat att cca ttt ggc cag ggg gat ttt tat tac cat Glu Ser Ala Ala Tyr Ile Pro Phe Gly Gln Gly Asp Phe Tyr Tyr His 275 280 285	864
gca gcc att ttt gga gga aca ccg att cag gtt ctc aac atc acc cag Ala Ala Ile Phe Gly Gly Thr Pro Ile Gln Val Leu Asn Ile Thr Gln 290 295 300	912
gag tgc ttt aag gga atc ctc ctg gac aag aaa aat gac ata gaa gcc Glu Cys Phe Lys Gly Ile Leu Leu Asp Lys Lys Asn Asp Ile Glu Ala 305 310 315 320	960
gag tgg cat gat gaa agc cac cta aac aag tat ttc ctt ctc aac aaa Glu Trp His Asp Glu Ser His Leu Asn Lys Tyr Phe Leu Leu Asn Lys 325 330 335	1008
ccc tct aaa atc tta tct cca gaa tac tgc tgg gat tat cat ata ggc Pro Ser Lys Ile Leu Ser Pro Glu Tyr Cys Trp Asp Tyr His Ile Gly 340 345 350	1056
ctg cct tca gat att aaa act gtc aag cta tca tgg caa aca aaa gag	1104

Leu Pro Ser Asp Ile Lys Thr Val Lys Leu Ser Trp Gln Thr Lys Glu
 355 360 365
 tat aat ttg gtt aga aag aat gtc tga
 Tyr Asn Leu Val Arg Lys Asn Val
 370 375

1131

<210> 6
 <211> 376
 <212> PRT
 <213> Mermoset alpha 1,3-GT

<400> 6
 Met Asn Val Lys Gly Lys Val Ile Leu Ser Met Leu Val Val Ser Thr
 1 5 10 15
 Val Ile Val Val Phe Trp Glu Tyr Ile Asn Ser Pro Glu Gly Ser Phe
 20 25 30
 Leu Trp Ile Tyr His Ser Lys Asn Pro Glu Val Asp Asp Ser Ser Ala
 35 40 45
 Gln Lys Asp Trp Trp Phe Pro Gly Trp Phe Asn Asn Gly Ile His Asn
 50 55 60
 Tyr Gln Gln Glu Glu Glu Asp Thr Asp Lys Glu Lys Gly Arg Glu Glu
 65 70 75 80
 Glu Gln Lys Lys Glu Asp Thr Thr Glu Leu Arg Leu Trp Asp Trp
 85 90 95
 Phe Asn Pro Lys Lys Arg Pro Glu Val Met Thr Val Thr Gln Trp Lys
 100 105 110
 Ala Pro Val Val Trp Glu Gly Thr Tyr Asn Lys Ala Ile Leu Glu Asn
 115 120 125
 Tyr Tyr Ala Lys Gln Lys Ile Thr Val Gly Leu Thr Val Phe Ala Ile
 130 135 140
 Gly Arg Tyr Ile Glu His Tyr Leu Glu Glu Phe Val Thr Ser Ala Asn
 145 150 155 160
 Arg Tyr Phe Met Val Gly His Lys Val Ile Phe Tyr Val Met Val Asp
 165 170 175
 Asp Val Ser Lys Ala Pro Phe Ile Glu Leu Gly Pro Leu Arg Ser Phe
 180 185 190
 Lys Val Phe Glu Val Lys Pro Glu Lys Arg Trp Gln Asp Ile Ser Met
 195 200 205
 Met Arg Met Lys Thr Ile Gly Glu His Ile Leu Ala His Ile Gln His
 210 215 220
 Glu Val Asp Phe Leu Phe Cys Met Asp Val Asp Gln Val Phe Gln Asp
 225 230 235 240
 His Phe Gly Val Glu Thr Leu Gly Gln Ser Val Ala Gln Leu Gln Ala
 245 250 255
 Trp Trp Tyr Lys Ala Asp Pro Asp Asp Phe Thr Tyr Glu Arg Arg Lys
 260 265 270
 Glu Ser Ala Ala Tyr Ile Pro Phe Gly Gln Gly Asp Phe Tyr Tyr His
 275 280 285
 Ala Ala Ile Phe Gly Gly Thr Pro Ile Gln Val Leu Asn Ile Thr Gln
 290 295 300
 Glu Cys Phe Lys Gly Ile Leu Leu Asp Lys Lys Asn Asp Ile Glu Ala
 305 310 315 320
 Glu Trp His Asp Glu Ser His Leu Asn Lys Tyr Phe Leu Leu Asn Lys
 325 330 335
 Pro Ser Lys Ile Leu Ser Pro Glu Tyr Cys Trp Asp Tyr His Ile Gly
 340 345 350
 Leu Pro Ser Asp Ile Lys Thr Val Lys Leu Ser Trp Gln Thr Lys Glu
 355 360 365
 Tyr Asn Leu Val Arg Lys Asn Val
 370 375

<210> 7
 <211> 1269
 <212> DNA
 <213> Sus scrofa

<220>
 <221> CDS
 <222> (16)..(1131)

<400> 7
 catgaggaga aaata atg aat gtc aaa gga aga gtg gtt ctg tca atg ctg 51
 Met Asn Val Lys Gly Arg Val Val Leu Ser Met Leu
 1 5 10

ctt gtc tca act gta atg gtt gtg ttt tgg gaa tac atc aac agc cca	99
Leu Val Ser Thr Val Met Val Val Phe Trp Glu Tyr Ile Asn Ser Pro	
15 20 25	
gaa ggt tct ttg ttc tgg ata tac cag tca aaa aac cca gaa gtt ggc	147
Glu Gly Ser Leu Phe Trp Ile Tyr Gln Ser Lys Asn Pro Glu Val Gly	
30 35 40	
agc agt gct cag agg ggc tgg tgg ttt ccg agc tgg ttt aac aat ggg	195
Ser Ser Ala Gln Arg Gly Trp Trp Phe Pro Ser Trp Phe Asn Asn Gly	
45 50 55 60	
act cac agt tac cac gaa gaa gaa gac gct ata ggc aac gaa aag gaa	243
Thr His Ser Tyr His Glu Glu Glu Asp Ala Ile Gly Asn Glu Lys Glu	
65 70 75	
caa aga aaa gaa gac aac aga gga gag ctt ccg cta gtg gac tgg ttt	291
Gln Arg Lys Glu Asp Asn Arg Gly Glu Leu Pro Leu Val Asp Trp Phe	
80 85 90	
aat cct gag aaa cgc cca gag gtc gtg acc ata acc aga tgg aag gct	339
Asn Pro Glu Lys Arg Pro Glu Val Val Thr Ile Thr Arg Trp Lys Ala	
95 100 105	
cca gtg gta tgg gaa ggc act tac aac aga gcc gtc tta gat aat tat	387
Pro Val Val Trp Glu Gly Thr Tyr Asn Arg Ala Val Leu Asp Asn Tyr	
110 115 120	
tat gcc aaa cag aaa att acc gtg ggc ttg acg gtt ttt gct gtc gga	435
Tyr Ala Lys Gln Lys Ile Thr Val Gly Leu Thr Val Phe Ala Val Gly	
125 130 135 140	
aga tac att gag cat tac ttg gag gag ttc tta ata tct gca aat aca	483
Arg Tyr Ile Glu His Tyr Leu Glu Glu Phe Leu Ile Ser Ala Asn Thr	
145 150 155	
tac ttc atg gtt ggc cac aaa gtc atc ttt tac atc atg gtg gat gat	531
Tyr Phe Met Val Gly His Lys Val Ile Phe Tyr Ile Met Val Asp Asp	
160 165 170	
atc tcc agg atg cct ttg ata gag ctg ggt cct ctg cgt tcc ttt aaa	579
Ile Ser Arg Met Pro Leu Ile Glu Leu Gly Pro Leu Arg Ser Phe Lys	
175 180 185	
gtg ttt gag atc aag tcc gag aag agg tgg caa gac atc agc atg atg	627
Val Phe Glu Ile Lys Ser Glu Lys Arg Trp Gln Asp Ile Ser Met Met	
190 195 200	
cgc atg aag acc atc ggg gag cac atc ctg gcc cac atc cag cac gag	675
Arg Met Lys Thr Ile Gly Glu His Ile Leu Ala His Ile Gln His Glu	
205 210 215 220	
gtg gac ttc ctc ttc tgc atg gac gtg gat cag gtc ttc caa aac aac	723
Val Asp Phe Leu Phe Cys Met Asp Val Asp Gln Val Phe Gln Asn Asn	
225 230 235	
ttt ggg gtg gag acc ctg ggc cag tgc gtg gct cag cta cag gcc tgg	771
Phe Gly Val Glu Thr Leu Gly Gln Ser Val Ala Gln Leu Gln Ala Trp	
240 245 250	
tgg tac aag gca cat cct gac gag ttc acc tac gag agg cgg aag gag	819
Trp Tyr Lys Ala His Pro Asp Glu Phe Thr Tyr Glu Arg Lys Glu	
255 260 265	
tcc gca gcc tac att ccg ttt ggc cag ggg gat ttt tat tac cac gca	867
Ser Ala Ala Tyr Ile Pro Phe Gly Gln Gly Asp Phe Tyr Tyr His Ala	
270 275 280	
gcc att ttt ggg gga aca ccc act cag gtt cta aac atc act cag gag	915
Ala Ile Phe Gly Gly Thr Pro Thr Gln Val Leu Asn Ile Thr Gln Glu	
285 290 295 300	
tgc ttc aag gga atc ctc cag gac aag gaa aat gac ata gaa gcc gag	963
Cys Phe Lys Gly Ile Leu Gln Asp Lys Glu Asn Asp Ile Glu Ala Glu	
305 310 315	
tgg cat gat gaa agc cat cta aac aag tat ttc ctt ctc aac aaa ccc	1011

```

Trp His Asp Glu Ser His Leu Asn Lys Tyr Phe Leu Leu Asn Lys Pro
      320                      325                      330

act aaa atc tta tcc cca gaa tac tgc tgg gat tat cat ata ggc atg 1059
Thr Lys Ile Leu Ser Pro Glu Tyr Cys Trp Asp Tyr His Ile Gly Met
      335                      340                      345

tct gtg gat att agg att gtc aag ata gct tgg cag aaa aaa gag tat 1107
Ser Val Asp Ile Arg Ile Val Lys Ile Ala Trp Gln Lys Lys Glu Tyr
      350                      355                      360

aat ttg gtt aga aat aac atc tga ctttaaattg tgccagcagt tttctgaatt 1161
Asn Leu Val Arg Asn Asn Ile
      365                      370

tgaaagagta ttactctggc tactctctcca gagaagtagc acttaatttt aactttttaa 1221

aaaatactaa caaaataacca acacagtaag tacatattat tcttcctt 1269
  
```

<210> 8
 <211> 371
 <212> PRT
 <213> Sus scrofa

```

<400> 8
Met Asn Val Lys Gly Arg Val Val Leu Ser Met Leu Leu Val Ser Thr
  1      5      10      15
Val Met Val Val Phe Trp Glu Tyr Ile Asn Ser Pro Glu Gly Ser Leu
      20      25      30
Phe Trp Ile Tyr Gln Ser Lys Asn Pro Glu Val Gly Ser Ser Ala Gln
      35      40      45
Arg Gly Trp Trp Phe Pro Ser Trp Phe Asn Asn Gly Thr His Ser Tyr
      50      55      60
His Glu Glu Glu Asp Ala Ile Gly Asn Glu Lys Glu Gln Arg Lys Glu
      65      70      75      80
Asp Asn Arg Gly Glu Leu Pro Leu Val Asp Trp Phe Asn Pro Glu Lys
      85      90      95
Arg Pro Glu Val Val Thr Ile Thr Arg Trp Lys Ala Pro Val Val Trp
      100      105      110
Glu Gly Thr Tyr Asn Arg Ala Val Leu Asp Asn Tyr Tyr Ala Lys Gln
      115      120      125
Lys Ile Thr Val Gly Leu Thr Val Phe Ala Val Gly Arg Tyr Ile Glu
      130      135      140
His Tyr Leu Glu Glu Phe Leu Ile Ser Ala Asn Thr Tyr Phe Met Val
      145      150      155      160
Gly His Lys Val Ile Phe Tyr Ile Met Val Asp Asp Ile Ser Arg Met
      165      170      175
Pro Leu Ile Glu Leu Gly Pro Leu Arg Ser Phe Lys Val Phe Glu Ile
      180      185      190
Lys Ser Glu Lys Arg Trp Gln Asp Ile Ser Met Met Arg Met Lys Thr
      195      200      205
Ile Gly Glu His Ile Leu Ala His Ile Gln His Glu Val Asp Phe Leu
      210      215      220
Phe Cys Met Asp Val Asp Gln Val Phe Gln Asn Asn Phe Gly Val Glu
      225      230      235      240
Thr Leu Gly Gln Ser Val Ala Gln Leu Gln Ala Trp Trp Tyr Lys Ala
      245      250      255
His Pro Asp Glu Phe Thr Tyr Glu Arg Arg Lys Glu Ser Ala Ala Tyr
      260      265      270
Ile Pro Phe Gly Gln Gly Asp Phe Tyr Tyr His Ala Ala Ile Phe Gly
      275      280      285
Gly Thr Pro Thr Gln Val Leu Asn Ile Thr Gln Glu Cys Phe Lys Gly
      290      295      300
Ile Leu Gln Asp Lys Glu Asn Asp Ile Glu Ala Glu Trp His Asp Glu
      305      310      315      320
Ser His Leu Asn Lys Tyr Phe Leu Leu Asn Lys Pro Thr Lys Ile Leu
      325      330      335
Ser Pro Glu Tyr Cys Trp Asp Tyr His Ile Gly Met Ser Val Asp Ile
      340      345      350
Arg Ile Val Lys Ile Ala Trp Gln Lys Lys Glu Tyr Asn Leu Val Arg
      355      360      365
Asn Asn Ile
      370
  
```

<210> 9

```

<211> 1500
<212> DNA
<213> Musca sp.

<220>
<221> CDS
<222> (277)..(1461)

<400> 9
ccttccttg tagactcttc ttggaatgag aagtaccgat tctgctgaag acctcgcgct 60

ctcaggctct gggagttgga accctgtacc ttcctttcct ctgctgagcc ctgcctcctt 120

aggcaggcca gagctcgaca gaactcgggt gctttgctgt ttgctttgga gggaacacag 180

ctgacgatga ggctgacttt gaactcaaga gatctgctta cccagtcctc ctggaattaa 240

aggcctgtac tacatttgcc tggacctaag attttc atg atc act atg ctt caa 294
                Met Ile Thr Met Leu Gln
                1                    5

gat ctc cat gtc aac aag atc tcc atg tca aga tcc aag tca gaa aca 342
Asp Leu His Val Asn Lys Ile Ser Met Ser Arg Ser Lys Ser Glu Thr
                10                15                20

agt ctt cca tcc tca aga tct gga tca cag gag aaa ata atg aat gtc 390
Ser Leu Pro Ser Ser Arg Ser Gly Ser Gln Glu Lys Ile Met Asn Val
                25                30                35

aag gga aaa gta atc ctg ttg atg ctg att gtc tca acc gtg gtt gtc 438
Lys Gly Lys Val Ile Leu Leu Met Leu Ile Val Ser Thr Val Val Val
                40                45                50

gtg ttt tgg gaa tat gtc aac aga att cca gag gtt ggt gag aac aga 486
Val Phe Trp Glu Tyr Val Asn Arg Ile Pro Glu Val Gly Glu Asn Arg
                55                60                65                70

tgg cag aag gac tgg tgg ttc cca agc tgg ttt aaa aat ggg acc cac 534
Trp Gln Lys Asp Trp Trp Phe Pro Ser Trp Phe Lys Asn Gly Thr His
                75                80                85

agt tat caa gaa gac aac gta gaa gga cgg aga gaa aag ggt aga aat 582
Ser Tyr Gln Glu Asp Asn Val Glu Gly Arg Arg Glu Lys Gly Arg Asn
                90                95                100

gga gat cgc att gaa gag cct cag cta tgg gac tgg ttc aat cca aag 630
Gly Asp Arg Ile Glu Glu Pro Gln Leu Trp Asp Trp Phe Asn Pro Lys
                105                110                115

aac cgc ccg gat gtt ttg aca gtg acc ccg tgg aag gcg ccg att gtg 678
Asn Arg Pro Asp Val Leu Thr Val Thr Pro Trp Lys Ala Pro Ile Val
                120                125                130

tgg gaa ggc act tat gac aca gct ctg ctg gaa aag tac tac gcc aca 726
Trp Glu Gly Thr Tyr Asp Thr Ala Leu Leu Glu Lys Tyr Tyr Ala Thr
                135                140                145                150

cag aaa ctc act gtg ggg ctg aca gtg ttt gct gtg gga aag tac att 774
Gln Lys Leu Thr Val Gly Leu Thr Val Phe Ala Val Gly Lys Tyr Ile
                155                160                165

gag cat tac tta gaa gac ttt ctg gag tct gct gac atg tac ttc atg 822
Glu His Tyr Leu Glu Asp Phe Leu Glu Ser Ala Asp Met Tyr Phe Met
                170                175                180

gtt ggc cat cgg gtc ata ttt tac gtc atg ata gac gac acc tcc cgg 870
Val Gly His Arg Val Ile Phe Tyr Val Met Ile Asp Asp Thr Ser Arg
                185                190                195

atg cct gtc gtg cac ctg aac cct cta cat tcc tta caa gtc ttt gag 918
Met Pro Val Val His Leu Asn Pro Leu His Ser Leu Gln Val Phe Glu
                200                205                210

atc agg tct gag aag agg tgg cag gat atc agc atg atg cgc atg aag 966
Ile Arg Ser Glu Lys Arg Trp Gln Asp Ile Ser Met Met Arg Met Lys
                215                220                225                230

acc att ggg gag cac atc ctg gcc cac atc cag cac gag gtc gac ttc 1014
    
```

Thr	Ile	Gly	Glu	His	Ile	Leu	Ala	His	Ile	Gln	His	Glu	Val	Asp	Phe		
				235					240					245			
ctc	ttc	tcg	atg	gac	gtg	gat	caa	gtc	ttt	caa	gac	aac	ttc	ggg	gtg	1062	
Leu	Phe	Cys	Met	Asp	Val	Asp	Gln	Val	Phe	Gln	Asp	Asn	Phe	Gly	Val		
			250					255					260				
gaa	act	ctg	ggc	cag	ctg	gta	gca	cag	ctc	cag	gcc	tcg	tcg	tac	aag	1110	
Glu	Thr	Leu	Gly	Gln	Leu	Val	Ala	Gln	Leu	Gln	Ala	Trp	Trp	Tyr	Lys		
			265				270					275					
gcc	agt	ccc	gag	aag	ttc	acc	tat	gag	agg	cgg	gaa	ctg	tcg	gcc	gcg	1158	
Ala	Ser	Pro	Glu	Lys	Phe	Thr	Tyr	Glu	Arg	Arg	Glu	Leu	Ser	Ala	Ala		
			280			285					290						
tac	att	cca	ttc	gga	gag	ggg	gat	ttt	tac	tac	cac	gcg	gcc	att	ttt	1206	
Tyr	Ile	Pro	Phe	Gly	Glu	Gly	Asp	Phe	Tyr	Tyr	His	Ala	Ala	Ile	Phe		
					300				305						310		
gga	gga	acg	cct	act	cac	att	ctc	aac	ctc	acc	agg	gag	tcg	ttt	aag	1254	
Gly	Gly	Thr	Pro	Thr	His	Ile	Leu	Asn	Leu	Thr	Arg	Glu	Cys	Phe	Lys		
				315					320					325			
ggg	atc	ctc	cag	gac	aag	aaa	cat	gac	ata	gaa	gcc	cag	tcg	cat	gat	1302	
Gly	Ile	Leu	Gln	Asp	Lys	Lys	His	Asp	Ile	Glu	Ala	Gln	Trp	His	Asp		
			330					335					340				
gag	agc	cac	ctc	aac	aaa	tac	ttc	ctt	ttc	aac	aaa	ccc	act	aaa	atc	1350	
Glu	Ser	His	Leu	Asn	Lys	Tyr	Phe	Leu	Phe	Asn	Lys	Pro	Thr	Lys	Ile		
			345				350					355					
cta	tct	cca	gag	tat	tcg	tcg	gac	tat	cag	ata	ggc	ctg	cct	tca	gat	1398	
Leu	Ser	Pro	Glu	Tyr	Cys	Trp	Asp	Tyr	Gln	Ile	Gly	Leu	Pro	Ser	Asp		
			360			365					370						
att	aaa	agt	gtc	aag	gta	gct	tcg	cag	aca	aaa	gag	tat	aat	ttg	gtt	1446	
Ile	Lys	Ser	Val	Lys	Val	Ala	Trp	Gln	Thr	Lys	Glu	Tyr	Asn	Leu	Val		
					380					385				390			
aga	aat	aat	gtc	tga	cttcaaattg	tgatggaaac	ttgacactat	ttctaacca								1500	
Arg	Asn	Asn	Val		395												

<210> 10
 <211> 394
 <212> PRT
 <213> Musca sp.

<400> 10
 Met Ile Thr Met Leu Gln Asp Leu His Val Asn Lys Ile Ser Met Ser
 1 5 10 15
 Arg Ser Lys Ser Glu Thr Ser Leu Pro Ser Ser Arg Ser Gly Ser Gln
 20 25 30
 Glu Lys Ile Met Asn Val Lys Gly Lys Val Ile Leu Leu Met Leu Ile
 35 40 45
 Val Ser Thr Val Val Val Val Phe Trp Glu Tyr Val Asn Arg Ile Pro
 50 55 60
 Glu Val Gly Glu Asn Arg Trp Gln Lys Asp Trp Trp Phe Pro Ser Trp
 65 70 75 80
 Phe Lys Asn Gly Thr His Ser Tyr Gln Glu Asp Asn Val Glu Gly Arg
 85 90 95
 Arg Glu Lys Gly Arg Asn Gly Asp Arg Ile Glu Glu Pro Gln Leu Trp
 100 105 110
 Asp Trp Phe Asn Pro Lys Asn Arg Pro Asp Val Leu Thr Val Thr Pro
 115 120 125
 Trp Lys Ala Pro Ile Val Trp Glu Gly Thr Tyr Asp Thr Ala Leu Leu
 130 135 140
 Glu Lys Tyr Tyr Ala Thr Gln Lys Leu Thr Val Gly Leu Thr Val Phe
 145 150 155 160
 Ala Val Gly Lys Tyr Ile Glu His Tyr Leu Glu Asp Phe Leu Glu Ser
 165 170 175
 Ala Asp Met Tyr Phe Met Val Gly His Arg Val Ile Phe Tyr Val Met
 180 185 190
 Ile Asp Asp Thr Ser Arg Met Pro Val Val His Leu Asn Pro Leu His
 195 200 205
 Ser Leu Gln Val Phe Glu Ile Arg Ser Glu Lys Arg Trp Gln Asp Ile
 210 215 220

Ser Met Met Arg Met Lys Thr Ile Gly Glu His Ile Leu Ala His Ile
225 230 235 240
Gln His Glu Val Asp Phe Leu Phe Cys Met Asp Val Asp Gln Val Phe
245 250 255
Gln Asp Asn Phe Gly Val Glu Thr Leu Gly Gln Leu Val Ala Gln Leu
260 265 270
Gln Ala Trp Trp Tyr Lys Ala Ser Pro Glu Lys Phe Thr Tyr Glu Arg
275 280 285
Arg Glu Leu Ser Ala Ala Tyr Ile Pro Phe Gly Glu Gly Asp Phe Tyr
290 295 300
Tyr His Ala Ala Ile Phe Gly Gly Thr Pro Thr His Ile Leu Asn Leu
305 310 315 320
Thr Arg Glu Cys Phe Lys Gly Ile Leu Gln Asp Lys Lys His Asp Ile
325 330 335
Glu Ala Gln Trp His Asp Glu Ser His Leu Asn Lys Tyr Phe Leu Phe
340 345 350
Asn Lys Pro Thr Lys Ile Leu Ser Pro Glu Tyr Cys Trp Asp Tyr Gln
355 360 365
Ile Gly Leu Pro Ser Asp Ile Lys Ser Val Lys Val Ala Trp Gln Thr
370 375 380
Lys Glu Tyr Asn Leu Val Arg Asn Asn Val
385 390

<210> 11
<211> 1885
<212> DNA
<213> Homo sapiens

<400> 11
tgcctcagcc tcccaaagtg ctggactaca ggcatgagcc aaccacgccc gccagccaa 60
atatggtgaa accctttctc tactaaaaat acaaaaatta gctgggcaga tgataaggag 120
aaaataatga atgtcaaagg aaacgtaatt cctccagtgc tggttgtctc aactgcgatt 180
gttgtggttt ggaaatgtat caacacccaa gaaggctctc tcttgtggat gtatcactta 240
aaacacccag aagttgttga cggcgcgagg tcaagcagag cagaagggcc ggtggtttcc aagctgcttc 300
aacaatggga ccacaaatcc tgacaaaaaa agagcttcgg ctatggaact ggtttaatcc 420
aaagaaaaaa gaaaagaaga tgacgggtgac cagttggaat gagccggttg tgtgggaagg 480
atacgtatgc ccagaggtgc tgacgggtgac cagttggaat gagccggttg tgtgggttg 540
cacttagaac agaaccatcc ttaaaataa ttatgcaaa cagaaaatta ctgtgggttg 600
acggtttttg ctgtcggaag acatgtagag tattacttga aggagtcat agcatctgct 660
gataggctact tcatggtaag ccacaaagtc atgttttaca tcatggccga taatccagga 720
tgctgttgat agagctgggt cctctgcgtt tcttcagagt gtttgagatc aagcccagga 780
agaggttagca ggtcatcagc atcgtgggca tgaagaccaa cagggagcac atgttgccc 840
acatccaaca ggaagttgac ggagaccctg taggagaggc ccatggatgt ggaccaagtg ttccaagaca 900
atgtttggat ggagaccctg taggagaggc ccatggatgt ggaccaagtg ttccaagaca 960
cacatcctga ggagaatact cagcgagcca tttttggttg aacaccattt cactttctca 1020
gccaggggga tttttattac aaggggaatcc tccaggacag gaaaaatgac ctccaagcca 1080
acatcaccca ggagtgcttt taaacaagta tttcttcctc aacataccct ctaagatcct 1140
agtggcatga taaagccacc attatcatta taggtcatca tgaagatatt aaaattgtca 1200
atcaccagaa tgctgtctgg gcaagcaaaa tggttagaaa tgatgactga cttcaaatg 1260
agctatcttg tttttgaatt tgagagaatt attattctgg ctacttctc agaaaaaat 1320
tgccaacagt agaaaatatt aatgaaacac caacattgca atcacatact atctctcctt 1380
tttaacttta gcaattgta atgtattctg aatttggggg aaatactatc agctgaacca gaaagaactt 1440
gtgatttctt atgtattctg aatttggggg aaatactatc agctgaacca gaaagaactt 1500
gtcataggca aagataaagc gagtaaacagg cagtgaggtc ggaggttcgag accagcttg 1560
agtactttgg gagggcaagg gagggtgagc cctgaggtca ggaggttcgag accagcttg 1620
ccaacatggt gaaatcccgt ctctactaaa aatacaaaaa attagccggg catgggtggc 1680
cacacctgta atcccaccta ctccaggaggc tgaggcggga gaatacactg aacctgggag 1740
gcagaggttg cattgagcca gattgtacca ttgtactcca gcctgggcaa aagagtga 1800
ttccatctaa aaacaaacaa acaaaactct acatgtgtca gataacatcc tggagaaaa 1860
caggtggtaa gggaagtgtt ggcag 1885

<210> 12
<211> 197
<212> PRT
<213> Homo sapiens

<400> 12
Ser Arg Met Leu Leu Ile Glu Leu Gly Pro Leu Arg Phe Phe Arg Val
1 5 10 15
Phe Glu Ile Lys Pro Glu Lys Arg Xaa Gln Val Ile Ser Ile Val Gly
20 25 30
Met Lys Thr Asn Arg Glu His Met Leu Ala His Ile Gln Gln Glu Val

35 40 45
Asp Phe Leu Phe Cys Met Asp Val Asp Gln Val Phe Gln Asp Asn Phe
50 55 60
Gly Val Glu Thr Leu Gly Gln Ser Val Ala Gln Leu Xaa Ala Trp Trp
65 70 75 80
Tyr Trp Thr His Pro Glu Glu Asn Thr Xaa Glu Arg Gln Lys Glu Ser
85 90 95
Val Ala Tyr Ile Pro Phe Gly Gln Gly Asp Phe Tyr Tyr His Ala Ala
100 105 110
Ile Phe Gly Gly Thr Pro Ile His Phe Leu Asn Ile Thr Gln Glu Cys
115 120 125
Phe Lys Gly Ile Leu Gln Asp Arg Lys Asn Asp Leu Glu Ala Lys Trp
130 135 140
His Asp Lys Ala Thr Xaa Thr Ser Ile Ser Ser Ser Thr Tyr Pro Leu
145 150 155 160
Arg Ser Tyr His Gln Asn Ala Ala Gly Ile Ile Ile Ile Gly His His
165 170 175
Glu Asp Ile Lys Ile Val Lys Leu Ser Trp Gln Gln Lys Glu Tyr Thr
180 185 190
Leu Val Arg Asn Asp
195

<210> 13
<211> 17141
<212> DNA
<213> BOVINE

<400> 13
ggagagtaga gtttctgagt ttagacacac tgaatcagcc aatcacagat gaagagcact 60
gagcaacaag agttcatott acattccccc aaaccaatga acttggtatta tgccctgggc 120
taatctgctc tcagaagcag ggagggcagg aggctgggtg gggctcaca ggaagaccag 180
ggcccctact gcttacacat gcttttgaca caactgacg ctgcacaaac acacatcatg 240
gtgtatctga ctcttgagaa gaaggctact gtcattgact tgtggagtaa gatgagggtg 300
gctgaagtgt gtccggatac tgtaggcagg caggatttca acttacaagg caggctgaag 360
gagagtgaat gtcagttggg tgtgtgggga cagagccatt gcctgagatt ctggcaggca 420
ctgactccct ctgaccttgt gctgttttca ccccctttgc tgcctgtcgt ctaccctcgt 480
actcagaggt tctttgacta ttgtggggac tgtcctttgc tgatttatgg gcaatgtttt 540
accttctttg tttccaggca tagtttcttc ttattcattc ttgtttttct ctgtttgttc 600
tctgcagtat ctcttttata tttaaacatt ttgactgttt aagtgtttga gtattaagac 660
tttcttcttt tatgtcactt aaaaattttg tctcatgatt ttcccttacc tcttcttttt 720
taagcaagga agacaaaatg atgtattgct tcttgaaaca gttcaaaaaa ataaaaaaa 780
tgatagcaag ttcagaatta agatagaaag agagaaacat ctctaagtat aaactcaggc 840
ttatatgggt ggcttcacat cagtagtaac atctacactt tagccatctt tctgcttata 900
ttctaggggc acagcttgag atgagactga aatactaagt ccaaattggg tgccctctgt 960
aacattgtoc ttgtttttco tctctaccac acagctcctg ggcaatatac tgatgagtac 1020
actggcctga aactttggca tctctaccac cccagaattt caggttgcct gtcagaaggt 1080
gggtggctggt gtgggttaatg ctctcaccta caaataccat tgagatcctg tcctattttt 1140
tattttcaaa tgagtattta ttcttaattg attgatgatt ggtttacaat attgggttga 1200
ttactatcat acattaatat gaattaacca taggtgtatg tatttccct cccagctgaa 1260
tctccctctc acctctggcc cattcccacc cctctaggtt attacagagt tcccattcga 1320
attcgaattc cttaggttga tgaccattgt gatagcttat gttgaatggt gtcagatttt 1380
tggtctccag agcagacagt ttcgatccgg ggccagagac aaaatttgat cactcagagc 1440
ttttgcgtgg cagttttatt acagtgaaaa ggggacagag aaagcttctg acatagacat 1500
cagaagggga acaggagact gtcccactag ctagtctcat caagacctta tataattttt 1560
cagttgggta ctacaatgg aaaggtctta tcaaaccctc tccctaaaac ctaaaataac 1620
aggattagtc agaaggttct taagaaggag aaccatgtcc tcaagcaaca tccattgttt 1680
ttctataatc attagtggac ttccctgatg gctcagaagg taaagcctct gtctacaatg 1740
cgagagacct ggtttcgatc cctgggttgg gaagattccc tgagaaggaa atagcaaccc 1800
actccggtag tcttgcttgg aaaatccctt gaaaatcccg tggatggagg agcttggtgc 1860
aggctactgt ccatggggtt gcaaagagtc ggggaatgact gcgcgacttc actttcactt 1920
tcactttctt tcaatcatta gtataaagt taaattcacc ttgagcaaga tgaattgttt 1980
tgttgtttaa tcatttagtt aagttcagtt cagtcactca gtcattgtccg actctttgcg 2040
accccatgaa tcacagcacg ccaggcctcc ctgtccatct cctcccggag ttcacccaac 2100
gtcacgtcca tcagtcggg gatgccatcc agccatctca tctctgtcgt tccccttttc 2160
ctcctgcccc caatccctcc cagcatcagg gtcttttcca gtgagtcaac tcttcacatg 2220
aggtgcccaa agtactggag tttcagtttt agcatcattc ctcccaaaca acaccccagg 2280
gcttatctcc tttagaatgg actggttgga tctccctgca gtccaagggg ctgcgaagaa 2340

tctttctccaa caccacagtt caaaagcatc aattttctcg cactcagctt tcttcacagt 2400
ccaactctca catccgtaca tgaccactgg aaaaaccata gccttgacta gacggacctt 2460
tggttgaacg taatgtctct gcttttcaat atgtctatca ggttggctat agctttcctt 2520
ccaaggagta agcatcattt aatcattagc tctgggctta aagaaagtta atcttcagac 2580
tggtgtcaaa acaactcaaa gttaagggaa aaattttcta tgtgactaag acaatgtaat 2640
gcaaaaaaaa atagtttgtc cttttctcct ccttgacaac actctctcaa ctggaagatc ctatttccct 2700
tggaactcctt atcaatctac ctaagagtta actctctcaa atttttgagt tacaatattg 2760
acattcttctt attgtttaac aattcaaaaa ttgtttttta ggccacaaga catgtcagat cttagctccc 2820
ttctctgtgtt ttttatgttc ttgtttttta tagaccaagc ttaaacacta gactgtcatg 2880
tgaacagaat agaactctca ccccttgcat tctgaacttg gcgaaataat gtccaccctc 2940
gaagtccagc tttttcccca gattttatct ttcagctcaa ttctctgatt cattttactc 3000
aatgatattga cttcttctca ataaagaact cgctaaggat atgggaaagt ccttgaggtc tacagataga 3060
atttttttttt tttttcttct gagagaacaa gggaatagag aaaagtaagg ggaccacaca 3120
aaggctttgt gtcttatata ctgtctcaaa gcataagaac tataagaagg tttaaaatat 3180
gtcaataacg gatgacattc aggggctcat gggaaacttc aaatttagac gcaaaacttca 3240
agttaggata ctgatcatat ccactaagta tcaagaaata atgtgtctcag agacaaaatg 3300
gggtaacact attgctcgag aaactgttat taatgtttcc ttttttctta cttcccttgc ctgcacattt 3360
attgctcgag tagctatgta aaccaggtgt tctctattct ccaacctccg atgtataatc tccctctccc 3420
taggcaacaa aaacacctcc acttcttgac ctccactccc ataagtgttt ctgccttttg tttactaag 3480
atltgccccca acttgcttga atcttttgac ctccactccc tccatagaca gtaagtgtat gttactaag 3540
ctcacataac tttccaaaact tgctatgta aaaaatlaacc cttggcatca gtgaaatttc cagtattgct 3600
taaggaaatt tagcacaccc atgtcttaca caattatttc ttgtcccaaa actcctggga gtagaggaca 3660
acttctgtgc atagctatc tatgtctatt catagtgttt ctttgggtgt agtgctacaa tatacaatga 3720
cataattacc tgtatgaatg atgtctattg ttactgtatt agatatttgc tttctgatta tagtagactt 3780
tgtagtaact atctgaaaaa ggaagcacac aaaaattttt gaactctatt taatacgaat tccccaaact ccctcgcatc 3840
atctgaaaaa ggaagcacac aaaaattttt aagtgtcaac catatcatc attgacttcc gtgtacttgt ccatcccaaa caggaacctt 3900
aaaattttttt aagtgtcaac catatcatc attgacttcc gtgtacttgt ccatcccaaa caggaacctt 3960
aaggctcagc caggctggca tccatttttaa tttttgtcat taaatctata acataaaaatg gtttactgtt tctcatgttt 4020
caggctggca tccatttttaa tttttgtcat taaatctata acataaaaatg gtttactgtt tctcatgttt 4080
tgtagaaatta tgcatttctt acagatcatg agtgcataaa atttggtttct ctatgtttta taaccacagg gtcacatccc 4140
gggtattggc aaatgagctt gaatccttta acatctcagg taagaattag tttggaaatg atatctgagg tctagataaa 4200
aaatgagctt gaatccttta acatctcagg taagaattag tttggaaatg atatctgagg tctagataaa 4260
gaatccttta acatctcagg taagaattag tttggaaatg atatctgagg tctagataaa 4320
acatctcagg taagaattag tttggaaatg atatctgagg tctagataaa 4380
taagaattag tttggaaatg atatctgagg tctagataaa 4440
taagaattag tttggaaatg atatctgagg tctagataaa 4500
taagaattag tttggaaatg atatctgagg tctagataaa 4560
taagaattag tttggaaatg atatctgagg tctagataaa 4620
taagaattag tttggaaatg atatctgagg tctagataaa 4680
taagaattag tttggaaatg atatctgagg tctagataaa 4740
taagaattag tttggaaatg atatctgagg tctagataaa 4800
taagaattag tttggaaatg atatctgagg tctagataaa 4860
taagaattag tttggaaatg atatctgagg tctagataaa 4920
taagaattag tttggaaatg atatctgagg tctagataaa 4980
taagaattag tttggaaatg atatctgagg tctagataaa 5040
taagaattag tttggaaatg atatctgagg tctagataaa 5100
taagaattag tttggaaatg atatctgagg tctagataaa 5160
taagaattag tttggaaatg atatctgagg tctagataaa 5220
taagaattag tttggaaatg atatctgagg tctagataaa 5280
taagaattag tttggaaatg atatctgagg tctagataaa 5340
taagaattag tttggaaatg atatctgagg tctagataaa 5400
taagaattag tttggaaatg atatctgagg tctagataaa 5460
taagaattag tttggaaatg atatctgagg tctagataaa 5520
taagaattag tttggaaatg atatctgagg tctagataaa 5580
taagaattag tttggaaatg atatctgagg tctagataaa 5640
taagaattag tttggaaatg atatctgagg tctagataaa 5700
taagaattag tttggaaatg atatctgagg tctagataaa 5760
taagaattag tttggaaatg atatctgagg tctagataaa 5820
taagaattag tttggaaatg atatctgagg tctagataaa 5880
taagaattag tttggaaatg atatctgagg tctagataaa 5940
taagaattag tttggaaatg atatctgagg tctagataaa 6000
taagaattag tttggaaatg atatctgagg tctagataaa 6060
taagaattag tttggaaatg atatctgagg tctagataaa 6120
taagaattag tttggaaatg atatctgagg tctagataaa 6180
taagaattag tttggaaatg atatctgagg tctagataaa 6240
taagaattag tttggaaatg atatctgagg tctagataaa 6300
taagaattag tttggaaatg atatctgagg tctagataaa 6360
taagaattag tttggaaatg atatctgagg tctagataaa 6420
taagaattag tttggaaatg atatctgagg tctagataaa 6480
taagaattag tttggaaatg atatctgagg tctagataaa 6540
taagaattag tttggaaatg atatctgagg tctagataaa 6600
taagaattag tttggaaatg atatctgagg tctagataaa 6660
taagaattag tttggaaatg atatctgagg tctagataaa 6720
taagaattag tttggaaatg atatctgagg tctagataaa 6780
taagaattag tttggaaatg atatctgagg tctagataaa 6840
taagaattag tttggaaatg atatctgagg tctagataaa 6900
taagaattag tttggaaatg atatctgagg tctagataaa 6960
taagaattag tttggaaatg atatctgagg tctagataaa 7020

gagagagggg aggggagggg caggataggg aaaggaaatt aaaagataca aattactgtg 7080
tacaaaatag attagcaaca aggatataatt gtacagaaca gaaaacatag tcaataattt 7140
attgcaactt taaatggtgc atagtcctta aaactactga atcactatgt tgtatatctg 7200
aaactaatat aatatttatag atcaaatatt ttaaaataat taattcgaat caaatgaatt 7260
agggaaatca tttctgaaaa cagaaaaggga taggggaagt ctttaagtac atgctaattt 7320
ctgtcagtc agagggcaaa attgtagccc tggcaatttg gctcctttac aagaaaatat 7380
agaaatagac tatactatta gttagtaagt tctgtgagtt ttccataaca cagagtccct 7440
gaaaagatat gtccaaagtt ttccagaaga agtctttaac tcacatatgc ctgacctctg 7500
atatcagaga tataaaatag gtcttttaaa gagtacaaat ataaaaaat gataaagcta 7560
atggagattt cagtttaatc gattgaaaat caaaactcaa gatcaaatca aatgtagctt 7620
tttgttttta acatttaaaa tatttaaaaga tttcttttcc cagaagtcaa catgtggaaa 7680
tttttttcta agtatagacc aatagtttaga gcttctttct ttgaaggttg cagaaaagag 7740
tgaatataaa ttgaaaatgt ttaaactcta tattttttcc cctataatct tgtgggcata 7800
taatcctacc ctaacttcca gagagccaag caagagccaa cacttttcta catttctgaa 7860
aatatcagga tgaatttgtt cacaattac ttgaatggga atgggcccaga ctttctgtaa 7920
aagaaatctt cagttaccta gcaatgatgg gcaatgagaa ttttggaggc tggagtaatt 7980
aaaactggac atttatgaat ttctttgtaa caactagaaa tgcagaagtc ctttctattt 8040
agttccccta aaaatatatt agttggagtt acagagacat agagctgaaa gaatgagaga 8100
tttttaaaaa tagtttttgc cgggtgatgg gcaaaagggt agagaaagggt gattctagac 8160
atcaagttgt ctgaatcagg agaaggttct aaggtgagag aagggagta aatatatatg 8220
ctcctctcct tactaaaagg aagtggaaat tcaagaagaa gggaagatgc agaaagtaga 8280
gatcatagaa agtaggggga cctcagggaa ctctgagatc taatgctgag ctcaaaatg 8340
ctttctgctt ttgctttttc attaaatctt ctagttagta gaagcagacc tctacacttc 8400
agaagttctt ctccctaag aaggttaaga ggatttatta ccacgggttg gaggaggtgc 8460
aaatagagaa gaaatatttg aaaagctgta gataaagaag gatacatctt agtaaaagag 8520
gtataaacia agtatataga gaaaacagaa ttaaagatga actgaaatag aagaaatctt 8580
tatgcacact gtactcttag aggttttaggg gagaaaacca aataatctga ttcaacttgg 8640
aatgcttttc cacaatttta tccctccttt taaatcacag agaagtttct ctgttcttga 8700
agacactttc ccaggtcagt ttatgaggaa acaatttata tgccctgatt tagtctttga 8760
acacatttgc tatctcaggg ttattgaaac tttgggagtt tgattgattt tttactttgt 8820
atctcttact acatggaggg gctctctatg tttcatctat gggttaatgg agtagctatt 8880
tcataggaat tcttgatcca tacttattct atttttctat cattatttat ttggtcataa 8940
atctaaattt gaaaaaatga atgagtagat tagcaaatga atatttgttt tcataccaga 9000
acaacttaat ccaacaacaag agatgcataat agatgcataat ttagaacagg gacagaggtt 9060
ttatccatgc tgctcttcta attattttgt gtattctgaa ggcacaggag atgatccatc 9120
cacatcgtct taagctgaat catagtggac aaatccttct agagattact tctgtgctga 9180
cttcatttgt ataataagaa aattgaggag gtggtttcca gaggagaggg gctgcctcac 9240
ttctaaaatc tctgtaagca aacttgctaa ggaagatgat tttagtagca gtttgattg 9300
ctggaaatgac tgagacctag agatgccag cattcaagcc caccctgtg taagcacacc 9360
aggaagacta aggaagaggt cagagaggtc gggaggtcag gaggcagggt taagcataaa 9420
ttggcctgag ccaatctgct cagagaggtc ttgcttctga cacaaccgtg ttacttagca 9480
aggaagagct gggccagctg ctgcttacac gaggagaggg gctgcctcac ctccctattt 9540
actacacaaa aagtggatga gctgagcgtc gaggagaggg gaggcctgag atcctgctta 9600
gccaaggtga aagtggatga agttgggtgt tgctgtcagg cgtgtccgac tctgtgagc 9660
caagacaggt ttgctgtctg cagagccatc aggtcttacc tgccttccag aagaacattg 9720
cccatagacg ccatttctct ctccaatgca tgaaagttaa aagtgaaggt gaagtcgctc 9780
gagtgggttg ccatttctct cagcgatccc atggactcgg ccttccaggc tctcccttcc 9840
agtcatgtcc ccattggact gtaacggaggt ggggtgccc agccgtccct gacaagacag 9900
atgggatttt agtgaaatgc accctggcgt ttttctcccc ctaggctgct ggtgtctac 10020
gtttaaggag ctccctctga ccttctcttg tgagttctt cctctgcccga tgccattttg 10080
aagctgtctg ccttggaact agaggttctt ccatggcaag aaggtgctgg actccttctg tgagggcctg 10140
ccctggactc aggtgaaggc ggggtccttt gcttcgctga gtgagctgca ctgtgataag 10200
gaaaccctta atgacctcaa cttcaggggt agtttgtgga atcctcaata ttctctttt 10260
ctgcacgtgg atcctgagaa gggagagggt tgactggcag gacgtagttt agaatggaga 10320
atggctcaagc ttgtgtcatg ggttaaaagt gcttaaggact atttagattc ttttaatttc 10380
agatgtattc ttgtgtcaca ataactattt ttagtgttca atttgaataa aagatttctt 10440
tttgtctaca ttatactctt tcccttctat tgcttcttcc tctgtgtct gcaatgtctt 10500
ctctttttta tctaataatt ataataaaaa tgataacaag ttctggatta agatagaaag 10560
aaacataata gcttttcgaa gtgatttcaa aaattcagcc tgctatgggt accttcatat cagcagtagc 10620
gcttttcgaa ttctaaatat tgtgctaata ccttaggggc acagcttggg atgaatctga 10680
aatgaaacat cagtcactt agtcaacctg ggcacctgca ctaacctgct ccttgcctaa tgtcttttcc 10740
atctatactt agtactctga atctaacctg gctggtggtc gtgctggctc ggcgttttgg cagtgaattc 10800
agtaactctg tgggcaacgt ctttcagaag gctgtgactg gtgtggccaa tgccctggcc 10860
acacagctcc tcccgggagc actaagctcc aatatggaaa aattatgaag cgttttctgc tgcctaataa 10920
cacagatctc ccaaaaactg tttcattgca actggtgact taaattattt cactgtctct tactcagatg 11000
agacatttat gggcaacagg atcagtatct actgaagaca taaagaaatg aaggcctaag ttgagacttt 11060
ggcacacggg gagaaaatac ggtctgtct catctacaca gtcatttaga tgccttttcc ctgtctctg 11120
gagaaaatac ggtctgtct catctacaca gtcatttaga tgccttttcc ctgtctctg 11180
gttgctttta atgctttctc cttcaataac cgtttatccg tctgtgactc taattctgaa gttcagttcc 11240
ttttagtaat gttgtacaat tctttgcaac cctatggact gacagatgac aggttccct 11300
gtggctcagt gtcctcacc aactcctgga gcttgcctaa attcatgccc attgagttgg tgatgccatt 11360

caaccatctc atccctctgtt atcccccttct cttgccttca atctttccca gcatcagggt 11760
cttttccaat gagtcagttc ttccatcac ggttccaaag tattgaagct tcacgttcgg 11820
tatcagtcct tccaatgaat attcaggact aatatccttc aggtttgatt gggttgatct 11880
ccttgacgtc caagggaact tcaggagtct tctccaacat cacagttcaa aagcatcaat 11940
tcttcagcgg tcacctttct tcattgtcca actctcacat ccacacatga ctactggaaa 12000
aaccatagcc ttgactagat ggacatttgt tgataaagta gtgtctctgc tttttaatat 12060
gctgtctaga tttgtgtag cttttcttcc aagaagcaag catctttgaa tttcatggct 12120
gcagtcacca tcttcagtgat ctttggagcc ccccaaaata aagtgtctca ctgtttccat 12180
tgcttcccca tatatttgc atcaaatgat ggtaccagat gccatggctc tggtttttgg 12240
aatgctgact tttacgccag ctcttttact ctctctttc actttcacca agaggctctt 12300
tagctcctct ttgctttctt ccataagggg ggtgaccact gcatatctga gcttattgat 12360
atttctccag gcaatcttga ttcagcttg tgcttoatcc agcctgccat tttgcataat 12420
gtactttgca tagaggttaa ataagcaggg tgacaatata cagccttgac gcattccttt 12480
ccctattctg aatctagttg gggagggttct gcttttatga gatctgagga tttgcataat 12540
aataacgcat ctaataaatg ggtgtaacac gaaagtaacg catctaacaa gtgactatct 12600
ggatgaaat ggtgtaagag gtcaagtcac gcttttatga tagacaattg tccagaagac aagaagcaa 12660
aagtcaaaa agaaaaggag ataactgaag gtatgaatga tgatgaataa tgtgtttgtg tttctgaga 12720
atctcaggtt aacaggaaag ggtgaacaca caaaaactgcc tgagatagaa tagaatagat 12780
tataaatttt agccattact ctatgttgaat ttcttaaagt taaaaattca cagacaagag 12840
gatacaattc gtttgaacaa gtgaaaattc atcagacagc aaggattgaa taaagtaaga 12900
tagtttaaca ctctgacctt tgcaaaaaaa tttacaaga ggtgtcaat ttggatatata aatatgtcgt 13020
tacttattag tgcagaaaaa caggtgagaa ggggtggcaa tattgaagag tagggaattt 13080
cttttaagatt aagttaatgt aatgcagccc atctcagccc caacaggcaa ccatgctagc agcgtctatg 13140
ccttttaacaa tctcttccca tttttttttt tggatcttaa ctggaatcaa ggtgtgagat aggtgtggt 13200
tctagaagaa agttgaatta atgttttagg ataacacagg gctgtatgca tagatcatca atgtcctct 13260
tttaagacaa tccagttgaa ttaatcagtt tattttcaag tgatgggaac ttctcaaaaa cccagatgac cactcattat 13320
tataaaaaatg ttttttgcgt ttttatagata gtcattgtctg gcaagaatac ggaaccgagt taaatataca 13380
tagtcaactca gttcatgtctg gcaagaatac ggaaccgagt taaatataca 13440
gatttctccag acccaggaat taaatataca tagtataaa actattctag acatctagtt cttaaact 13500
acataaactg caacctctga tttcaaaact cttaaact tttcatctt tgaggtctcc 13560
aatgtattta ttttcaaaact cttaaact tttcatctt tgaggtctcc 13620
caaatctgcc ttttcaaaact cttaaact tttcatctt tgaggtctcc 13680
gaatctgctt gcaaaagtggt agacctgggt tctgtacaa ccatgtggtc 13740
cctggagttg agaagctggc tttgaagaaa ggggaaattt cacagcctgc tatcatgaat 13800
cacattatgc catctattta agagtgcac tgggtgaagta gatactgatt ttttagactta 13860
tggttgccat tgaataatta taattataaa ggttaaagaa cttctgcca 13920
agagttgttc gctttccagg tggcgcaagt ctctgggtg gaaagatccc 13980
tctgcttttg tgcaaggacc taggttccat attctggcct gaaaaaaacc agctactaac 14040
tgcaaggacc taggttccat attctggcct gaaaaaaacc agctactaac 14100
ccacttaaat catgaggttg ttttgggtc tatctatttc aaaaagttac ataggtgtct 14160
catgaggttg agtcaaggat atcatttcca aaggacagaa actgcccctga gctcagagga 14220
actgtagaat atgcttccaa atcagcatc aaactcacct cccaattcag aaataatggg 14280
cagtggtggg attctggttg ctctgaataa tttccctgtg aacagaaaaa ctctttggc 14340
gtactttctt atacttttct ttctctgaag aagcttgaag atccagatc tgaattgcag 14400
agttgcatct ttgggcatca atccagatc tgaattgcag acgtccatcg 14460
tccgactctt ccggagttc actcagactc ctctctctc tcgcatgagg 14520
tctgtcgtcc cctctctcct cccagggctg atctccttca ctccaacacc 14580
agtcaactct ccaagaaat caagagtctt cacagtccaa aacctttgtt 14640
cagccttctt tgactagacg ttttcttcca aggagtaagc agtaagtaat 14700
tggtcataac ttttggagccc ttttcttcca aggagtaagc agtaagtaat 14760
ctgtagtgtat ttttggagccc ttttcttcca aggagtaagc agtaagtaat 14820
ctatttccca tgaagtgtat gaaacgggat ctttcttcca aggagtaagc agtaagtaat 14880
ttaagtcaac tttttcactc tccactttca ctttcatcaa gaggtctttg agttcctctt 14940

```

cattttctgt cataagggtg gtgtcatctg catatctgag gttattgata tttgtcccg 16440
caatcttgat tccggcctgt gtttcttcca gtccagcgtt tctcatgatg tactctgcac 16500
agaagttaaa taaacagggt gacaatatac agccttgacg aactcctttt cctatttgga 16560
accagtctgt tgttccatgt ccagttctaa ctgttgcttc ctgacctgca tacaatttc 16620
tcaaggagga gatcagggtg tatggtattc ccatctcttt cagaattttc cacagttgat 16680
tgtgatccac acagtcaaaag ggtttggcat agtcaataaa gcagaaatag atgcttttct 16740
ggaactctct tgctttttcc atgatccagc agatgttggt aatttgattc tctggttcct 16800
ctgcctttct aaatccagct tgaacatcta gaagtccacg gttcacatat tctgaagcc 16860
tggcttgagg aattttgagc attactttac tagcgtggga gatgagtga attgtgcgt 16920
agtgtgagca ttctttgcat tgcctttctt tggagttgga atgaaaactg accttttcca 16980
gtctctgtgg cactgctgag ttttccaaat ttgctggcat attgagtga gcactttcac 17040
agcatcatct ttcaggattt ggaatagctc aactggaatt cgaaaactga ccttttccag 17100
tcctgtggcc actgctgagt ttcccaaatt tgcgtgcata t 17141

```

<210> 14
<211> 95
<212> DNA
<213> Ovis sp.

```

<400> 14
aattcgagaa aataatgaat gtcaaaggaa aagtgattct gtcaatgctg gttgtotcaa 60
ctgtcattgt tgtgttttgg gaatatatcc acagg 95

```

<210> 15
<211> 2479
<212> DNA
<213> Ovis sp.

```

<400> 15
gagttctgct tgcctgtgag tctccattca ggtgttcaca ggctccttga aattcatgca 60
tccaaggagg aactcatcat tattttcttc caagcctatt cctcctccaa ccaatctgac 120
tgaattctac aacctacctg cttaagcaga aaccttattt cctccttcc cctaattggc 180
taaattacca gccaaatcct atcaattctc tctctaaagt atgttttgaa tgaattcaac 240
cattgagcca gcccatctcc ccttttttaa agaatttcat gtatttaatt ttggttgccc 300
tggtctcttg ttgctaggca agggctttct ctagtgtggg tgggcagact tctcattgag 360
atggctctct ttgttgcgga tcacaggctc tgagcatgtg gcccttcagt ggctgtagca 420
cataggctca acagtagttg ttgcttgagg gcttcagagc gcctggtagt tgggatcatc 480
ccagactgag cactgaaccc ttgtcccctg catcggcagg cagattctta accactggac 540
caccagggac gtctccaccc catcacccct gttgcaatta gaattgtcta gcttgcgtt 600
ttatccgttc cccacaccca gtgcccagat gggctctctc gaatgaagat gggctcgggtg 660
actctccagc ttcagatgct ttgtgggtc cccacctctc tccatgccc ttccagcctc 720
tgactgcccc tgccgcctct ctgactcctg ccatcaccac caccaccgcg ctcttcactc 780
aggtgagaca gctgcactat tttttctcgt ccacgttttt gcttttgttt cccaaacaca 840
ggaagctttt ctctaataca cctgttatag atgctatttc tgaatatagc tcatcccttc 900
tcatgggact ttcttttcca tctatcttcc accccatggg aagctttaa atcatctgcc 960
cagtaagccc ttcccacacc acccaaatac aagtaactcc caagctgtag ttctctaacc 1020
agcacccttt ccccttttga tcacaatttc atgcagcaat gaagaaatat ttatgtacct 1080
actacgcacc agctgtgtgg gtatgggagg gaaaggccta cctgggaaat ggttgggtct 1140
caattgtaaa agaccagcat gctttctgct ctgaacggcg gagcacgtag ttaggatac 1200
agaggcagca gagccattga actgatcatt cccaagggtc acatgcagag agttagtgtc 1260
atcgagtcaag aggaggccag caaccatggg aaccattagc tcaaccctca ctctagaaaa 1320
atggtacaga tgaactgttt tgcaaagtag aaatagtcac agatgtagag aacaaattta 1380
aggttatcaa gtgggggagg ggcgagatgg ggtgaattga gggatttgta ttcacatact 1440
gatcctgctg tgtattaaat agataactaa tgagaacctg atgactaatg agaaccttct 1500
ggaacacaag gaactgtact cagtgtctct tggtagccta actgggaagg cggagaaggc 1560
aatggcatcc cactccagta accttgctg gaaaatcccg tggatggagg agcctggtag 1620
gctgcagtc atggggtcgc taagagttag acacgactga tcaacttcac ttctactttt 1680
ccctttcatg cattggagaa ggaatggca accactcca gtgttcttgc ctggagaatc 1740
ccagggacgg gggagcctgg tgggtgcca tctctgggtg cgcacagagt cggacacgac 1800
tgaagtgact tagcagtagc agcagctagg aaggaaatct aaaaatgagg ggatatgtgt 1860
atatgtatag ctgatttact ttactgtata gtgaaaacta atacaacatt ttagagtaac 1920
tgtactgtaa taataatgaa taaacctctc cccatgtcta tgggtgatct tgtgatcagt 1980
caggatactt tccctctgag cctcaaagtg gccttagcat ctttcgcaac tcaggcagcc 2040
ccatcagttc attgaattgg ctatttgccg ttgcagacc atgcaattta aggtagaacc 2100
ttctccttgc acgtgtgctt gctcagttgc ttcagtctgt tccaactctt tgcaacgcta 2160
tggactgttg cccaccggac acttctgtcc atggaattct ccaggcaaga gtactggagt 2220
gggttgccgt gccctccttc aggggggtct ctccatccag ggaatgaact tgcatctcct 2280
gcattgcagg cggattcttc actgtgagc ccctggggaa gcccagaaca tgtgccttag 2340
cacttgtaa atattcatca ccttttctt ttagaaagga cataggtaga aataattatt 2400
gaaaaaatc atatccact cttgatatat ttaactatc tccccccctc ttcttttctt 2460
ttcccaggag aaataatg 2479

```

<210> 16
<211> 1096
<212> DNA

<213> Ovis sp.

<400> 16
gtttttggaa tatatccaca ggtaattatg gaacatgata aagtgatgtt aatgaacgtc 60
tccatcagcc aagtcaccag gttgaattga aattaggact tcttctctcc tgtttccctg 120
agccctagac tttaatgact ctctttaaaa tcattagagc ttcaagcact ttctaaggaa 180
ttaattatct ttcttctctg catgttcccta atatctcaat ttttatatag cttgttcttg 240
gcaggctaga gccagaaaca gtaagggtctt attaagacca aaatgtcata ttaaaatatg 300
accagatatg gaaattgcat taagaaattt cagacaggaa ttccacgaga aattcacctc 360
gattttttgca gtccataaaat atttgcaaaag ttcaaaggaa caactcaaag ttgttgactt 420
ttgtcgcaaa atacactttg agtcgctggt gattcatttg tgccctggcta aacttttgag 480
tgctttgtct gttttttttt tttttttaac tctggaaaac aaaatgaatg aaatatttct 540
gagttttcaa attcatcagt ggattcacct caaatatttg agctgcttca tgtgttttga 600
gaaaatataa tgccttgagg gttccagctg gagaggcttc tgacagaaag aagtctcccc 660
aggcagctac aaaaatgcac aatgggtttg actttaagag gcacccgtac agctcagcct 720
ttctttcgaa aaggccacct tacacctaga ggtggatgaa cctagagcct gttatacata 780
gtgaataaag tcagaaagag agaacaagt gttatatatt aacgctttta tatggaatct 840
ggaaagatgg tgcagatgaa actatctgca gagcagcaaa ggagatgcag actcaaagaa 900
caggcttggtg gacacagtga ggggaaggaga ggggtgcaatg aactgagaga acagcattga 960
aaaatatata ttgccgtatg taaatagaga gccagtggga atttgctggg tgcctcaggg 1020
agatcaaatc caatgctctg tgacaatctt agaggggtgt gatgggatgg gtggtgggag 1080
ggaggtccag agggggg 1096

<210> 17

<211> 815

<212> DNA

<213> Ovis sp.

<400> 17
tgcagactca aagaacaggc ttgtggacac agtgagggaa ggagaggggt caatgaactg 60
agagaacagc attgaaaaat atatatgtcc gtatgtaaaa tagagagcca gtgggaattt 120
gctgggtgct gccaggagat caaatccaat gctctgtgac aatttagagg ggtgtgatgg 180
gatgggtgct gccaggaggg ttcaagaggg akgggacata tgtatacgta tgactgattc 240
atgtttatgt atggcagaaa ccaacacaat attgttatta tcttccaatt agaaataaat 300
tcaaaataat aaaaaaggcc accgtacaac aactctgggc caggagcact gtcttgtcac 360
tattgatatc ttcatggtct tagtaggttc ccaagttcaa aatgatggcc tggataaaca 420
ttcagttcag ttcatgctgt cagtcgtgtc ckactctttg cgaccccatg taatcgagc 480
acgccaggcc tccctgtcta tcaccaactc ctagagtcca ctcaaactcg tgtccattga 540
gttggtggtg ccatccagcc atctcatcct ctgtcgtccc ctctctctct tgccccaat 600
ccctcccagc ttcatgagtc ttttccatat gagtcaactt cttctcatga ggtggcctta 660
gtactggagt ttcagcttta gcatcattcc ttccaaagaa caccagggc tgatctcctt 720
tagaatggac tgggtggatc tccctgcagt ccaagggact ctcaagagtc ttctccaaca 780
ccacagttca aaagcatcga ttcttcgggg ctcag 815

<210> 18

<211> 11034

<212> DNA

<213> Ovis sp.

<400> 18
gagttctgct tgccctgtgag tctccattca ggtgttcaca ggctccttga aattcatgca 60
tccaagaggg aactcatcat tattttctct caagcctatt cctcctccaa ccaatctgac 120
tgaattctac aacctacctg ctttaagcaga aaccttatct cttccttctt cctaattggc 180
taaattacca gccaaatcct atcaattctc tctctaaagt atgttttgaa tgaaatcaac 240
cattgagcca gccatctccc ccttttttaa agaatttcat gtatttaatt ttggttgccc 300
tggctctttt ttgctaggca agggctttct ctagttgtgg tgggcagact tctcattgag 360
atggcttctt ttgttgcgga tcacaggctc tgagcatgtg gcccttcagt ggctgtagca 420
cataggctca acagtagttg ttgcttgagg gcttcagagc gcctggtagt tgggatcatc 480
ccagactagg gattgaaccc ttgtcccctg catcggcagg cagattctta accactggac 540
caccagggac gtctccaccc catcaccctt gttgcaatta gaatggctca gcttgtcgtt 600
ttatccgttc ccacaccca gtgcccagat gggctctctt gaatgaagat gggtcgggtg 660
actctccagc ttcatagctt tttgtgggtc cccaccctct ttccatgccc ttccagcctc 720
tgactgcccc tgcccgccct ctgactctct ccacaccac caccacccgc ctcttactc 780
aggtgagaca gctgcactat tttttctcgt ccacgttttt gcttttggtt cccaaacaca 840
ggaagctttt cctctaataa cctggtatag atgctatttc tgaaatagtc tcatcccttc 900
tcatgggact ttcttttcca tcttatcttc accccatggg aagcttttaa atcatctgcc 960
cagtaagccc ttccccaacc acccaaatca aagtacttcc caagctgtag ttctctaacc 1020
agcaccctt ccccttttga tcacaatttc atgcagcaat gaagaaatat ttatgtacct 1080
actacgcacc agctgtgtgg gtatgggagg gctttctgct ctgaacggcg gagcacgtag ttaggatata 1200
caattgtaaa agaccagcat gctttctgct ccccaaggtc acatgcagag agttagtgtc 1260
agaggcagca gagccattga actgatcat ccccaaggtc tcaaccctca ctctagaaaa 1320
atcgagtcag aggaggccag caaccatggg aaccattagc agatgtagag aacaaattta 1380
atggtacaga tgaacttgtt tgcaaaagta ggtgaattga gggatttggt ttacataact 1440
aggttatcaa gtgggggagg ggcgagatgg ggtgaattga gggatttggt ttacataact 1440
gatcctgctg tgtattaaat agataactaa tgagaacctg atgactaatg agaaccctct 1500
ggaacacaag gaactgtact cagtgtctctg ttgtgacctt actgggaagg cggagaaggc 1560

aatggcatcc cactccagta accttgccctg gaaaatcccg tggatggagg agcctggtag 1620
gctgcagtc c atgggggtcgc taagagtcag acacgactga tcaacttcac tttcactttt 1680
ccctttcatg cattggagaa ggaatggca acccactcca gtgttcttgc ctggagaatc 1740
ccagggacgg gggagcctgg tgggctgcca tctctggggt cgcacagagt cggacacgac 1800
tgaagtgact tagcagtagc agcagctagg aaggaaatct aaaaatgagg ggaatagtgt 1860
atatgtatag ctgatttact ttactgtata gtgaaaacta atacaacatt ttagagtaac 1920
tgtactgtaa taaaaatgaa cctcatgtcta tgggtgatct tgtgatcagt 1980
caggatactt tccctctgag cctcaaagtg gccttagcat ctttcgcaac tcaggcagcc 2040
ccatcagttc attgaattgg ctatttgccg ttgcagacc atgcaattta aggtagaacc 2100
ttctccttgc acgtgtgctt gctcagttgc ttcagtcgtg tccaactctt tgcaacgcta 2160
tggactgttg cccacgggac acttctgtcc atggaattct ccaggcaaga gtactggagt 2220
gggttgccgt gccctccttc agggggctct cctcatccag ggatcgaact tgcctcct 2280
gcattgcagg cggattcttc actgtgagc ccttgggaa gcccagaaca tgtgccttag 2340
cacttgtaa atattcatca ccttttccct ttagaaagga cataggtaga aataattatt 2400
gaaaaaaatc atatccact cttgatata ttaactatt ttccccctc ttcttttctt 2460
ttcccaggag aaaaataatgn trnbnndary startednnd rndgrstnsn cndcatdasn 2520
grsdntrnb ndarygtttt gggaatatat ccacaggtaa ttatggaaca tgataaagt 2580
atgttaatga acgtctccat cagccaagtc accaggttga attgaaatta ggacttcttc 2640
cttctctgtt cctgtgagcc tagactttaa tgactctctt taaaatcatt agagcttcaa 2700
gcactttcta aggaattaat tatctttctt cctgcatagt tcctaatac tcaattttta 2760
tatagttgt tctgggcagg cttagagccag atatggaaat aatttcagac aggaattcca 2820
tcataataaa accctgattt ttgcagtcct aaaatatttg caaagttaa aggaacaact 2880
cgagaaattc caaagttgtt gacttttgc gcaaaataca ctttgagtcg ctgggtattc atttgtgct 2940
ggctaaactt ttgtgtgctt ttgtttttt ttaactctgg ttaactctgg aaaacaaaat 3000
gaatgaata tttctgagtt ttcaaattca tcagtggatt cactcaaat atttgagctg 3060
cttcatgtgt tttgagaaaa tataatgcct tggaggttcc agctggagag gcttctgaca 3120
gaaagaagtc tcccaggca gctacaaaaa tgcacaatgg ttttgacttt aagaggtc 3180
cgtacagctc agcctttctt tcgaaaaggc cacttacac cttagaggtg atgaacctag 3240
agcctgttat acatagttaa aatctggaaa gatgggtcag agtgagggaa caagtgttat gcaaaggaga 3300
ttttatatgg aagaacaggc ataatgtgca atgaaactat ctgcagagca caatgaactg 3360
tgcagactca agcctgtgct caggagagtc tccagagggg ggtatgtaaat agagagccag ggtgtgatg 3420
agagaacagg ctgggtgctg gggagggagg acagtgggg cctgtgaca atcttagagg sdtgcagact 3480
gatgggtggg caaagaacag gcttgtggac atatatattg atgtctgtg tatgtatac ttagaaataa 3540
gcattgaaaa atcaaatcca ggakgggaca atattgttat tatectcaa cctgtctgtc 3600
ctgcagggag ggttcaagag aaccaacaca caaactctg gccaggagca cctggataaa 3660
gtatgtcaga cctacgtgta atctgtgca aatccaatg ggrstnsnncn tgcaatgaac 3720
ataaaaaagg ccaccgtaca cttagtaggt tcccaagtc tccactctt cactcaaat 3780
tcttcatggt agttcagtcg tatcaccac cctctgtctc atgagtcaac aacaccagg 3840
cctccctgtc tgccatccag tcttttccat ccttccaaag gtccaaggga ggtcaggrs 3900
gcttcatgag tagcatcatt tctccttgca gattcttcgg atcgattctt atagccttga 3960
actggttgga caaaagcatc caacaccaca gtccaagaac tgaatatgct ataaacatta 4020
tcacatccat caaagtaatg tctctgctt atttagatgg gctgcctggc ctgtcctgga 4080
aaattctaag cttcaggtac gacctaacca gttctggagt atgttaagg ggtctacaaa 4140
ggacaagcta gagagtacc gtacttagtc ggaagaaag tctgtgactt tgggcaagtt 4200
gaaaccatgg ggctcccttt ctgtgccatg ggttttcaat aagtttccct tattgtgtat 4260
gcttctgtag gtttcttggg gtttcttggg atcaccatca tccaccatc 4320
taagatttgg caaataagaag ggttcttggc ctgagctgag agcagtttga agtaacctt 4380
gcgtcccttg gagctctgaa tgcttgattg gataaccttg gcgttttgaa ttgcagccag 4440
cgaattttt ggtaacttca cctccatagr ntrncsnrcm gatcccccg cccacacactc 4500
cggccgctct agaactagtg atcttttctc cggagcttcc ccttctctct tgggttccct 4560
agatagcccg aggaccgaag tgactaagcg cggagcttcc ccttctctct tgggttccct 4620
ggcttccgca caaccagaac ttcttcttcc caaactgcaa tttgtgtat tttttttt 4680
tttagaatga aatagtttaa aatataacc ttcttacttt cctattagc gggaaagttga 4740
cgaaagcaaa atcttttctg cctcatctgt ctgagtgagg atctgtgcat cttcactccc 4800
tggtgaaggc ccgggtggat ccagcccaga gcccagaagc catcgcctc accctactgg tcaagtcctg 4860
atctcactcc aagaccgtcc atgtcaccac

Sequence = 2165650

ctgtgctgat	cccaggggca	tctgtgatgg	agaaggggtga	ctctggaatt	ttgacatttt	6300
tactggaaga	atctgtactg	ttatgcgtct	ggagcagatg	cctagctcac	ctcatccttt	6360
ggatagagag	gggatgagcc	agccaccctg	tagactgatt	tactcctgat	gttccacaaa	6420
gaacagaatg	tggcctgcgg	ttccacgatg	gcttcaccct	cgtattcgca	gcttcacaga	6480
accaaacagt	aaattgtaca	ccctgagctc	tcctcttgga	ggccggaggg	gactgcttgt	6540
actctgcagc	aataaatcct	cccaagagtg	gatctggact	ttaggagggt	tgaagtttgg	6600
tttgttttca	aataacagtg	cccggagcca	attgcaatgc	tttcatctct	aaataatgtt	6660
aaacctcaca	agggccccct	cccctcccc	taggattgtt	tcccagctt	cagggcacaa	6720
tagatttttt	tttcagagcc	atggcaaagt	ccctcttcat	attgctcaga	tatatctctac	6780
tgtaaacccc	ggggtttttc	cagagaccaa	tattaaaacc	acagtttatt	ttttagataa	6840
tgaacaggaa	tccaaactgc	aactaaggag	caaaaacaaa	tgccagttat	tattactcac	6900
aaaatgtcat	aactggccgt	gagtgtgatc	agtaaatata	acttagtcca	catccgctga	6960
gcatgagtct	gggggtgatg	caagtgtgtg	taagccaact	cccgctttcc	ttctctatca	7020
tccccacgct	gtcacgtgat	aagtgtgtag	tttggctcac	aaaagacata	aacatgtttt	7080
cggaatgaat	aagtaaatag	ctaaaaatcc	acatctatta	gaaggacct	agtccaaaac	7140
actgacaaca	aaaactgctg	gcaaaaatat	ggagcaagca	gaactctgat	tcactgctgg	7200
cgagaaggca	agatggttca	gctgcttttg	aagaaagctg	aacatattct	tatcatcacg	7260
tctagcaatt	gcatccttgg	tattcaccaa	aaaaagctga	aactttacag	cgcacacaga	7320
acttacatac	agatgtttta	acgcagcttt	agtcacagtt	tctaaaactt	ggacataact	7380
aagatgtcct	ttagtaggtg	aatggattaa	taaactgttg	tgccacgtca	ggtgtgtgaa	7440
tatatattat	gtgcaaaaac	acaaatctgt	caagccatgg	aagagataga	ggaacttaat	7500
gcatatttatt	aagtaaaaga	accatctgaa	agattgcctg	ctgtcagatt	ccagrnrnc	7560
snrmarkbt	kbwthrscct	nndcatdasn	grsdtaggga	acaaaagctg	ggtacgatata	7620
catacatagt	gaaaaaact	tgctattaca	tatttgcga	aacctataga	atacacacaa	7680
ccaagagtga	acttttttta	gaaaaggaaa	tgagatagtt	aaaataagtt	taaatacagag	7740
ggtgttttgc	ctgggtattg	gatgggtcct	ataatggtgg	tagctggata	atggagtggg	7800
gtttggggta	accactagaa	aattctttaa	gggaatgtat	aatgtggaag	gatattcatg	7860
tccccataaa	cccattctct	gggtcccaga	gaagaagaga	gtggtgatgc	ttagtcttaa	7920
ggcatcccca	aaggacctaa	gaggcttgct	acccttctcat	ctgatagggc	aggataacat	7980
tggagcggat	gttggggttt	ctgagagatg	cctgagaact	agcgccccct	gatgttgatc	8040
acgggtgtaca	accttccagt	tataaaatga	gcaagttctg	gggatctgat	gtaaaagcatt	8100
gtgggttattg	ttaataatat	tgttttctat	actcataaag	ttattcagat	aataaatctc	8160
aaatctctct	ccccaaaacg	aaatgatgat	tatgtgatgc	aatgaagggt	ataagacggca	8220
ctactgtctg	ctctgagtcg	cttcagtcgt	gtgcgactct	gtgcgacccc	atagacggca	8280
gcccaccagg	ctcccctgtc	cctgggattc	tccaggcaag	aacactggag	tggtgtgcca	8340
tttctctctc	caatgcatag	aggtgaaaag	agaaagtga	gtcactcagt	cggtgtctgac	8400
tcttagcgac	cccattggact	agcccttacc	agccttctcc	gtccatggga	ttttccaggc	8460
aagagtactg	gagtgggggtg	ccattgcctt	ctccgaacta	atgctacagt	ggtgggrntr	8520
ncsnrmarm	mdatytnndc	atdasngrsd	tcctctctca	ggggctcttc	ctgacccag	8580
gcgtcaaac	gcctctcct	gcgtctcttg	catcacagcc	agattctcta	cccactgagc	8640
catctgggaa	gcctttttat	aatatatgaa	tataccaaat	caacacttgg	cacattttaa	8700
acttaaaact	tgctatatgt	caattatatc	tcaataaaaac	aggaccaaaa	aaggactagc	8760
acactttcac	ctaccgggag	ctgataaata	ctgataaata	agacaaaagg	ataaataagg	8820
tagatggtag	tgatgatcat	ttaaaagctg	ttaaaagctg	atattgaaga	atattgggtta	8880
taaaactgaa	ggccctgggg	tgaaccacag	aattagaag	aactagaag	acgtaggcac	8940
ccttcatacca	tgatgatgaga	ctcctgatgt	gtctggatgt	tggagaagg	cctgtatcat	9000
ttagctacat	tgaggggccc	aactgcaggt	gagatctgtt	taaacctcga	gggcccggag	9060
gtcgagcagt	gtgggtttca	aaaagcctct	aaaagcctct	ccacccaggc	ctggaatgtt	9120
ttcacccaat	gtcgagcagt	aagaggaagc	aagaggaagc	aaaaagcctc	tcacccagg	9180
cctggaatgt	ttcaccccaa	crmarmdat	crmarmdat	ytndcatda	sngrsdctt	9240
ctatcgctt	cttgacgagt	tctcttgagg	ggatcgga	taaaaagaca	gaataaaacg	9300
cacgggtgtt	gggtcggttg	tcgacaggcc	tcgacaggcc	tacctgcgga	tattaagctt	9360
gtcaagatgt	cttggcagac	aaaagagtat	aatgtgggtta	gaaataacgt	ctgactttgt	9420
gcagtagcat	ttttgaattt	tattctggct	tattctggct	acttctcag	aaaagtaaca	9480
cttaatttta	acttaaaaaa	taacaaaaga	taacaaaaga	ccaacacagc	aagtacacat	9540
tatttctcct	tgtaacattg	agccttgtaa	tacgggagaa	tgaacctgtg	gtaatcggt	9600
gtaaatcccc	agtgatttct	tacctattct	cagttgcggg	ggaggggaaat	ggatacacta	9660
tcagttgaac	caaaaaagag	aaaaaattat	catagacaaa	agccagaaac	atttctacatg	9720
tgccaattaa	cttactggag	agaagtacgc	aaagggacgt	gtttggcaac	aagacaatga	9780
ttgtgagggg	ctgtcctctt	gatttcagt	tcttctgtc	tctgctgggt	ctgaagcaac	9840
acagagttgc	ttttgcagca	ggagaactct	tagtaggaca	tagtctacct	tgccgatcct	9900
caaagtgttt	agtcagtgtc	ctttccttat	caggatattg	gcttctgtgc	caagactagt	9960
caagattccc	agtacatatg	tggaagatgt	tggggaatca	caggcaatct	gagtcagtgg	10020
gtgctcagca	caaaatgaaa	acaaagcctc	caagtaagtt	ggccatgaaa	taagcaaga	10080
gagagtagaa	aggrnrncs	ncrmarkbtk	bwthrscctn	ndcatdasng	rsdttactca	10140
caagtgtgaa	acaccataga	aggtctactg	acataataaa	tgatgcatac	cttttaaaaga	10200
gagaaagcta	gggttaagtg	ggatctactg	ttcaagtctc	agggattcaa	accagcact	10260
gtctgactct	aaatcctttg	ttctttccac	agctcaagtc	tttctcttct	aaacacacac	10320
acacacacac	acacacacac	caatttctgt	cattttgttt	ttgagaccga	gggcatcaag	10380
gaatcaccac	caagaactct	ggttaggtcta	actagcatta	aagaaagaga	acttagttga	10440
ctcaaacttc	acagatggat	acagaggtcta	aactcatcct	ggagcctggc	tggaagacag	10500
tcaaacagaa	cctgagcgat	ggaaggtcta	gggaagttca	agggctgaga	gggtacagag	10560
gagagaaggt	ctgggaggtg	gaaacagtct	cagaggggct	gcttctgaat	taagcactga	10620
gagaagagaa	agggatcact	aagaagtgga	aatggaatga	ggtttcggag	agaggaacag	10680
caggtacgaa	gcatggagga	ctattctgag	gcttttaggg	agaccctgga	tgaaatctca	10740
taggagagcc	tggttgaaaa	gcagcaaaaga	gcttgaaagg	gctttggctg	gttgggagct	10800
gcacatttgc	ccagcatctg	tgtctttctt	tctcgttcta	tctccttcat	agagttctat	10860
tggtttccat	ggcaactaat	gccatagttg	ggccaagtga	cccagactaa	gctaatacaac	10920

attttccctc cccccgcccc caggggggca gatgatctaa actagtccaa tcaagttgaa 10980
tctcaggcct ttaattaagc ggccgccacc gcggtggagc tccattcgcc ctat 11034

<210> 19
<211> 1813
<212> DNA
<213> Ovis sp.

<400> 19
tgcagactca aagaacaggc ttgtggacac agtgagggaa ggagaggggtg caatgaactg 60
agagaacagc attgaaaaat atatattgcc gtatgtaaaa tagagagcca gtgggaattt 120
gctgggtgct gcaggggagat caaatccaat gctctgtgac aatttagagg ggtgtgatgg 180
gatgggtggg gggagggagg ttcaagaggg akgggacata tgtatacgta tgactgattc 240
atgtttatgt atggcagaaa ccaacacaaat attgttatta tcctccaatt agaaataaat 300
tcaaataaat aaaaaaggcc accgtacaac aactctgggc caggagcact gtcttgtcac 360
tattgatatc ttcatggtct tagtaggttc ccaagttcaa aatgatggcc tggataaaca 420
ttcagttcag ttcagtcggt cagtcgtgtc ckactctttg cgaccccatg taatcgagc 480
acgccaggcc tccctgtcta tcaccaactc ctgagttca ctcaaactcg tgtccattga 540
ggtggtggtt ccatccagcc atctcatcct ctgtcgtccc ctctcctctc tgcccccaat 600
ccctccagc ttcatgagtc ttttccatat gagtcaactt ctctcatga ggtggcctta 660
gtactggagt ttcatgttta gcatcattcc ttccaaagaa caccaggggc tgatctcctt 720
tagaatggac tgggttgatc tcttgcagc ccaagggact ctcaagagtc ttctccaaca 780
ccacagttca aaagcatcga ttcttcgggg ctcagccttc ttcatagtcc aactctcaca 840
tccatatatg accactggaa aaaccatagc cttgacatag atggaccttt gttggcaaag 900
taatgtctct gcttttgaat atgtataaaa cattagaatg ttgctttcag ttcttaaat 960
ctaagattta gatgggctgg taggactgtc ctggctgctt ataaaggatc tgtaccttca 1020
ggtacatcag tgggaaggagg aatctctgga ctctggagct gtttttcccc aggggtgacct 1080
aaccagttct ggagttatc tggtttcattc tgaaaaaact gttttaaaag aaacaggaca 1140
agctagagag tgaccatggt aaaggggtct acaaaaccagg atgcagggac cctggggctc 1200
catgggtact tagtctgaag aaaaggtgac tcagtgttgg ggaactaggc tgcctggggc 1260
ccttttctgt ccatgacttg cctcctctgt gactttgggc aagttaactc accactctgt 1320
tccttgggtt tccctgtttg tccctgtttg ttaaaatggg cataatggta gtacctgctt 1380
tgtaggggtg ttggattaaa taagttattg tgtatagagc acttagggca gtgccctcag 1440
aaaacgttct ctgccatcac catcatcacc accatttctc tcatctgctc agaggtaaga 1500
tttggcaaat agaaaggaaga gctccagcag ttggaagaat cctacagaag agtgagcgct 1560
ctttggggtc ttgccctgag ctgagctact tgtgtaggta acottgagag catttgagct 1620
ctgaatgctt gattggataa ccttggcggt ttgaattgca gccagagtca cacttccaaa 1680
ttttgggtac ttcacaaaat taaaatatgg gagccaaagg cccaaatgtg catattggca 1740
ctgggctccc ata 1800
1813

<210> 20
<211> 1379
<212> DNA
<213> Ovis sp.

<400> 20
actggcacac ccgggggtgc aggtagagct gggctgtggg tttgagacga gacccggggc 60
accgggagtg ggtgggaggg cctggttggg tctagaacag gaggaccgca gagcttgggtg 120
gcggaaggac aggaggtgtg gacgagtgtc tcttgggggc tggggtgagg aggaggtgac 180
ctggccttgc ccagccccc ttgaaaaact tagcttcacc cctggcagag gggcagtggt 240
gtgaaaaacc actctccacc catgtgtgag ggagagagga agttctcagt gggctgatct 300
atttgccaat atctctttga tagcctcacc aaggccactt gcacacagca ggggcccgat 360
ggggccacca agacttttgc ccagtcactg ggcctctccc cgagtggtc gaagtgcagg 420
cacatggcgt ggcccttgtg tgacaggggt tgctctaaat gactgtgctt cagtctccac 480
ttcccgccag ggaagggcag tctcttgcaa acccaaattg ggttggagct gactccccac 540
ccatttccg ccttagcctg ggcgccagcc gctgtcagc ctctctgcat ttactcttta 600
tggttgggtg gtttgtcttc gctcttacct tgcttctgt gtttgtattg gctctgcaa 660
gtccctttca agtgtgctga gctcacagaa cccccctc cccaccccc ggctttgtaa 720
ggaggaaacg tgatctgaga gaggtgacag ccagggtccc tgtgtttcat ccttggtac 780
tgtgagcctg caggatcctt tcttagtgac tgtctgtccc ttgtatgtca aatgaacaat 840
aacaccagaa accccttagt cctataccca ggtaacaacc aaaaattcct ntctggcaaa 900
aggcagattg aaacagcttc ttctcttttc agctctaatt tcaactgtctt gtccccctgc 960
gtcaagcatc agggctttct ctgggtcaga tggcaccat tgggataaat aaggtctaaa 1020
gatgccgctg gcagcttagg aaggggctgg ggagatggga gtgggatatt gaaggaagat 1080
gaggataggg gaggaaggaa agggggacag agggcatgag gtataaagg aagaccccn 1140
tagggccccc gctaaagcag ccccaggca cctgggccac cgtctcctgt tctcaccaca 1200
gaagatgccg cagatgtctc actgccagct gactgttggg gttaaactcc cattaggatt 1260
caaggatggt taccaccagc cacggctgag ccgttttcca tcagatgtct ctgtccccc 1320
ttagcaaggc catcatgact catggactct gttttgtcac cagtaaacgc cctgaggtt 1379

<210> 21
<211> 1973
<212> DNA
<213> Ovis sp.

<400> 21
cggccgctct agaactagtg gatcccccg gctgcaggaa ttccaaaaat gccagcnatt 60
agatagcccg aacgtgtgtc attgtttctc ccacacactc aagaccccaa ctgagaacta 120
aggaccgaag tgactaagcg cggagcttcc ccacgtcagc ctggctgacc actctccccg 180
ggcttccgca gctgcctctg cccttctcct cctagaggct ttggcccccg gagatctggc 240
caaccagaac ttcttcttcc agaggttgga tgggttctct tttctgcttc cattctcttg 300
tttagaatga catttctccc caaactgcaa tcattcttac ttaaaagtcg gagctgtgat 360
aatagtttaa aatataaccc attttgttcc tctctccctg caacccccct ccacgggcct 420
cgaaagcaaa ggtttacttt tctattagc ctcctccctg ctgctcgtct gtacagagag 540
tcccactctg atcttttctg agcgcacatc gggaagtga ctgctcgtct aagaccgtcc 600
tgggtgaaggc ccgggtggat ctgagtggg atctgtgcac tcaagtctct atgtcaccac 660
ccagcccaga gcccgagaagc catcgccctc accctactgg cttcactccc aagaccgtcc 600
ctgtgctgat cccaggggca tctgtgatgg agaagggtga ctctggaatt ttgacatttt 720
tactggaaga atctgtactg ttatgcgtct ggagcagatg cctagctcac ctcactcttt 780
ggatgagag gggatgagcc agccaccctg tagactgatt tactctgat gttccacaaa 840
gaacagaatg tggcctgcgg ttccacgatg gcttcaccct cgtattcgca gcttcacaga 900
accaaacagt aaattgtaca ccttgagctc tctcttggga ggccggaggg gactgcttgt 960
actctgcagc aataaatcct cccaagagtg gatctggact ttagggagtg tgaagtttgg 1020
tttgttttca aataacagtg cccggagcca attgcaatgc tttcatctct aaataatgtt 1080
aaacctcaca agggcccccct cccctcccc atggatttgtt tcccaagctt cagggcacaa 1140
tagatttttt ttccagagcc cctcttcatc cctcttcatc attgctcaga tatattctac 1200
tgtaaacccc ggggtttttc cagagaccaa tattaatacc acagtttatt tttgtagaaa 1260
tgaacaggaa tccaaactgc aactaaggag agtaaatata acttagtcca catccgtga 1320
aaaatgtcat aactggccgt gagtgtgatc agtaaatata acttagtcca catccgtga 1380
gcatgagtct gggggtgatg caagtgtgtg taagccaact cccgcttctc ttctctatca 1440
tccccacgct gtcacgtgat aagtgtgtag acatctatta gaaggaccta agtccaaaac 1500
cggaatgaa aagtaaatag ctaaaaatacc ggagcaagca gaactctgat tcaactgctg 1560
actgacaaca caaactgctg gcaaaaatat ggaagagctg aacatattct tatcatagag 1620
cgagaaggca agatggttca gctgcttttg aagaaagctg aactttacag ccgcacagaa 1680
tctagcaatt gatccttgg tattaccaa aaaaagctga tctaaaactt ggacataact 1740
acttacatac agatgtttta acgcagcttt agtcacagtt ttaaaactt ggaataact 1800
aagatgtcct ttagtaggtg aatggattaa taaactgttg tggcacgtca ggtggtgaa 1860
tatattatca ttgcaaaaac acaatctgtg caagccatgg aagagataga ggaacttaat 1920
gcatattatt aagtaagaa accatctgaa agattgcctg ctgtcagatt cca 1973

<210> 22
<211> 920
<212> DNA
<213> Ovis sp.

<400> 22
agggaacaaa agctgggtac gatatcatat atagtgaata atacttgtca ttacatattt 60
gtcgaaaccc atagaatata cacaaccaag agtgaacttt ttttagaaaa ggaaatgaga 120
tagtttaaat aagttttaa cagaggggtg ttgctctggg atttggatgg gtcttataat 180
gggtgtagct ggataatgga gtggtgtttg gggttaaccac tagaaaaattc ttaaagggaa 240
tgtataatgt ggaaggatat tcatgtcccc cataaccat tctctgggtc ccagagaaga 300
agagagtggg gatgcttagt ctttaaggcat ccccaaggga cctaagaggc ttgtcacctc 360
ttcatctgat agggcaggat aacattggag cggatgttgg ggtttctgag agatgcctga 420
gaactagcgc ccctgatgt tgatcacggg gtacaacctt ccagttataa aatgagcaag 480
ttctggggat ctgatgtaaa gcatgtgtgt tattgttaat aatattgttt tctatactca 540
taaagtattt cagataataa atctcaaatc ttctcccaa aacagaaatg atgattatgt 600
gatgcaatga aggtgttaac taatgtctact gctgtgctg agtcgcttca gtcgtgtgag 660
actctgtgag acccataga cggcagccca ccaggctccc ctgtccctgg gattctccag 720
gcaagaacac tggagtgggt tgccatttcc ttctccaatg catgaagggt aaaagagaaa 780
gtgaagtcac tcagtcgtgt ctgactctta gcgaccccat ggactgcagc ctaccagcct 840
tctccgtcca tgggattttc caggcaagag tactggagtg ggggtgccatt gccttctccg 900
aactaatgct acagtgtggt 920

<210> 23
<211> 650
<212> DNA
<213> Ovis sp.

<400> 23
cctctccag gggctcttcc tgaccccgag cgtcaaaccc gcatctctct cgtctcttgc 60
atcacaggca gattctctac ccactgagcc atctgggaag cccttttata atatatgaat 120
ataccaaatc aacacttggc acatttttaa cttaaactat gctatatgtc aatttatctt 180
caataaaaaca ggacaaaaaa aggactagca cactttcacc taccggaggt ctgaaccaac 240
tgataaataa gacaaaagga taaataaggt agatggtagt gatgatcatc ttactgtgtg 300
taaaaagctga tattgaagaa tatgggttat aaaactgaag gccctgggac tctgtatgtt 360
gaaccacaga attagaagaa cgttaggcacc cttcatccat agcatgagaa actgcagggt 420
tctggatgtt ggagaagggc ctgtatcatt tagctacatt gcaggggcct agatagatag 480
agatctgttt aaacctcgag ggccggaggg tcgagcagtg tggttttcaa gagggaagcaa 540
aaagcctctc caccaggcc tggatgttt ccaccaatg tcgagcagtg tgggttttga 600
agagggaagca aaaaacctct cccaccaggc ctggaatgtt tccaccaat 650

<210> 24
<211> 705
<212> DNA
<213> Ovis sp.

<400> 24
tataatgtgg ttagaaataa cgtctgactt tgtgccagta catttttgaa tttgagagag 60
tattattctg gctacttcc t cagaaaagta acacttaatt ttaacttaaa aaaaaaaaaa 120
aactaacaaa agaccaacac agcaagtaca cattatttct ccttgtaaca ttgagccttg 180
taatacggga gaatgaacct gtggaatcg gatgtaaatt ccagtgatt tcttacctat 240
tctcagttgc gggggagggg aatggataca ctatcagttg aaccaaaaaa gagaaaaaat 300
tatcatagac aaaagccaga aacattctac atgtgccaat taacttactg gagagaagta 360
cgcaaaggga cgtgtttggc aacaagacaa tgattgtgag gggctgtcct cttgatttca 420
gtgtcttcc tctctgctg ggtctgaagc aacacagagt tgcttttgca gcaggagaac 480
tcttagtagg acatagtcta ccttggcgat cctcaaatgg tttagtcagt gtcctttcct 540
tatcaggata ttggcttctg tgccaagact agtcaagatt ccagttacat atggtgaaga 600
tgttggggaa tcacaggcaa tctgagtcag tgggtgctca gcacaaaatg aaaacaaagc 660
ctccaagtaa gttggccatg aaataagcaa agagagagta gaaaag 705

<210> 25
<211> 900
<212> DNA
<213> Ovis sp.

<400> 25
tactcacaag tgtgaaacac catagaaggc atgaatacat aataaatgat gcataccttt 60
taaagagaga aagctagggt aagtggggat ctactgttca agtctcaggg attcaaacc 120
agcactgtct gactctaaat cctttgttct ttccacagct caagtctttc tctttcaaac 180
acacacacac acacacacac acacacacac ttttaaccatt ttgtttttga gaccgagggc 240
atcaaggaaat caccaccaag aactctcaat tcttgtacta gcattaaaga aagagaactt 300
agttgactca aacttcacag atggatggta ggtctaaact catcctggag cctggctgga 360
aagcagtcac acagaacctg agcgatacga ggtcagggg agttcaaggg ctgagagggg 420
acagaggaga gaaggtctgg gaggtggaaa cagtctcaga ggggctgctt ctgaattaag 480
cactgagaga agagaaaagg atcactaaga agtggaaatg gaatgaggtt tcggagagag 540
gaacagcagg tacgaagcat ggaggactat tctgaggctt ttagggagac cctggatgaa 600
atctcatagg agagcctgtg tgaaaagcag caaagagctt gaaagggctt tggctgggtg 660
ggagctgcac atttgccag catctgtgtc tttctttctc gctttatctc cttcatagag 720
tctatgtggt ttccatggca actaatgcca tagttgggcc aagtgaacca gactaagcta 780
atcaacattt tccctccccc cgccccagg ggggcagatg atctaaacta gtccaatcaa 840
gttgaatctc aggcctttaa ttaagcggcc gccaccgcgg tggagctcca ttcgccctat 900

<210> 26
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 26
gagaaaataa tgaatgtcaa agga 24

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 27
tgataatccc agcagtattc 20

<210> 28
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR

Primers

<400> 28
cttgatgggt ttatccagaa ca 22

<210> 29
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 29
ctgtggatat attcccaaaa cac 23

<210> 30
<211> 95
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 30
aattcgagaa aataatgaat gtcaaaggaa aagtgattct gtcaatgctg gttgtctcaa 60
ctgtcattgt tgtgttttgg gaatatatcc acagg 95

<210> 31
<211> 95
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 31
aattcctgtg gatatatcc caaaacacaa caatgacagt tgagacaacc agcattgaca 60
gaatcacttt tcctttgaca ttcattatct tctcg 95

<210> 32
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 32
gggtggttcc gagatggttt aaca 24

<210> 33
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 33
gggttgaacc agtccgatag ctta 24

<210> 34
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 34
tccaggatgc ctttgataga g 21

<210> 35
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 35
gggaggaagc gaaggtgca 19

<210> 36
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 36
acgtggctcc aagaattctc caggcaagag tactgg 36

<210> 37
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 37
catcttggtc aatggccgat cccattatct tctcctggga aaagaaaag 49

<210> 38
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 38
cttttctttt cccaggagaa aataatggga tcggccattg aacaagatg 49

<210> 39
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 39
caggtcgacg gatccgaaca aac 23

<210> 40
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 40
cagatctaac gaggattcaa tgtcaaagga aaagtgattc tgtcaat 47

<210> 41
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 41
ctgaactgaa tggttatcca ggccatc 27

<210> 42
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 42
gcgcaccgtg ggcttgact cggtcattat tttctcctgg gaaaagaaaa g 51

<210> 43
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 43
gagaaaataa tgaccgagta caagcccacg gtgc 34

<210> 44
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 44
ctggggatcc agacatgata agatac 26

<210> 45
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 45
ctggttggtt ctagaacagg agga 24

<210> 46
<211> 66
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 46
catcttggtc aatggccgat cccattcctc ctctctctcc actgggtgaca aaacagagtc 60
catgag 66

<210> 47
<211> 66
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 47
ctcatggact ctgttttgtc accagtggag gaggaggagg aatgggatcg gccattgaac 60
aagatg 66

<210> 48
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 48
caggtcgacg gatccgaaca aac 23

<210> 49
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 49
cagctgtgtg ggtatgggag gg 22

<210> 50
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 50
ctgaactgaa tgtttatcca ggccatc 27

<210> 51
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probes and PCR
Primers

<400> 51
agccgattgt ctgttgtgcc cagtcat 27

* * * * *

5 It is understood that certain adaptations of the description and illustrations provided in
this disclosure are a matter of routine optimization for those skilled in the art, and can be
implemented without departing from the spirit of the invention, or the scope of the appended
claims.

CLAIMS

What is claimed as the invention is:

1. Ovine tissue devoid of antibody-detectable Gal α (1,3)Gal determinants.
2. The tissue of claim 1, which is selected from the group consisting of lung tissue, kidney tissue, liver tissue, cardiac tissue, pancreatic tissue, and ocular tissue.
3. Isolated ovine cell or tissue that expresses glycosyl transferase enzymes but does not detectably express α (1,3)galactosyltransferase(α 1,3GT).
4. An ovine cell which is heterozygous or homozygous for inactivation of an α 1,3GT gene.
5. The cell of claim 4, produced by transfer of a nucleus from a donor cell heterozygous or homozygous for inactivation of an α 1,3GT gene, to an enucleated recipient cell.
6. An ovine animal that is homozygous for inactivation of an α 1,3GT gene.
7. A polynucleotide construct effective for inactivating an α 1,3GT gene in an ovine cell.
8. The polynucleotide construct of claim 7, comprising at least two polynucleotide sequences from an ovine α 1,3GT gene in a non-natural arrangement, for inactivating the α 1,3GT gene by homologous recombination.

9. The polynucleotide construct of claim 7, comprising an intron sequence of at least 30 consecutive nucleotides found in any of recombinant phage **B**, **C** and **G**, deposited under Accession Nos. NCIMB 41056, 41059, 41060, and 41061.
10. The polynucleotide construct of claims 7, comprising a selectable marker.
11. The polynucleotide construct of claim 10, wherein the selectable marker is flanked on either side by polynucleotide sequences from an ovine α 1,3GT gene.
12. A method for inactivating an α 1,3GT gene in an ovine cell, comprising contacting the cell with the polynucleotide construct of claims 7 under conditions suitable for homologous recombination of the construct into the genome of the cell.
13. A method for producing an ovine that is homozygous for inactivation of an α 1,3GT gene, comprising providing an ovine embryo of cells according to claim 4, engrafting the embryo into the uterus of a female, birthing an ovine with an inactivated α 1,3GT gene from the engrafted female, and if the birthed ovine has the α 1,3GT gene inactivated on only one allele, then mating it with another ovine with an inactivated α 1,3GT gene, thereby producing an ovine that is homozygous for inactivation of the α 1,3GT gene.
14. A method for producing an isolated ovine cell that expresses glycosyl transferase enzymes but does not detectably express α 1,3GT, comprising isolating the cell from an ovine homozygous for inactivation of an α 1,3GT gene according to claim 6.

15. A method for producing ovine tissue devoid of antibody-detectable Gal α (1,3)Gal determinants, comprising harvesting the tissue from an ovine homozygous for inactivation of an α 1,3GT gene according to claim 6.
16. A method of xenotransplantation, comprising transplanting tissue devoid of antibody-detectable Gal α (1,3)Gal determinants according to claim 1 into a mammal having circulating antibody against Gal α (1,3)Gal determinants.
17. An isolated polynucleotide that comprises a sequence of at least 30 consecutive nucleotides with at least one of the following properties:
- a) it is contained in SEQ. ID NO:1 or any of SEQ. ID NOs:14 to 25, but not in any of SEQ. ID NOs: 3, 5, 7, 9, 11, and 13;
 - b) it is contained in phage **B**, **C** and **G** deposited under Accession Nos. NCIMB 41056, 41059, 41060, and 41061; but not in λ -phage or any of SEQ. ID NOs: 3, 5, 7, 9, 11, and 13; or
 - c) it hybridizes under stringent conditions to a polynucleotide with the sequence in SEQ. ID NO:1 or any of SEQ. ID NOs:14 to 25, but not to a polynucleotide with the sequence in any of SEQ. ID NOs: 3, 5, 7, 9, 11, and 13
18. The isolated polynucleotide of claim 17, wherein said sequence is contained in SEQ. ID NO:1 or any of SEQ. ID NOs:14 to 25, but not in any of SEQ. ID NOs: 3, 5, 7, 9, 11, and 13.
19. The isolated polynucleotide of claim 17, wherein said sequence is contained in phage **B**, **C** and **G** deposited under Accession Nos. NCIMB 41056, 41059, 41060, and 41061; but not in λ -phage or any of SEQ. ID NOs: 3, 5, 7, 9, 11, and 13.

20. The isolated polynucleotide of claim 17, wherein said sequence hybridizes under stringent conditions to a polynucleotide with the sequence in SEQ. ID NO:1 or any of SEQ. ID NOs:14 to 25, but not to a polynucleotide with the sequence in any of SEQ. ID NOs: 3, 5, 7, 9, 11, and 13.
21. The polynucleotide of claim 17, which is a construct effective for inactivating a $\alpha(1,3)$ galactosyltransferase ($\alpha 1,3GT$) gene in an ovine cell by homologous recombination.
22. An isolated polypeptide that comprises a sequence of at least 10 consecutive amino acids with at least one of the following properties:
- a) it is contained in SEQ. ID NO:2 but not in any of SEQ. ID NOs: 4, 6, 8, 10, and 12;
 - b) it is encoded in phage **B**, **C** and **G** deposited under Accession Nos. NCIMB 41056, 41059, 41060, and 41061., but not encoded in λ -phage or present in any of SEQ. ID NOs: 4, 6, 8, 10, and 12; or
 - c) it is at least 80% identical to 15 consecutive amino acids contained in SEQ. ID NO:2, wherein said sequence is not present in any of SEQ. ID NOs: 4, 6, 8, 10, and 12
23. The isolated polypeptide of claim 22, wherein said sequence is contained in SEQ. ID NO:2 but not in any of SEQ. ID NOs: 4, 6, 8, 10, and 12.
24. The isolated polypeptide of claim 22, wherein said sequence is encoded in phage **B**, **C** and **G** deposited under Accession Nos. NCIMB 41056, 41059, 41060, and 41061., but not encoded in λ -phage or present in any of SEQ. ID NOs: 4, 6, 8, 10, and 12.

25. The isolated polypeptide of claim 22, wherein said sequence is at least 80% identical to 15 consecutive amino acids contained in SEQ. ID NO:2, wherein said sequence is not present in any of SEQ. ID NOs: 4, 6, 8, 10, and 12.
26. The polypeptide of claim 22, which has glycosyltransferase activity.
27. An isolated polynucleotide comprising a sequence encoding a polypeptide according to claim 22.
28. An isolated polyclonal antibody or a monoclonal antibody that binds specifically to a polypeptide with the sequence SEQ. ID NO:2 but not to a peptide with the sequence present in any of SEQ. ID NOs: 4, 6, 8, or 10.
29. An assay method for determining α 1,3GT expression by a cell, comprising contacting a polynucleotide according to claim 17 with the cell or with mRNA or cDNA obtained from the cell, detecting any hybrids that form as a result, and correlating presence of the hybrids with expression of α 1,3GT by the cell.
30. A method for producing the antibody specific for sheep α 1,3GT, comprising immunizing an animal or contacting an immunocompetent particle with a polypeptide according to claim 22.
31. A method for preparing a Gal α (1,3)Gal determinant, comprising contacting a galactose acceptor saccharide with the polypeptide of claim 26 in the presence of UDP-galactose.

32. An assay method for determining α 1,3GT in a sample, comprising preparing a reaction mixture comprising the sample and an antibody according to claim 28 under conditions that permit the antibody to complex with α 1,3GT, and correlating any complex formed with the presence or amount of α 1,3GT in the sample.

ABSTRACT

This invention provides immunologically compatible animal tissue, suitable for xenotransplantation into human patients. Sequence of the cDNA for the sheep $\alpha(1,3)$ galactosyltransferase has been determined, along with information about the flanking untranscribed regions and introns of the $\alpha 1,3$ GT gene. This in turn has led to the design and implementation of targeting vectors capable of inactivating the $\alpha 1,3$ GT gene by deleting or interrupting the protein coding region. Successfully targeted fibroblasts are used as nuclear donors for the cloning of animals in which the $\alpha 1,3$ GT gene is inactivated. The Gal $\alpha(1,3)$ Gal determinant does not form on endothelial and other cells of animals having homozygously inactivated $\alpha 1,3$ GT. The tissues can be transplanted into human patients, without being subject to hyperacute rejection that would otherwise occur due to naturally occurring antibodies to the Gal $\alpha(1,3)$ Gal determinant present in human serum. Because of the limited availability of human organs for transplantation, immunologically compatible animal tissue is an important alternative for human organs that are in such short supply for transplantation therapy.

Figure 1(A)

5' -AGCCGAGGACGCCCGGGGAGCCGAGGCTCCGGCCAGCCCCAGCGCGCCCAGCT
TCTGCAGATCAGGAGTCAGAACGCTGCACCTTCGCTTCCTCCCAGCCCTGCCTCCTTCTG
CAAAACGGAGCTCAATAGAACTTGGTACTTTTGCCTTTTACTCTGGGAGGAGAGAAGCAG
ACGATGAG|4|GAGAAAATAATGAATGTCAAAGGAAAAGTGATTCTGTCAATGCTGGTTG
M N V K G K V I L S M L V V
TCTCAACTGTCATTGTTGTGTTTTGGGAATATATCCACAG|5|CCCAGAAGGCTCTTTGT
S T V I V V F W E Y I H S P E G S L F
TCTGGATAAACCCATCAAG|6|AAACCCAGAAGTCAGTGGCGGCAGCAGCATTCAAGAGG
W I N P S R N P E V S G G S S I Q K G
GCTGGTGGTTTCCGAGATGGTTTAAACAATGG|7|TTACCAAGAAGAAGATGAAGACGTAG
W W F P R W F N N G Y Q E E D E D V D
ACGAAGAAAAGGAACAAAGAAAGGAAGACAAAAGCAAGCTTAAGCTATCGGACTGGTTCA
E E K E Q R K E D K S K L K L S D W F N
ACCCATT|8|TAAACGCCCTGAGGTTGTGACTATGACAGATTGGAAGGCACCCGTGGTGT
P F K R P E V V T M T D W K A P V V W
GGGAAGGCACTTACAACAGAGCCGTCTTAGACGATTACTACGCCAAGCAGAAAATTACCG
E G T Y N R A V L D D Y Y A K Q K I T V
TCGGCCTGACGGTTTTCGCCGTCGGAA|9|GATACATTGAGCATTACTTGGAGGAGTTCT
G L T V F A V G R Y I E H Y L E E F L
TAACGTCTGCTAATAAGCACTTCATGGTTGGCCACCGAGTCATCTTTTACGTCATGGTGG
T S A N K H F M V G H R V I F Y V M V D
ACGACGTCTCCAGGATGCCTTTGATAGAGCTGGGCCCTCTGCGCTCCTTCAAAGTGTTTG
D V S R M P L I E L G P L R S F K V F E
AGGTCAAGCCTGAGAGGAGGTGGCAGGACGTCAGCATGGTGCGCATGAAGACCATCGGGG
V K P E R R W Q D V S M V R M K T I G E
AGCACATCGTGGCCACATCCAGCGTGAGGTTGACTTCCTCTTCTGCATGGACGTGGACC
H I V A H I Q R E V D F L F C M D V D Q

Figure 1(B)

AGGTCTTCCAAGACGAGTTTCGGGGTGGAGACCCTGGGTGAGTCGGTGGCCCAGCTACAGG
V F Q D E F G V E T L G E S V A Q L Q A

CCTGGTGGTACAAGGCAGATCCCGATGAGTTTACCTACGAGAGGCGCAAGGAGTCTGCAG
W W Y K A D P D E F T Y E R R K E S A A

CATACATTCCCTTCGGCGAAGGGGATTTTTATTACCACGCAGCCATTTTTGGGGGAACAC
Y I P F G E G D F Y Y H A A I F G G T P

CCACTCAGGTCCTTAACATCACCCAGGAATGCTTCAAAGGAATCCTCAAGGACAAGAAAA
T Q V L N I T Q E C F K G I L K D K K N

ATGACATAGAAGCCCAATGGCATGATGAGAGCCATCTAAACAAGTATTTCTTCTCAACA
D I E A Q W H D E S H L N K Y F L L N K

AACCCACTAAAATCTTATCCCCGGAATACTGCTGGGATTATCATATAGGCCTACCTGCGG
P T K I L S P E Y C W D Y H I G L P A D

ATATTAAGCTTGTCAAGATGTCTTGGCAGACAAAAGAGTATAATGTGGTTAGAAATAACG
I K L V K M S W Q T K E Y N V V R N N V

TCTGAAGCCGAGGACGCCGCCGGGGAGCCGAGGCTCCGCCAGCCCCAGCGCGCCCAGC

TTCTGCAGATCAGGAGTCAGAACGCTGCACCTTCGCTTCCTCCCAGCCCTGCCTCCTTCT

GCAAAACGGAGCTCAATAGAACTTGGTACTTTTGCCTTTTACTCTGGGAGGAGAGAAGCA

GACGATGAGGAGAAAATA

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Figure 2(A)

```
sheep -----
bovine CCGGGGGCCGGGCCGAGCTGGGAGCGTCGAGCCCGCTGCCAGCGCCCGCGGCTCCCTC

sheep -----
bovine GCGCCCCCTGCCCGCCGCCCGGAGGAGCGCCGGCGGCCGGCCGACGGGAGCGCAGCGGC

sheep -----
bovine ACACCCCGCCCCGGCAGCCCCGCGGGGCTCGGGAGGAGGCAGCGCGCCGACTGTTCCGGC

sheep AGCCGAGGACGCCGCCGGGGAGCCGAGGCTCCGGCCAGCCCCAGCGCGCCAGCTTCTG
bovine AGCCGAGGACGCCGCCGGGGAGCCGAGGCGCCGGCCAGCCCCAGCGCGCCAGCTTCTG
*****

sheep CAGATCAGG-----
bovine CGGATCAGGGAACACAGTGTCTCAAGTGGCCAGCCAGCTGTCCCAAGAGGAAGTTC
* *****

sheep -----AGTCAGAACGCTGCAC
bovine CTGGCATTTCACGGAAGACGAGACACTTCACAAATCAACGGAGTCAGAAGGCTGCAC
*****

sheep CTTCGCTTCCTCCCAGCCCTGCCTCCTTCTGCAAAACGGAGCTCAATAGAACTTGGTACT
bovine CTTCGCTTCCTCCCAGCCCTGCCTCCTTCTGCAGAACGGAGCTCAGTAGAACTTGGTACT
*****
                               ↓
sheep TTTGCCTTTTACTCTGGGAGGAGAGAAGCAGACGATGAGGAGAAAATAATGAATGTCAAA
bovine TTTGCCTTTTACTCTAGGAGGAGAGAAGCAGACGATGAGGAGAAAATAATGAATGTCAAA
*****

sheep GGAAAAGTGATTCTGTCAATGCTGGTTGTCTCAACTGTCATTGTTGTGTTTTGGGAATAT
bovine GGAAAAGTGATTCTGTCAATGCTGGTTGTCTCAACTGTCATTGTTGTGTTTTGGGAATAT
*****

sheep ATCCACAGCCCAGAAGGCTCTTTGTTCTGGATAAACCCATCAAGAAACCCAGAAGTCAGT
bovine ATCCACAGCCCAGAAGGCTCTTTGTTCTGGATAAACCCATCAAGAAACCCAGAAGT---T
*****

sheep GGCGGCAGCAGCATTGAGAAGGGCTGGTGGTTTCCGAGATGGTTTAACAATGGTTACCAA
bovine GGTGGCAGCAGCATTGAGAAGGGCTGGTGGCTTCCGAGATGGTTTAACAATGGTTACCAT
** *****
```

Figure 2(B)

sheep	GAAGAAGATGAAGACGTAGACGAAGAAAAGGAACAAAGAAAGGAAGACAAAAGCAAGCTT
bovine	GAAGAAGATGGAGACATAAACGAAGAAAAGGAACAAAGAAACGAAGACGAAAGCAAGCTT
	***** ** *
sheep	AAGCTATCGGACTGGTTCAACCCATTTAAACGCCCTGAGGTTGTGACTATGACAGATTGG
bovine	AAGCTATCGGACTGGTTCAACCCATTTAAACGCCCCGAGGTTGTGACCATGACGAAGTGG
	***** ** *
sheep	AAGGCACCCGTGGTGTGGGAAGGCACTTACAACAGAGCCGTCTTAGACGATTACTACGCC
bovine	AAGGCTCCAGTGGTGTGGGAAGGCACTTACAACAGAGCCGTCTTAGACAATTATTATGCC
	***** ** *
sheep	AAGCAGAAAATTACCGTCGGCCTGACGGTTTTCGCCGTCGGAAGATACATTGAGCATTAC
bovine	AAGCAGAAAATTACCGTCGGCCTGACGGTTTTCGCCGTCGGAAGATACATTGAGCATTAC

sheep	TTGGAGGAGTTCTTAACGTCTGCTAATAAGCACTTCATGGTTGGCCACCGAGTCATCTTT
bovine	TTGGAGGAGTTCTTAACGTCTGCTAATAAGCACTTCATGGTGGGCCACCCAGTCATCTTT
	***** ** *
sheep	TACGTCATGGTGGACGACGTCTCCAGGATGCCTTTGATAGAGCTGGGCCCTCTGCGCTCC
bovine	TATATCATGGTAGATGATGTCTCCAGGATGCCTTTGATAGAGTTGGGTCTCTGCGCTCC
	** ***** ** *
sheep	TTCAAAGTGTTTGAAGTCAAGCCTGAGAGGAGGTGGCAGGACCTCAGCATGGTGCGCATG
bovine	TTCAAAGTGTTTGAAGTCAAGCCTGAGAAGAGGTGGCAGGACATCAGCATGATGCGCATG
	***** ** *
sheep	AAGACCATCGGGGAGCACATCGTGGCCACATCCAGCGTGAGGTTGACTTCCTCTTCTGC
bovine	AAGACTATCGGGGAGCACATTGTGGCCACATCCAGCATGAGGTTGACTTCCTTTTCTGC

sheep	ATGGACGTGGACCAGGTCTTCCAAGACGAGTTTCGGGGTGGAGACCCTGGGTGAGTCGGTG
bovine	ATGGATGTGGACCAGGTCTTCCAAGACAAGTTTGGGGTGGAGACCCTGGGCGAGTCGGTG

sheep	GCCCAGCTACAGGCCTGGTGGTACAAGGCAGATCCCGATGAGTTTACCTACGAGAGGCGC
bovine	GCCCAGCTACAAGCCTGGTGGTACAAGGCAGATCCCAATGACTTCACCTACGAGAGGCGG
	***** ** *
sheep	AAGGAGTCTGCAGCATACATTCCCTTCGGCGAAGGGGATTTTATTACCACGCAGCCATT
bovine	AAGGAGTCTGCAGCATACATTCCCTTCGGCGAAGGGGATTTTATTACCATGCAGCCATT

	07/2009	08/2009	09/2009	10/2009	11/2009	12/2009	01/2010	02/2010	03/2010	04/2010	05/2010	06/2010	07/2010	08/2010	09/2010	10/2010	11/2010	12/2010	01/2011	02/2011	03/2011	04/2011	05/2011	06/2011	07/2011	08/2011	09/2011	10/2011	11/2011	12/2011	01/2012	02/2012	03/2012	04/2012	05/2012	06/2012	07/2012	08/2012	09/2012	10/2012	11/2012	12/2012	01/2013	02/2013	03/2013	04/2013	05/2013	06/2013	07/2013	08/2013	09/2013	10/2013	11/2013	12/2013	01/2014	02/2014	03/2014	04/2014	05/2014	06/2014	07/2014	08/2014	09/2014	10/2014	11/2014	12/2014	01/2015	02/2015	03/2015	04/2015	05/2015	06/2015	07/2015	08/2015	09/2015	10/2015	11/2015	12/2015	01/2016	02/2016	03/2016	04/2016	05/2016	06/2016	07/2016	08/2016	09/2016	10/2016	11/2016	12/2016	01/2017	02/2017	03/2017	04/2017	05/2017	06/2017	07/2017	08/2017	09/2017	10/2017	11/2017	12/2017	01/2018	02/2018	03/2018	04/2018	05/2018	06/2018	07/2018	08/2018	09/2018	10/2018	11/2018	12/2018	01/2019	02/2019	03/2019	04/2019	05/2019	06/2019	07/2019	08/2019	09/2019	10/2019	11/2019	12/2019	01/2020	02/2020	03/2020	04/2020	05/2020	06/2020	07/2020	08/2020	09/2020	10/2020	11/2020	12/2020	01/2021	02/2021	03/2021	04/2021	05/2021	06/2021	07/2021	08/2021	09/2021	10/2021	11/2021	12/2021	01/2022	02/2022	03/2022	04/2022	05/2022	06/2022	07/2022	08/2022	09/2022	10/2022	11/2022	12/2022	01/2023	02/2023	03/2023	04/2023	05/2023	06/2023	07/2023	08/2023	09/2023	10/2023	11/2023	12/2023	01/2024	02/2024	03/2024	04/2024	05/2024	06/2024	07/2024	08/2024	09/2024	10/2024	11/2024	12/2024	01/2025	02/2025	03/2025	04/2025	05/2025	06/2025	07/2025	08/2025	09/2025	10/2025	11/2025	12/2025	01/2026	02/2026	03/2026	04/2026	05/2026	06/2026	07/2026	08/2026	09/2026	10/2026	11/2026	12/2026	01/2027	02/2027	03/2027	04/2027	05/2027	06/2027	07/2027	08/2027	09/2027	10/2027	11/2027	12/2027	01/2028	02/2028	03/2028	04/2028	05/2028	06/2028	07/2028	08/2028	09/2028	10/2028	11/2028	12/2028	01/2029	02/2029	03/2029	04/2029	05/2029	06/2029	07/2029	08/2029	09/2029	10/2029	11/2029	12/2029	01/2030	02/2030	03/2030	04/2030	05/2030	06/2030	07/2030	08/2030	09/2030	10/2030	11/2030	12/2030	01/2031	02/2031	03/2031	04/2031	05/2031	06/2031	07/2031	08/2031	09/2031	10/2031	11/2031	12/2031	01/2032	02/2032	03/2032	04/2032	05/2032	06/2032	07/2032	08/2032	09/2032	10/2032	11/2032	12/2032	01/2033	02/2033	03/2033	04/2033	05/2033	06/2033	07/2033	08/2033	09/2033	10/2033	11/2033	12/2033	01/2034	02/2034	03/2034	04/2034	05/2034	06/2034	07/2034	08/2034	09/2034	10/2034	11/2034	12/2034	01/2035	02/2035	03/2035	04/2035	05/2035	06/2035	07/2035	08/2035	09/2035	10/2035	11/2035	12/2035	01/2036	02/2036	03/2036	04/2036	05/2036	06/2036	07/2036	08/2036	09/2036	10/2036	11/2036	12/2036	01/2037	02/2037	03/2037	04/2037	05/2037	06/2037	07/2037	08/2037	09/2037	10/2037
--	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------

sheep	TTTGGGGGAACACCCACTCAGGTCCTTAACATCACCCAGGAATGCTTCAAAGGAATCCTC
bovine	TTTGGGGGAACACCCACTCAGGTCCTTAACATCACCCAGGAATGCTTCAAAGGAATCCTC

sheep	AAGGACAAGAAAAATGACATAGAAGCCCAATGGCATGATGAGAGCCATCTAAACAAGTAT
bovine	AAGGACAAGAAAAATGACATAGAAGCCCAATGGCATGATGAAAGCCATCTAAACAAGTAT

sheep	TTCTTCTCAACAAACCCACTAAAATCTTATCCCCGGAATACTGCTGGGATTATCATATA
bovine	TTCTTCTCAACAAACCTACTAAAATCTTATCCCCGGAATACTGCTGGGATTATCACATA

sheep	GGCTACCTGCGGATATTAAGCTTGTCAAGATGTCTTGGCAGACAAAAGAGTATAATGTG
bovine	GGCTACCTGCGGATATTAAGCTTGTCAAGATGTCTTGGCAGACAAAAGAGTATAATGTG

sheep	GTTAGAAATAACGTCTGA-----
bovine	GTTAGAAATAATGTCTGACTTTGTGCCAGTACATTTCTGAATTTGAGAGAGTATTATTCT

Figure 3

	1		50
bovine	MNVKGVLS MLVVSTVIVV FWEYIHSPEG SLFWINPSRN PEV.GGSSIQ		
sheep	MNVKGVLS MLVVSTVIVV FWEYIHSPEG SLFWINPSRN PEVSGGSSIQ		
	*****	*****	***
	51		100
bovine	KGWWLPRWFN NGYHEEDGDI NEEKEQRNED ESKLKLSDWF NPFKRPEVVT		
sheep	KGWWFPRWFN NGYQEEDEDV DEEKEQRKED KSKLKLSDWF NPFKRPEVVT		
	****	***	*****
	101		150
bovine	MTKWKAPVVW EGTYNRAVL D NYYAKQKITV GLTVFAVGRI IEHYLEEFIT		
sheep	MTDWKAPVVW EGTYNRAVL D DYYAKQKITV GLTVFAVGRI IEHYLEEFIT		
	**	*****	*****
	151		200
bovine	SANKHFMVGH PVIFYIMVDD VSRMPLIELG PLRSFKVFKI KPEKRWQDIS		
sheep	SANKHFMVGH RVIFYVMVDD VSRMPLIELG PLRSFKVFEV KPERRWQDVS		
	*****	****	***
	201		250
bovine	MMRMKTIGEH IVAHIQHEVD FLFCMDVDQV FQDKFGVETL GESVAQLQAW		
sheep	MVRMKTIGEH IVAHIQREVD FLFCMDVDQV FQDEFGVETL GESVAQLQAW		
	*****	*****	*****
	251		300
bovine	WYKADPNDFI YERRKESAAY IPFGEGDFYY HAAIFGGTPT QVLNITQECF		
sheep	WYKADPDEFT YERRKESAAY IPFGEGDFYY HAAIFGGTPT QVLNITQECF		
	*****	*****	*****
	301		350
bovine	KGILKDKKND IEAQWHDESH LNKYFLLNKP TKILSPEYCW DYHIGLPADI		
sheep	KGILKDKKND IEAQWHDESH LNKYFLLNKP TKILSPEYCW DYHIGLPADI		
	*****	*****	*****
	351	370	
bovine	KLVKMSWQTK EYNVVRNNV*		
sheep	KLVKMSWQTK EYNVVRNNV*		
	*****	*****	

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted September 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11






Figure 12






Figure 14




Figure 15




Figure 16







Figure 17



DECLARATION

DECLARATION

As a below named inventor, I hereby declare that my residence, post office address, and citizenship are as stated below next to my name. Further, I hereby declare that I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled, ANIMAL TISSUE FOR XENOTRANSPLANTATION, the specification of which is filed herewith; and

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

FOREIGN PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

None

U. S. PRIORITY CLAIM

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<i>Serial Number</i>	<i>Filing Date</i>	<i>Status (patented / pending / abandoned)</i>
60/204,148	May 15, 2000	Pending

Send correspondence to:

J. Michael Schiff
GERON CORPORATION
230 Constitution Drive
Menlo Park, CA 94025

Direct telephone calls to: J. Michael Schiff
telephone number 650-473-7715

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

First Inventor's Signature:

Date:

Full Name: John Clark

Citizenship: United Kingdom

Residence Address: Midlothian, United Kingdom

Second Inventor's Signature: _____ Date: _____
Full Name: Chris Denning _____ Citizenship: United Kingdom
Residence Address: Midlothian, United Kingdom